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Abstract 
 
Invasive nontyphoidal Salmonella disease (iNTS) is a leading cause of death and 
morbidity in developing countries and no vaccines are currently available. The most 
common pathogens are Salmonella enterica serovars Typhimurium and Enteritidis. 
The O-antigen (OAg) portion of their lipopolysaccharide (LPS) is a target of 
protective immunity and two OAg-based vaccine strategies have been evaluated at 
GSK Vaccines Institute for Global Health (GVGH): bivalent formulation of S. 
Typhimurium and S. Enteritidis Generalized Modules for Membrane Antigens 
(GMMA) and conjugation of S. Typhimurium and S. Enteritidis OAg to CRM197 
carrier protein. 
The first part of my Ph.D. project focused on the characterization of GMMA 
produced by S. Typhimurium and S. Enteritidis mutated strains, with particular 
attention to the OAg component, in a process of screening to identify the most 
suitable GMMA candidate vaccines. GMMA are outer membrane vesicles naturally 
released by Gram-negative bacteria. S. Typhimurium and S. Enteritidis strains were 
engineered to increase GMMA production and detoxify the lipid A moiety of LPS. 
We found that genetic mutations can impact expression of OAg chains and their 
structural characteristics, such as chain length and level and position of O-acetylation. 
However, when tested in mice, all GMMA induced high levels of anti-OAg-specific 
IgG functional antibodies, despite variation in density and OAg structural 
modifications. 
Methods to check quality, consistency of production, stability of GMMA vaccines are 
of fundamental importance. Not only it is important to characterize the key antigens 
displayed on GMMA surface and presented to the immune system, but also to 
characterize GMMA as particles. In this context, we compared Dynamic Light 
Scattering (DLS), Multi-Angle Light Scattering (MALS) and Nanoparticle Tracking 
Analysis (NTA) for size distribution determination and for verifying integrity and 
eventual aggregation of GMMA particles. Each methodology resulted to have 
strengths and weaknesses, but all the three techniques provided complementary 
information allowing a more complete evaluation of GMMA size. 
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Unlike the MALS diameter, the DLS diameter correlated with the number of OAg 
chains per GMMA particle. NTA allows real time visualization and simultaneously 
tracking and counting of individual particles, but it is deeply operator dependent, 
making more difficult to obtain consistent results. 
Second part of my Ph.D. project focused on the in depth characterization of OAg-
CRM197 glycoconjugates. OAg was extracted by direct acid hydrolysis of bacteria and 
conjugated to CRM197 through reductive amination of the terminal reducing sugar, 
which is expected to be 3-Deoxy-D-manno-oct-2-ulosonic acid (KDO) of the LPS 
core region. KDO structural rearrangements after acid hydrolysis have been reported 
in literature and its high reactivity in reaction of reductive amination has been 
attributed to these chemical modifications. Here, analysis by MS and NMR of the 
core oligosaccharide (OS) extracted from S. Typhimurium bacteria showed the 
presence of KDO in its native form with no structural changes. Core OS was fully 
characterized and conjugated to CRM197, through insertion of adipic acid dihydrazide 
(ADH) and adipic acid bis-(N-hydroxysuccinimide) ester (SIDEA) as linkers. KDO 
was the sugar involved in the first step, with kinetic of reductive amination with ADH 
faster than KDO monosaccharide, due to the linkage in position 5 to the sugar chain. 
The step of SIDEA introduction was not selective as the linker reacted also with the 
pyrophosphorylethanolamine (PPEtN) group present in the core region, even in the 
presence of ADH and by performing the reaction at low pH. Glycosylation sites 
investigation confirmed that the conjugation process used is highly random involving 
many lysine residues of CRM197, with preference for those surface exposed. The 
method also allowed investigation of the regioselectivity of the reaction confirming 
that OAg chains linkage to the protein happened through both SIDEA on PPEtN 
group and on ADH. 
These studies contributed to better characterize the Salmonella antigens and help to 
define and improve manufacturing processes and analytical methods for OAg-based 
vaccines in general. 
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Riassunto 
 
La malattia invasiva provocata da Salmonelle non tifoidee (iNTS) è una delle 
principali cause di morte e morbilità nei paesi in via di sviluppo e nessun vaccino è 
attualmente disponibile. Gli agenti patogeni più comuni sono Salmonella enterica 
sierotipi Typhimurium ed Enteritidis. L’antigene O (OAg) del loro lipopolisaccaride 
(LPS) è un bersaglio per la protezione immunitaria e due strategie per lo sviluppo di 
vaccini basate sull’OAg sono state prese in considerazione in GSK Vaccines Institute 
for Global Health (GVGH): una formulazione bivalente di Generalized Modules for 
Membrane Antigens (GMMA) prodotte da S. Typhimurium e S. Enteritidis e la 
coniugazione delle catene di OAg di S. Typhimurium e S. Enteridis alla proteina 
carrier CRM197. 
La prima parte del mio progetto di dottorato è focalizzata sulla caratterizzazione delle 
GMMA prodotte da ceppi mutati di S. Typhimurium e S. Enteridis, con particolare 
attenzione all’OAg, in un processo di screening per individuare i candidati più idonei 
per lo sviluppo di un vaccino basato sulle GMMA. Le GMMA sono vescicole di 
membrana esterna spontaneamente rilasciate da batteri Gram-negativi. Ceppi di S. 
Typhimurium e di S. Enteridis sono stati geneticamente modificati per aumentare la 
produzione stessa di GMMA e per detossificare la componente di lipide A dell’LPS. 
Abbiamo riscontrato che le mutazioni genetiche introdotte possono influenzare 
l’espressione stessa delle catene di OAg e le loro caratteristiche strutturali, quali la 
lunghezza di catena e il livello e la posizione dei gruppi O-acetile. Tuttavia, quando 
testate nei topi a parità di dose di OAg iniettata, tutte le GMMA hanno indotto simili 
alti livelli di anticorpi funzionali specifici per l’OAg, indipendentemente dalla densità 
delle catene di OAg sulle GMMA e dalle loro differenze strutturali. 
Metodi per verificare qualità, consistenza della produzione, stabilità dei vaccini basati 
sulle GMMA sono di fondamentale importanza. Non solo è importante caratterizzare 
gli antigeni chiave esposti sulla superficie delle GMMA e presentati al sistema 
immunitario, ma anche caratterizzare le GMMA come particelle. In questo contesto, 
abbiamo confrontato varie tecniche fra cui Dynamic Light Scattering (DLS), Multi-
Angle Light Scattering (MALS) e Nanoparticle Tracking Analysis (NTA) per la 
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determinazione della distribuzione delle dimensioni e per la verifica dell’integrità e 
dell’eventuale aggregazione delle GMMA. Ogni tecnica ha mostrato punti di forza e 
punti deboli, ma tutte e tre hanno fornito informazioni complementari consentendo 
una valutazione più completa delle dimensioni delle GMMA. Diversamente dal 
diametro ottenuto dopo analisi MALS, il diametro ottenuto dopo analisi DLS aveva 
una correlazione con il numero delle catene di OAg per particella di GMMA. L’NTA 
permette la visualizzazione in tempo reale e il monitoraggio e il conteggio simultaneo 
di singole particelle, ma è profondamente dipendente dall’operatore, rendendo più 
difficile ottenere risultati coerenti. 
La seconda parte del mio progetto di dottorato è incentrata sulla caratterizzazione 
approfondita dei coniugati OAg-CRM197. L’OAg è stato estratto per idrolisi acida 
diretta sui batteri e coniugato con il CRM197 attraverso l’amminazione riduttiva dello 
zucchero all’estremità riducente, che dovrebbe essere l’acido 3-Deossi-D-manno-ott-
2-ulosonico (KDO) della regione core dell’LPS. Riarrangiamenti strutturali del KDO 
dopo idrolisi acida sono stati riportati in letteratura e la sua elevata reattività nelle 
reazioni di amminazione riduttiva è stata attribuita a queste modifiche chimiche. In 
questo lavoro, analisi di spettrometria di massa (MS) e di spettroscopia di risonanza 
magnetica nucleare (NMR) del core oligosaccaridico (OS) estratto da batteri di S. 
Typhimurium hanno mostrato la presenza del KDO nella sua forma nativa senza 
modifiche strutturali. Il core OS è stato completamente caratterizzato e coniugato con 
il CRM197, attraverso l’inserimento della diidrazide dell’acido adipico (ADH) e 
dell’estere disuccinimidil adipato (SIDEA) come molecole linker. Il KDO è stato lo 
zucchero coinvolto nella prima fase, con una cinetica di reazione di amminazione 
riduttiva con ADH più rapida rispetto al KDO monosaccaride, a causa del legame in 
posizione 5 alla catena saccaridica. Il passaggio di introduzione della SIDEA non è 
risultato essere selettivo poiché il linker reagisce non solo con l’ADH, ma anche con 
la fosfoetanolammina presente nella regione del core oligosaccaridico, anche 
effettuando la reazione a un basso valore di pH. L’analisi dei siti di glicosilazione del 
CRM197 ha confermato che il processo di coniugazione usato è molto casuale 
coinvolgendo molti residui di lisina, con preferenza per quelli esposti in superficie. Il 
metodo ha permesso anche un’indagine della regioselettività della reazione, che 
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conferma che la coniugazione delle catene di OAg alla proteina è avvenuta sia 
attraverso la SIDEA legata alla fosfoetanolammina che all’ADH. 
Questi studi hanno contribuito a caratterizzare meglio gli antigeni di Salmonella e ad 
aiutare a definire e migliorare i processi di produzione e i metodi analitici applicabili 
a vaccini basati sull’OAg in generale. 
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1.1 Salmonella classification and host range infections 
 
Salmonellae are Gram-negative, facultative anaerobic and nonspore-forming 
bacilli, with cell diameters between 0.7 and 1.5 µm, lengths from 2 to 5 µm and 
peritrichous flagella [1, 2]. Salmonella species are facultative intracellular pathogens, 
capable to infect a wide range of species, from reptiles and birds to mammals, 
including humans, causing a wide spectrum of diseases [3]. Host infection (also 
known as salmonellosis) is generally due to oral ingestion of contaminated food or 
water, direct faecal-oral spread, contact with infected animals and nosocomial 
exposure [4, 5]. Contact with pet reptiles and amphibians, also represents a risk for 
salmonellosis [6]. Salmonellae have been isolated from rivers, sewage, and soil, 
demonstrating a wide colonization of the environment. Moreover, they have been 
detected in fruits, vegetables and animal feeds. 
The genus Salmonella belongs to the family of Enterobacteriaceae [7]. The genus 
comprises a large and closely related population of medically relevant pathogens. 
They take name from the veterinary pathologist Daniel Elmer Salmon, administrator 
of the Veterinary Division of the United States Department of Agriculture in 1885, 
where the medical research scientist Theobald Smith discovered this new type of 
bacteria in porcine intestine. 
Despite Salmonella has been recognized as an important pathogen, its complex 
nomenclature system is quite confusing and remains unfamiliar to clinicians. 
Although uniformity in nomenclature is considered necessary for communication 
among scientists, health officers and the public, different systems have been used to 
refer to this genus. Since its isolation, several taxonomy classification systems have 
been proposed, inconsistently dividing the genus into species, subspecies, subgenera, 
groups, subgroups, and serotypes or serovars. The terms serotype and serovar (short 
for serological variant) have been both frequently used, but the latter has been 
preferred, according to the rules proposed by the Judicial Commission of the 
International Committee on the Systematics of Prokaryotes in 1990. Initially many 
Salmonellae were differentiated [8] on the basis of the serologic identification of 
bacterial surface moieties such as the O-antigen (OAg) of lipopolysaccharide (LPS) 
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(O somatic antigen), the Vi capsular polysaccharide (CPS) antigen and the flagellar 
antigen (H antigen). In agreement with this classification system introduced in 1966, 
known as Kauffmann-White classification [9], each serotype was considered a 
separate species, resulting in more than 2,500 Salmonella species. Agglutination 
reactions based on O and H antigens have been used by clinical laboratories to divide 
Salmonella into serogroups which include A, B, C1, C2, D, E [10]. Other taxonomic 
proposals have been based on the animal species from which the organism was 
isolated, on the clinical role of a strain, on the biochemical characteristics, on 
genomic relatedness, or on the geographical area where the strain was first isolated. 
Many of these names, after being commonly used for years, were accepted with no 
revision of the antigenic formulae system [7]. 
The current antigenic classification system of the genus Salmonella, accepted and 
used by World Health Organization (WHO), Centers for Disease Control and 
Prevention (CDC) and the American Society for Microbiology (ASM), is the result of 
many changes made overtime and it is still evolving [11]. The genus contains two 
species: S. enterica, and S. bongori. These two species are further divided into 
subspecies, which are referred to by a Roman number and a name. Subspecies within 
S. bongori are more associated with cold-blooded animals, such as reptiles and birds, 
and have only rarely been known to infect humans [12]. S. enterica consists of six 
subspecies (subsp.): I, S. enterica subsp. enterica; II, S. enterica subsp. salamae; IIIa, 
S. enterica subsp. arizonae; IIIb, S. enterica subsp. diarizonae; IV, S. enterica subsp. 
houtenae; VI, S. enterica subsp. indica. S. bongori has only one subspecies, subsp. V. 
Subspecies are differentiated biochemically and by genomic relatedness. In 
subspecies I, serovars are designated by a name, indicative of associated diseases, 
geographic origins, or usual hosts, for example serotypes Enteritidis, Typhimurium, 
Typhi, and Choleraesuis [10] (Fig. 1). 
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Fig. 1. Currently accepted taxonomic classification of Salmonella genus. 
 
From a clinical point of view, Salmonella enterica serotypes, which contains over 
60% of the total number of serovars of the genus and 99% of which are capable of 
infection in humans [2], have been categorized as typhoidal Salmonellae and 
nontyphoidal Salmonellae (NTS) serovars, based on host preference and disease 
manifestations in humans [4, 13]. Typhoidal serovars, which include Salmonella 
enterica subsp. enterica Typhi and S. Paratyphi A, B, and C, are specific for humans 
and do not occur in animals. They are usually contracted through direct contact with 
the faecal matter of an infected person. NTS serovars instead are zoonotic in origin, 
meaning that they can be transferred between animals and humans [14]. Poultry and 
eggs represent the most common source of NTS, together with reptiles, rodents, cats 
and dogs [15, 16]. NTS strains may be host generalists, infecting or colonizing a 
broad range of vertebrate animals, or may be adapted or restricted to particular 
nonhuman animal species. 
Despite their genetic similarity, serovars of typhoidal and nontyphoidal Salmonella 
can elicit very different diseases, in relation to their targets in the infected organisms 
and symptoms they can cause, as well as distinct immune responses, reflecting also 
host factors [17, 18]. The spectrum of diseases can range from gastroenteritis, enteric 
systemic fever (typhoid and paratyphoid fever), bacteraemia, focal infections, to a 
convalescent lifetime carrier state. Though primarily enteric pathogen, provoking 
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common diarrheal illness symptoms, Salmonella enterica (both typhoidal and NTS) is 
responsible for a considerable yet under-appreciated global burden of invasive 
disease, especially in developing countries of both Asia and Africa [19-22]. Since the 
early use of blood cultures, invasive S. enterica infections appeared to be common in 
Africa [23, 24]. 
 
1.2 Nontyphoidal Salmonella burden of disease 
 
NTS serovars are responsible of a huge burden of morbidity and mortality 
worldwide [21, 25-28]. The global incidence of NTS gastroenteritis was estimated to 
be 93 million episodes in 2010, and 80 million contracted the infection via food-borne 
transmission [29]. 2010 estimates reported that NTS infections were associated with 
4,847,000 disability-adjusted life years (DALY) lost and 81,300 diarrheal deaths [30, 
31]. Of the more than 2,500 NTS serovars, Salmonella Typhimurium and Salmonella 
Enteritidis account for approximately 50% of all human isolates of NTS reported 
globally [32]. 
In developed countries, NTS serovars are predominantly responsible of self-
limiting food-borne diarrheal illness in healthy individuals, with rare cases of 
bloodstream and focal infections and rarely life-threatening [33], except for specific 
risk factors [34]. NTS infection, instead, has emerged as a leading cause of 
community-acquired extra-intestinal, invasive bacteraemia, referred to as invasive 
nontyphoidal Salmonella disease (iNTS), in developing countries [14, 35] (Fig 2). 
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Fig. 2. Geographical distribution invasive nontyphoidal Salmonella disease (iNTS) indicating countries 
with high (> 100 cases/100,000 population/year) and medium (10-100 cases/100,000 population/year) 
disease burden [25]. 
 
Recent published data suggest that, globally, there are 49 cases (range of 30-94) of 
iNTS per 100,000 population which means that 3.4 (range 2.1-6.5) million cases 
occur globally each year (681,316 deaths annually, range of 415,164 to 1,301,520) 
[36]. In Africa, the iNTS incidence is high (227 cases per 100,000, range of 142-341), 
associated with case fatality rates of 20%. Metanalyses data which were extrapolated 
from 22 studies conducted in 34 African sites showed that 29% of community-
acquired bloodstream infections were caused by Salmonella enterica [37], and a high 
proportion of these infections (87-97%) were attributable to NTS [14]. iNTS had 
comparable incidence rates as invasive pneumococcal infection, for which a vaccine 
is available [37]. S. Typhimurium and S. Enteritidis were the most common serovars 
causing iNTS, accounting for 65.2% and 33.1% of all NTS serotyped isolates 
respectively, as also indicated by the WHO Global Food-borne Infections Network 
(GFN) [38]. Other serotypes implicated in provoking iNTS are S. Isangi, S. Concord, 
S. Stanleyville, and S. Dublin [39]. 
There are not clear ideas of why invasive Salmonella disease is a problem in 
middle- and low-income countries and not in developed world [26]. However, there 
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are several established factors that include increased invasiveness of distinct clades 
specific to Africa, increased opportunities for transmission and differences in routes 
of transmission and compromised host immunity in those individuals with HIV 
infection, malaria, malnutrition [25, 32]. The routes of transmission of iNTS are 
poorly understood. Studies of Salmonella carriage among livestock of families with 
iNTS cases have found that animal isolates are distinct from those associated with 
iNTS in man [25]. This suggests that iNTS in Africa, unlike in industrialized 
countries, does not have an animal reservoir. Recently, a strain of S. Typhimurium, 
known as ST313, has been identified as responsible for a notable proportion of iNTS 
in multiple sites in sub-Saharan Africa (SSA). The pathogen appears to be restricted 
to Africa [35], with strong genomic associations with S. Typhi. In particular, aside 
from showing multiple drug resistance, this strain has adapted itself to 
immunosuppressed persons, above all those living with HIV. 
 
1.3 iNTS risk factors 
 
Predisposing host factors appear to be important for iNTS infection and genetic 
immunodeficiency that affect innate and acquired immunity pathways and 
comorbidities are associated with iNTS [40-43]. In Africa, high incidence and 
increased severity of iNTS have been observed in young children below 72 months of 
age, in patients with acute or recent malaria, malarial anaemia and severe anaemia, in 
individuals with malnutrition, HIV, sickle cell disease, and haemolysis [44-50] 
resulting in high case-fatality rates.  
A study conducted in Mozambique reported an incidence of 388/100,000 in infants 
less than one year of age, and 262/100,000 in those under the age of five [51]. 
Significant discordance in the burden of iNTS between continents exists [52], and 
surveillance data from the United States showed, for example, that the incidence of 
iNTS was 7.8 cases per 100,000 in infants (aged less than one year) compared to less 
than 0.8 cases per 100,000 in older children [53]. 
In adults with HIV infection, recurrent iNTS cases have been well documented. 
NTS bacteraemia is particularly virulent in HIV-infected African adults who have a 
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mortality rate of 47% and recurrence rate of 43% [54]. However, severe iNTS 
accompanied by high case-fatality rates is also a common cause of bacteraemia in 
countries such as Mali, where HIV prevalence is low, and continues to be a problem 
in children not infected with HIV [39]. In contrast, HIV infection does not appear to 
predispose to infection with S. Typhi in those parts of Africa where typhoid fever is 
reported [55]. 
The high prevalence of malaria, and its association with iNTS, has been postulated 
as one reason for the different incidence between Africa and other continents [56]. 
Association between malaria and invasive Salmonella infections was suggested in 
1929 [57] and confirmed in 1987 [58]. Interestingly, recent studies in Gambia, Kenya 
and Tanzania have shown that the marked decline in malaria prevalence has been 
paralleled by a similar reduction in iNTS [59]. Nevertheless, iNTS remains a problem 
in locations where malaria is absent [59]. 
 
1.4 iNTS as neglected disease 
 
iNTS has been overshadowed in the past by other diseases for which better data 
were available, such as malaria and AIDS [32]. A key problem, common for the 
whole invasive Salmonella disease and not only iNTS, is the lack of appropriate 
diagnostic facilities, especially in Africa rural settings [25]. At the moment, 
microbiological blood cultures are the only way for the detection of Salmonella 
infections and for a proper clinical diagnosis of invasive Salmonella and iNTS, and 
facilities for blood cultures and other culture-based methods are extremely rare in 
low-resource settings of African countries [60]. This lack of wide available 
Salmonella diagnostic facilities does not produce results in time to inform the initial 
management of individual patients [61]. Moreover, efforts should be made also to 
develop non-culture-based diagnostic tests that are useful especially in more remote 
environments. Such efforts are needed not only to improve individual patient 
diagnosis and treatment, but also to better assess burden of disease and to support 
prevention measures, including vaccines [62, 63]. 
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Another problem is that a proper and specific diagnosis of iNTS is troublesome, 
due to the lack of distinctive clinical features associated with this disease, being 
confused with malaria [58] or severe pneumonia [26, 56]. In fact, signs and symptoms 
that distinguish iNTS from other common febrile infections do not exist [22, 55]. 
iNTS usually presents as febrile illness, frequently without diarrhoea and other 
gastrointestinal symptoms, in both adults and children. Because of these diagnostic 
problems, invasive Salmonella infections, and in particular iNTS, have been neglected 
and not considered as a significant global disease burden. By definition, neglected 
diseases fail to receive the level of support of better-known infectious diseases in 
Africa, such as HIV, malaria and tuberculosis. As a result, progress towards non-
vaccine and vaccine strategies against iNTS has also been slow [64]. Antibiotics have 
been widely used, although not always available in rural African settings, but 
increasing levels of multidrug-resistance to several antimicrobial classes [22], 
including extended spectrum cephalosporins and fluoroquinolones, are limiting their 
effectiveness [34, 52, 65-68]. A recent study conducted in Malawi emphasized that 
90% of invasive NTS serovars isolates were multidrug resistant [34]. 
Until good sanitary and hygienic conditions, provision of clean drinking water, 
food safety and appropriate diagnostic facilities are not available, alternative ways for 
the control of iNTS in developing countries are strongly needed [69, 70]. Vaccines 
against typhoid fever are widely available, but unfortunately there are no licensed 
vaccines against iNTS, in particular against S. Typhimurium and S. Enteritidis. Efforts 
should be intensified to identify protective antigens and best strategies for vaccine 
development [25, 32, 71, 72]. 
 
1.5 Targets for Salmonella vaccines development 
 
For the development of vaccines mediating protection against Salmonella, 
components of the outer surface of bacteria can be targeted, representing both 
essential virulence factors and important target antigens for protective antibodies 
induction [32]. 
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The cell wall of Gram-negative bacteria is composed of a lipid outer and inner 
membrane with a layer of peptidoglycan in between. The outer membrane is an 
asymmetric lipid bilayer with phospholipids in the inner leaflet and glycolipids, 
predominantly LPS, in the outer leaflet [73]. The LPS layer surrounding Gram-
negative bacteria constitutes a strong barrier against toxic compounds, such as 
antibiotics and allowing survival in harsh environments. LPS is also a potent activator 
of the innate immune response and acts as a conserved pathogen associated molecular 
pattern (PAMP) recognized by innate immune receptors [74]. LPS is a powerful 
immunomodulatory and may cause endotoxic shock in infected people. Architecture 
of LPS is shared by Gram-negative bacteria, but structural motifs vary considerably 
from one serovar to another (Fig. 3) [75]. 
 
 
 
Fig. 3. Structure of the LPS molecule found in the outer membrane of S. Typhimurium and S. 
Enteritidis. 
 
LPS molecules generally consist of three components [75]: 
 the lipid A; 
 the core oligosaccharide; 
 the O-antigen (OAg) chain. 
The lipid A is anchored in the outermost membrane leaflet and represents the 
hydrophobic part of LPS. Lipid A is composed by a backbone consisting of a β-1,6-
linked D-glucosamine (D-GlcN) disaccharide, O- and N-acylated with fatty acids of 
variable length, and phosphate groups at positions C-1 and C-4'. The lipid A domain 
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is responsible for much of the toxicity of Gram-negative bacteria and is a much 
conserved component of the LPS. 
The core oligosaccharide is covalently bound at the position C-6' of the non-
reducing glucosamine residue of lipid A through the acidic sugar 3-Deoxy-D-manno-
oct-2-ulopyranosonic acid (KDO). The proximal “inner core” region contains heptose 
residues (Hep), often substituted by phosphate (P), phosphorylethanolamine (PEtN) or 
pyrophosphorylethanolamine (PPEtN) groups. The “outer core” region of NTS 
serovars usually consists of neutral or amino hexoses such as D-glucose, D-galactose, 
D-glucosamine or N-acetyl derivatives. 
The OAg is a repetitive glycan polymer attached to the core oligosaccharide, and 
comprises the outermost domain of the LPS molecule. The composition of the OAg 
chains varies from strain to strain. OAg has been reported to help the bacteria to 
escape the host defence system, and in particular the attack of serum complement. 
Antibodies directed against OAg have been shown to be able to mediate bacterial 
killing [64, 76] and to confer protection against infection in animal models [77-80]. 
Passive transfer of targeting-OAg antibodies has been reported to protect against 
challenge [81, 82]. In addition, immunization with heat-killed S. Typhimurium ST313 
bacteria evoked bactericidal antibodies directed against OAg [76]. 
In addition to the OAg chains of the LPS, Salmonella surface proteins have been 
proposed as target antigens. Salmonella flagella are virulence factors that extend from 
the outer membrane and act in response to chemical information from the 
environment, allowing regulated movements of the bacteria [83]. Flagellin is a 
globular protein that arranges itself in a hollow cylinder to form the filament in a 
bacterial flagellum. Flagella consist of three elements, a basal body, a transmembrane 
motor and a filament consisting of multiple repeats of flagellin protein. Amino acid 
sequences for flagellin differ among serovars [84]. Mice have shown protection after 
immunization both with flagellin alone [79, 85, 86] or flagellin as carrier protein in 
OAg-based glycoconjugates [79, 87]. Flagellin is also crucial for Toll-like receptor 5 
(TLR5) stimulation and consequently involved in innate immune signalling [88, 89]. 
Salmonella porins are particularly abundant in the outer membrane and are channel 
proteins allowing passive diffusion of small molecules. Typically they consist of 
  
SDBM - School of 
Molecular Biomedicine 
 
 
12 
 
around 16 tilted β-strands connected by periplasmic and extraplasmic loops [90], and 
are exclusively found as homo- or heterotrimers in the membrane [91]. Porins differs 
in their loop topology and surface charge, and the most common porins found in 
Salmonella are outer membrane porin (Omp) C, OmpF and OmpD [92]. Porins are 
useful widely-conserved Salmonella surface proteins and have shown potential for 
use in broadly protective vaccines [82]. 
 
1.6 Vaccines against iNTS 
 
The development of vaccines against iNTS has been slower with respect to 
vaccines against typhoid fever [20]. This is likely to be attributable to a general lack 
of appreciation and awareness of the problem of iNTS in the global health community 
[69]. The development of iNTS vaccines was also complicated by the 
immunocompromised nature of susceptible patients [48, 49], which should be 
addressed early in clinical development. However, the enhanced activity in the field 
of vaccine development against Salmonella in the recent years has increased the 
attention on iNTS and strategies for vaccine design are being evaluated and several 
preparations are in preclinical studies phase [32]. Although several groups are 
working towards vaccines against iNTS, no licensed vaccines against iNTS are 
currently available [25]. Vaccines strategies against iNTS consist of live attenuated 
whole bacterial cells or nonliving preparations [28] (Fig. 4). 
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Fig. 4. Schematic representation of NTS, highlighting the main approaches currently under evaluation 
to develop vaccines against iNTS [28]. 
 
Live attenuated vaccines show a number of potential advantages, having the 
possibility of inducing broad protection against several Salmonella serovars, since 
multiple Salmonella antigens are delivered to the immune system [93]. Many 
attenuating mutations have been considered and tested in preclinical studies, 
conferring protection against challenge with the homologous serovars [25, 94]. 
Potential candidates for iNTS vaccination are S. Typhimurium and S. Enteritidis 
∆guaBA ∆clpX, which showed encouraging safety, high immunogenicity, and 
protection against lethal challenge with the homologous serovars in mice [95, 96]. 
The only live attenuated iNTS vaccine to be tested to date in man is WT05, a S. 
Typhimurium ∆aroC ∆ssaV mutant [97]. When tested in Phase 1 study, it induced 
variable serum antibody responses and prolonged stool shedding was found in 
volunteers for up to 23 days, so that the vaccine has not been tested further. The 
achievement of the right balance between immunogenicity and safety remains a major 
challenge of live attenuated iNTS vaccines. 
Nonliving iNTS vaccines consist either of defined antigens or preparations that 
contain multiple antigens together. Glycoconjugation technology [98] represents one 
of the most advanced strategies for the development of a vaccine against iNTS [72]. 
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Glycoconjugates against iNTS are based on the covalent conjugation of surface OAg 
to suitable carrier proteins [72, 99-101]. Tetanus toxoid (TT) [80, 102, 103], 
diphtheria toxoid (DT) [104] and nontoxic recombinant form of diphtheria toxin 
(CRM197) [77, 105-107], have been used as heterologous carrier proteins. These non-
Salmonella proteins are known to be safe and effective at inducing strong immune 
response against the polysaccharide antigen [78]. In addition to these carrier proteins, 
the use of Salmonella proteins has been considered. This could result in more 
effective vaccines than those with exogenous carriers, as they would target the 
immune response to two different Salmonella antigens. Svenson et al showed that S. 
Typhimurium OAg conjugated to S. Typhimurium porins gave better protection in 
mice that vaccination with porin vaccines alone or an analogous DT conjugate [86, 
108-110]. Simon et al showed enhanced immunogenicity with S. Typhimurium and S. 
Enteritidis conjugates of Salmonella flagellin compared with flagellin alone [79, 87]. 
Outer membrane proteins (OMPs) constitute the main alternative subunit approach 
for Salmonella vaccine development. The NTS surface proteins that have received 
most attention have been flagellin and porins OmpC, F and D. In preclinical studies, 
these antigens showed to successfully protect mice against Salmonella challenge [79, 
87, 88]. OmpC and OmpF induce long-lasting antibody responses in mice [111] and 
have been found to be safe and immunogenic when tested in a Phase 1 study in man 
[110, 112]. However, manufacturing processes in purifying and producing outer 
membrane proteins are quite complicated. It may be crucial to preserve the correct 
conformation of these antigens and failure of recombinant Salmonella porins to 
protect mice has been reported [113]. Flagellin and porins, with high level of 
homology between serovars, have been linked to OAg and conjugates have shown 
high immune response. 
An innovative strategy for the development of a vaccine against iNTS is 
represented by Generalized Modules for Membrane Antigens (GMMA) technology 
[114]. GMMA are small outer membrane vesicles-like blebs (40-200 nm diameter) 
spontaneously released by Gram-negative bacteria mutated to increase blebbing. 
Multiple surface antigens are presented to the immune system in the context of a 
membrane, in their native conformation. GMMA are also self-adjuvants, delivering 
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innate signals through TLR ligands and other pathogen-associated molecular patterns 
(PAMPs). Unlike the case with live attenuated vaccines, there is no possibility of 
infection. Salmonella GMMA remain to be evaluated in humans, but Shigella sonnei 
GMMA have shown to be safe and immunogenic in Phase 1 trials in adults [115, 
116]. GMMA are produced through a simple and low cost process, that make this 
technology particularly suited for the development of vaccines for low- and middle-
income countries, where the cost of production is a key consideration [69, 70]. 
 
1.7 Development of a vaccine against iNTS in GVGH 
 
GSK Vaccines Institute for Global Health (GVGH) [117] is working at the 
development of a vaccine against iNTS [25, 32]. Two approaches, both OAg-based, 
have been evaluated. The first approach is based on glycoconjugation, where S. 
Typhimurium and S. Enteritidis OAg are independently linked to CRM197 as carrier 
protein. The second approach is represented by the development of a bivalent 
formulation of S. Typhimurium and S. Enteritidis GMMA. 
 
1.7.1 OAg-CRM197 conjugate vaccines 
 
GVGH has developed a simplified method for OAg extraction and purification 
[118]. In the adopted strategy, the labile linkage between the KDO of the core region 
and the lipid A is cleaved directly in the bacterial growth medium by acetic acid 
hydrolysis. The OAg, still linked to the core oligosaccharide, is then easily purified 
from the cells and used for the production of conjugate vaccines. In this way, LPS 
purification from bacterial membranes, a very time consuming process that makes use 
of hazardous chemicals, is avoided. The conjugation approach used involves the 
terminal KDO sugar, without affecting the OAg sugar chain [106] (Fig. 5). 
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Fig. 5. Glycoconjugation technology for the synthesis of OAg-CRM197 conjugates developed in 
GVGH. 
 
Different S. Typhimurium and S. Enteritidis strains, as source of OAg, were 
screened to identify the most suitable and appropriate strains for large scale OAg 
production and generation of conjugates [119]. It was found that OAg structural 
characteristics, such as chain length, O-acetylation and glucosylation level and 
position can affect the immunogenicity of corresponding glycoconjugate vaccines 
[77] as well as OAg/carrier protein ratios, conjugation chemistry involved [107, 120] 
and glycosylation sites in which the carrier protein is attached to the OAg [121]. 
 
1.7.2 GMMA vaccines 
 
GMMA are naturally released from the surface of NTS bacteria, but the natural 
shedding is too low to be useful for vaccine production (Fig. 6). 
 
 
 
Fig. 6. Schematic representation of GMMA blebbing from the outer membrane of Gram-negative 
bacteria. 
 
NTS parent strains have been genetically modified to increase shedding [114, 122]. 
Additional genetic modifications have been introduced into S. Typhimurium and S. 
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Enteritidis parent strains to reduce lipid A toxicity [123, 124]. Several mutated NTS 
strains have been tested to identify the most suitable GMMA producers. 
 
1.8 Description of research aims 
 
In the context of the development of a bivalent vaccine against iNTS, this project 
had three main objectives: 
 
1) full characterization of the OAg component of GMMA produced by mutated 
strains of S. Typhimurium and S. Enteritidis to verify the impact that 
mutations introduced to increase GMMA production and reduce reactogenicity 
can have on the key target antigen for inducing an immune response against 
iNTS; 
 
2) determination of the particle size distribution of NTS GMMA, by use of 
different techniques suitable for size measurements; 
 
3) investigation on the presence and the structure of the terminal KDO unit at the 
reducing end of the OAg chain after direct extraction on bacteria and study of 
its reactivity and selectivity in the synthesis of OAg-CRM197 glycoconjugate 
vaccines. 
 
All these objectives have as main targets the improvement of technologies for the 
production and the development of analytical methods for the characterization of 
vaccines against iNTS. 
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2. Characterization of OAg delivered by Generalized Modules 
for Membrane Antigens (GMMA) vaccine candidates against 
iNTS 
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2.1 Introduction 
 
Salmonella enterica Typhimurium and Enteritidis are the most common serovars 
responsible for invasive nontyphoidal Salmonella disease (iNTS) in Africa [21, 22, 
26, 31, 32], resulting in case-fatality rates of around 20% [36]. iNTS is closely 
associated with malaria and malnutrition among African infants and children and with 
HIV infection in all age groups [14]. Antibiotics are not always available in rural 
African settings, and increasing levels of multidrug-resistance are limiting their 
effectiveness [34, 67, 68], making this disease a high priority for vaccine 
development. Currently, there are no licensed vaccines against iNTS and efforts are 
ongoing to identify protective antigens and best strategies for vaccine development 
[25, 28, 32]. 
Antibodies directed against the OAg portion of Salmonella LPS have been shown 
to be able to mediate killing [76-78, 125, 126] and protect against infection in animal 
models [77, 78, 80]. S. Typhimurium and S. Enteritidis OAg share a common 
backbone consisting of mannose (Man), rhamnose (Rha) and galactose (Gal), which 
serologically constitutes epitope O:12 [127]. A different 3,6-dideoxy-hexose residue 
is linked to Man in these two serovars: abequose (Abe), conferring O:4 specificity to 
S. Typhimurium or tyvelose (Tyv), conferring O:9 specificity to S. Enteritidis [128, 
129] (Fig. 7). 
 
 
 
Fig. 7. OAg repeating unit structure of (a) S. Typhimurium (O:4,5) and (b) S. Enteritidis (O:9) [128, 
129]. 
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Salmonella OAg can demonstrate high levels of heterogeneity in terms of chain 
length and variation in O-acetylation and glucosylation of the repeating units [77, 
119, 130-132]. For S. Typhimurium, Abe may be O-acetylated at position C-2, which 
adds O:5 specificity [133]. The additional presence of O-acetyl groups at C-2 and C-3 
of Rha has also been reported [130, 131, 134]. OAg chains can also be variably 
glucosylated, with glucose (Glc) linked at C-4 (O:122 specificity) or C-6 (O:1 
specificity) to Gal [130, 135]. Studies in mice indicated that all these structural 
modifications can impact the immunogenicity of the corresponding glycoconjugate 
vaccines [77, 119]. 
GVGH is investigating the Generalized Modules for Membrane Antigens 
(GMMA) [114] approach for the development of a bivalent vaccine against S. 
Typhimurium and S. Enteritidis [124]. In Salmonella, deletion of the tolR gene has 
been used to increase blebbing. Such mutation affects the stability of the linkage 
between the inner and the outer membrane, and results in an enhanced shedding 
process [114, 115, 122-124]. GMMA derived from the surface of Gram-negative 
bacteria contain potent immunostimulatory components, such as lipoproteins and 
LPS, which can contribute to their immunogenicity, but also to reactogenicity [136, 
137]. In GMMA vaccine development, removal or modification of such components 
may alter the balance between reactogenicity and immunogenicity. One way of 
detoxifying LPS, the most abundant immunostimulatory component on GMMA, is to 
modify its acylation pathway, for example by deletion of msbB, pagP and htrB genes 
[115, 123, 124]. A lipid A with a decreased number of fatty acid chains bound 
through ester and amide linkages at the sugar component of LPS resulted in a 
substantially reduced ability of NTS GMMA to stimulate cytokine release from 
human peripheral blood monocytes (PBMC) [123, 124]. Deletions of genes encoding 
the late acyltransferase enzymes msbB, pagP, and htrB result in the removal of acyl 
groups from the wild type mixture of hexa- and hepta-acylated lipid A, obtaining a 
pure penta-acylated lipid A. A strongly reduced stimulation of human Toll-like 
receptor 2 (TLR2) and 4 (TLR4) was showed by GMMA of ΔmsbB and ΔpagP 
mutants S. Enteritidis and S. Typhimurium [124]. The steps of removal of acyl chains 
and consequent reduced reactogenicity applied to Salmonella were different with 
  
SDBM - School of 
Molecular Biomedicine 
 
 
21 
 
respect to other Enterobacteriaceae genus members like Shigella [138]. Salmonella 
wild type lipid A is constituted by a mixture of hepta- and hexa-acylated lipid A 
molecules (Fig. 8-a). The enzyme involved in the production of hepta-acylated lipid A 
is the acyltransferase pagP, which transfers a palmitoyl (C16:0) chain in the 
secondary position of the hydroxymyristate chain at position 2 in the classical wild 
type hexa-acylated lipid A [139]. Acyl transferase msbB [140, 141] transfers a 
secondary myristoyl (C14:0) chain in position 2’ and deletion of its encoding gene in 
both S. Enteritidis and S. Typhimurium resulted in a mixture of penta-acylated and 
hexa-acylated lipid A molecules (Fig. 8-b). After the deletion of the pagP gene in the 
msbB mutant, a pure penta-acylated lipid A in line with lack of palmitoylation due to 
the absence of pagP was obtained (Fig. 8-c). Acyl transferase htrB [142], which 
transfers a secondary lauroyl (C12:0) chain in position 3’, was deleted either in S. 
Enteritidis and S. Typhimurium and resulted in a variety of lipid A forms (Fig. 8-d). A 
mixture of penta-acylated lipid A species lacking the lauroyl chain from the wild type 
lipid A were observed, together with a pleiotropic effect, resulting in the replacement 
of the lauroyl chain with a palmitoleoyl chain. Thus ΔhtrB mutants, in addition to the 
presence of penta-acylation, were also characterized by a mixture of hexa- and hepta-
acylated species with the compensatory presence of palmitoleoyl chains respect to the 
hexa- and hepta-acylated wild type lipid A. 
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Fig. 8. Salmonella lipid A structures obtained after deletion of msbB (b) , pagP (c), and htrB (d) gene 
deletions to the wild type lipid A (a). 
 
Genetic mutations introduced in S. Typhimurium and S. Enteritidis strains to 
increase GMMA release and decrease reactogenicity could impact the expression of 
OAg chains, as well as result in changes of OAg structure. In this chapter, a panel of 
analytical methods was put in place for GMMA characterization, with particular 
attention to the OAg component. GMMA produced from different mutated strains 
were fully characterized and were tested in mice, with the aim to evaluate how 
mutations introduced can impact on OAg structure and GMMA immune response. 
 
2.2 Materials and Methods 
 
2.2.1 NTS parent strains for GMMA production 
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Salmonella enterica serovar Enteritidis SA618 (SEn 618) (CEESA EASSA II 
collection [143] of Quotient Bioresearch Limited) and Typhimurium isolate 
SGSC1418 (STm 1418) (LT-2 collection [144], University of Calgary), both isolated 
from animals, were chosen as parent strains [119]. Mutants (Scheme 1) were 
generated by GVGH staff as described by Rossi et al. [124]. 
 
 
 
Scheme 1. GMMA of S. Enteritidis and S. Typhimurium mutated strains chosen for characterization 
[124]. 
 
To generate mutants, the kanamycin resistance gene aph was used to replace the tolR 
gene, the chloramphenicol resistance gene cat was used to replace the htrB and pagP 
coding sequences, and the tetracycline resistance cassette tetRA was used to replace 
the msbB gene. The desired resistance cassette replacement constructs were amplified 
using forward and reverse primers composed of approximately 50 bp homologous to 
the flanking regions of the gene to be deleted and approximately 20 bp at the 3’ end 
matching the flanking region of the respective resistance gene. Approximately 2 µg of 
linear PCR product (purified using PCR purification Qiagen kit following 
manufacturer recommendations) were used for integration onto the chromosome of 
recombination-prone Salmonella recipient cells by following methods described 
previously [114, 145]. A modification of the lambda red method was used 
(pBADλred induced with 0.2% arabinose, for preparation of electro competent cells). 
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2.2.2 GMMA production and characterization 
 
GMMA were produced and purified as described [124]. Bacterial strains were 
routinely grown at 30 °C in liquid or on solid Luria-Bertani medium without salt 
(LBON). For GMMA production, overnight cultures were grown in the presence of 
the selective antibiotics, e.g., kanamycin (30 µg/mL), chloramphenicol (20 µg/mL), 
or tetracycline (20 µg/mL), and were used to inoculate the production medium 
(without antibiotics) to an optical density (OD) at 600 nm of 0.03 to 0.05. Production 
cultures were incubated at 30 °C and 200 rpm overnight. Culture supernatants were 
collected by centrifugation for 10 min at 5,000 x g, followed by 0.22 µm filtration. 
GMMA were concentrated using an Amicon stirrer cell with a regenerated cellulose 
filter with a nominal molecular size limit of 100 kDa (Amicon Ultracell) under a 
nitrogen flow, or a TFF (cut off 100 kDa) was performed. The retentate was collected 
in 70-mL propylene ultracentrifuge tubes (Beckman Coulter) and was ultracentrifuged 
at 186,000 x g for 2 h at 4 °C using a Ti rotor (Beckman Coulter). Additionally, S110-
AT 2121 (100000 rpm, 30 min, 4 °C) or S50-A 2109 (50000 rpm, 1 h, 4 °C) rotors on 
a Sorvall MX Plus Micro-Ultracentrifuge (Thermo Fisher) were used. Pellets were 
suspended in phosphate-buffered saline (PBS), followed by 0.22 µm filtration. 
GMMA were stored at 4 °C. 
GMMA samples were analysed by HPLC-SEC with Sepax SRT-C 2000-1000 
columns in series equilibrated in PBS and with in-line UV, fluorescence emission, 
dRI and MALS detectors. A volume of 80 L of samples with a concentration of 100 
g/mL protein content was injected and eluted with a flow rate of 0.5 mL/min. MALS 
data were collected and analysed using ASTRA 6 software (Wyatt Technology). 
GMMA quantities were expressed as the total protein content present in GMMA 
quantified using the Detergent Compatible (DC) protein assay (Bio-Rad), which is 
based on the Lowry assay [146, 147]. A 2 mg/mL solution of serum bovine albumin 
(BSA) was used to create a calibration curve in the 9.0 to 60.0 µg/mL range. Samples 
were diluted with phosphate buffered saline (PBS, 140 mM NaCl, 2.7 mM KCl, 20 
mM (PO4)
3-) in order to obtain sample protein concentration in the range of the 
calibration curve. Samples and calibration curves were created in duplicates and to a 
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final volume of 400 µL. CTC solution was prepared mixing 3 mL of 0.4% potassium 
tartrate/0.2% cupric sulphate solution and 3 mL of 20% sodium carbonate solution. 
Folin reactive was prepared mixing 1 mL of Folin Ciocalteaus solution and 5 mL of 
MilliQ water. Reagent A was prepared just before use. A volume of 400 µL of 
Reagent A (6 mL CTC solution + 6 mL SDS 10% + 6 mL 0.8 N NaOH + 6 mL 
MilliQ water) were added to each samples. Samples were vortexed and added of 200 
µL of Folin Reactive. Samples were incubated for 75 minute at room temperature 
(RT). Samples were analysed using a spectrophotometer and absorbance was 
measured at 750 nm. 
OAg sugar content was quantified by High-Performance Anion-Exchange 
Chromatography coupled to Pulsed Amperometric Detector (HPAEC-PAD) [106, 
130], after performing acid hydrolysis directly on GMMA. GMMA components did 
not interfere in the quantification of the OAg sugar monomers. Rha, Gal, Glc, and 
Man, each occurring once in the OAg chain repeating unit, and N-acetyl glucosamine 
(GlcNAc), a sugar uniquely present in the core oligosaccharide region, were estimated 
by HPAEC-PAD after acid hydrolysis of the OAg to release the monosaccharides. 
Commercial monomer sugars were used for building the calibration curves. For Rha, 
Gal, Glc, Man and GlcNAc quantification, OAg samples, diluted to have each sugar 
monomer in the range 0.5-10 µg/mL, were hydrolysed at 100 °C for 4 h in 2 M 
trifluoroacetic acid (TFA). This hydrolysis condition was optimal for release of all 
monomers without their degradation. For GlcNAc quantification, OAg samples, 
diluted to have a GlcNAc concentration in the range 0.5-10 µg/mL, were hydrolysed 
at 100 °C for 6 h in 1 M TFA. After the hydrolysis, samples were chilled at 2-8 °C for 
about 30 min, dried by SpeedVac overnight, reconstituted in MilliQ water, and 
filtered using 0.45-µm Acrodisc (PALL) filters before chromatographic analysis. 
HPAEC-PAD was performed with a Dionex ICS3000 equipped with a CarboPac 
PA10 column (4 x 250 mm) coupled with a PA10 guard column (4 x 50 mm). 
Separation of the sugars was performed with a flow rate of 1 mL/min, eluting in a 
gradient from 10 to 18 mM NaOH over 20 min. After being washed for 20 min with 
100 mM AcONa in 28 mM NaOH, the column was re-equilibrated with 10 mM 
NaOH for 20 min. The effluent was monitored using an electrochemical detector in 
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the pulsed amperometric mode with a gold working electrode and an Ag/AgCl 
reference electrode. The Dionex standard quadruple-potential waveform for 
carbohydrates was used. The resulting chromatographic data were processed using 
Chromeleon software 6.8. Calibration curves were built for each sugar monomer (0.5-
10 µg/mL). The standards were hydrolysed and analysed in the same way as samples. 
For GlcNAc, glucosamine was the species detected by HPAEC-PAD after hydrolysis. 
The amount of core oligosaccharide reducing end unit, KDO (2-keto-3-deoxy-
octonate) was assumed equal to the amount of lipid A and quantified by 
semicarbazide/High Performance Liquid Chromatography - Size Exclusion 
Chromatography (HPLC-SEC) method after sugar extraction [130]. OAg samples 
were analysed by HPLC-SEC after derivatization with semicarbazide to quantify α-
ketoacid present at the reducing end. This reaction was performed as a slight 
modification of the semicarbazide assay for α-ketoacid determination [148]. OAg 
samples and KDO standards (100 µL of total volume in water), with a C=O 
concentration between 15.7 and 156.7 nmol/mL, were added to 100 µL of 
semicarbazide solution (100 mg semicarbazide hydrochloride + 90.5 mg of sodium 
acetate anhydrous in 10 mL of MilliQ water). Sample blanks were prepared by adding 
100 µL of sodium acetate (90.5 mg of sodium acetate anhydrous in 10 mL of MilliQ 
water) to 100 µL of the OAg samples at the same concentration used for the analysis. 
All samples and standards were heated at 50 °C for 50 min and then analysed by 
HPLC-SEC (80 µL injected), on a TSK gel G3000 PWXL column with guard column 
in 0.1 M NaCl, 0.1 M NaH2PO4, 5% CH3CN, pH 7.2, mobile phase at the flow rate of 
0.5 mL/min (isocratic method for 30 min). Detection was done at 252 nm. The peak 
area corresponding to OAg after derivatization with semicarbazide was corrected by 
subtracting the area of the corresponding blank. The amount of KDO was calculated 
using the calibration curve built with the peak areas of derivatized KDO standard at 
252 nm. The percentage of OAg chains was calculated as the molar ratio of their 
KDO divided by total KDO, including low molecular mass LPS molecules, including 
those containing only the core oligosaccharide without OAg repeating units. 
NMR analysis on the liquid state was performed to confirm the identity of the OAg 
samples by detecting typical signals of the OAg chain, confirming the presence of the 
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characteristic sugars, as well as for calculating the molar ratio of Tyv or Abe to Rha, 
by comparing the integrals of the two peaks corresponding to Tyv or Abe H-6 and 
Rha H-6 [130]. Dried OAg samples (2.5 mg total sugar) were solubilized in 650 µL 
deuterated water (D2O, Sigma-Aldrich) and transferred to 5-mm NMR tubes. Proton 
NMR experiments were recorded at 25 °C on a Varian VNMRS-500 spectrometer, 
equipped with a Pentaprobe. Acquisition time of 5 s, relaxation delay of 15 s, and 
number of scans of 64 were set for recording the spectra. For data acquisition and 
processing VNMRJ version 2.2 revision C and Mestrenova 6.1 (Mestrelab Research) 
were used, respectively. One-dimensional proton NMR spectra were collected using a 
standard one-pulse experiment. Chemical shifts were referenced to hydrogen 
deuterium oxide (HDO) at 4.768 ppm (1H). De-O-acetylation was performed by 
addition of sodium deuteroxide (NaOD, Sigma-Aldrich) to the tube containing the 
sample in D2O. 
Lipid A structures were investigated by Matrix-Assisted Laser 
Desorption/Ionization-Mass Spectrometry (MALDI-MS) [124]. 
Protein pattern profile was analysed by Sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) analysis. GMMA samples were analysed using 10% 
Bis-Tris gel (NuPAGE, Invitrogen). Samples (5 and 10 µg GMMA protein) were 
mixed with 0.5 M dithiothreitol (1/5 v/v), NuPAGE LDS sample buffer (1/5 v/v) and 
heated at 100 °C for 10 min. The gel, containing loaded samples, was electrophoresed 
at 80 mA in NuPAGE MOPS SDS running buffer (20x, Invitrogen) and stained with 
Brilliant Blue G - Colloidal Concentrate, Electrophoresis Reagent (Sigma). 
 
2.2.3 OAg purification and characterization 
 
OAg extraction and purification from wild type bacteria was performed as 
previously described [118]. For extraction of the OAg from GMMA, a similar 
procedure was used: mild acid hydrolysis (v/v 2% acetic acid at 100 °C for 1 h) was 
performed directly on the GMMA suspension (protein concentration of 1 mg/mL) to 
cleave the acid-labile KDO-lipid A linkage. The OAg chains released into the 
supernatant were recovered after centrifugation (14000 rpm, 1 h, 4 °C). The acidic 
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supernatant was evaporated under reduced pressure and washed 3 times with water, in 
order to remove the residual acetic acid, and then freeze-dried. Gel filtration 
chromatography with differential refractive index (dRI, WGE Dr. Bures Δn-1000, 
Labservice Analytica) detection was used to fractionate the OAg chains obtained after 
extraction from GMMA. Samples were separated on Sephacryl S-300 column (90 cm 
x 1.6 cm i.d., GE Healthcare Life Sciences). The mobile phase was NaNO3 0.05 M at 
the flow rate of 8 mL/h. Fractions from Sephacryl S-300 were collected at 15 min 
intervals and were desalted by gel filtration chromatography on Biogel P-2 column 
(90 cm x 1.6 cm i.d., flow rate 8 mL/h, Bio-Rad) or on a Bioline preparative 
chromatographic system equipped with Superdex 30 Prep Grade column (90 cm x 1.0 
cm i.d., flow rate 1.5 mL/min, GE Healthcare Life Sciences) and dRI (Smartline 
2300, Knauer). OAg structural analysis on OAg populations purified following gel 
filtration chromatography was performed as reported in the previous paragraph by 
HPAEC-PAD, HPLC-SEC after derivatization with semicarbazide, 1H NMR and 
phenol sulphuric acid assay. 
Sugar composition analysis of OAg either from SEn 618 and STm wild type 
strains and GMMA produced by SEn 618 and STm 1418 mutants was also performed 
by gas liquid chromatography (GLC), after hydrolysis of the polysaccharides with 2 
M TFA at 125 °C for 1 h, and derivatization to alditol acetates [149]. The sugar 
linkage positions were determined by GLC coupled to mass spectrometry (GLC-MS) 
after per-methylation of the samples, hydrolysis with 2 M TFA at 125 °C for 1 h, 
followed by reduction and per-acetylation to obtain the partially methylated alditol 
acetates (PMAA) derivatives [150]. Peak areas were corrected by using the effective 
carbon response factors [151]; for Tyv and the response factor of 6-deoxy hexose 
were applied. Determination of the absolute configuration of the sugar residues of 
OAg samples was performed as described by Gerwig et al [152]. Trimethylsilylated 
(+)-2-butyl methyl glycosides were obtained by derivatization with the reagent 
Sylon™ HTP (Sigma) after methanolysis of the polysaccharide with 2 M HCl in 
methanol at 85 °C for 16 h and after butanolysis in 1 M HCl in S-(+)-2-butanol for 16 
hr at 80 °C. In order to determine the position of the O-acetyl groups, the O-
polysaccharides were per-methylated following the method of Prehm [153], which 
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leaves the O-acetyl groups in their native positions. Samples were then treated as 
above to obtain the PMAA derivatives, which were then analysed by GLC and GLC-
MS. Analytical GLC was performed on a Perkin Elmer Autosystem XL gas 
chromatograph equipped with a flame ionization detector (FID) and a SP2330 
capillary column (Supelco, 30 m), using He as carrier gas. The following temperature 
programs were used: for alditol acetates, 200 °C 1 min, 200-245 °C at 4 °C/min; for 
PMAA on SP2330 column, 150-245 °C at 2 °C/min and on HP-1 column (Agilent 
J&W, 30 m), 150-245 °C at 2 °C/min. Separation of the Trimethylsilylated (+)-2-
butyl glycosides, for determining the absolute configuration of the sugars, was 
obtained on a HP-1 column, using the following temperature program: 50 °C 1 min, 
50-130 °C at 45 °C/min, hold 1 min, 130-200 °C at 1 °C/min, hold 10 min. GLC-MS 
analyses were carried out on an Agilent Technologies 7890A gas chromatograph 
coupled to an Agilent Technologies 5975C VL MSD. The following temperature 
programs were used: for PMAA on SP2330 column, 150 °C for 2’, 150-250 °C at 2 
°C/min, at 245 °C for 20’and on HP-1 column, 140 °C for 1’, 140-280 °C at 5°C/min, 
at 280 °C for 30’. 
OAg peak molecular weight (MW) was calculated after HPLC-SEC analysis and 
using a calibration curve obtained with standard dextrans (12-150 kDa) having 
different peak MW on TSK gel G3000 PWXL column (30 cm x 7.8 mm; particle size 
7 µm, Tosoh Bioscience) and with in-line dRI detector. A volume of 80 µL of 
samples with a concentration of 100 µg/mL polysaccharide content was injected and 
eluted at the flow rate of 0.5 mL/min with 0.1 NaCl, 0.1 NaH2PO4, 5% CH3CN, pH 
7.2 as mobile phase. 
 
2.2.4. Immunogenicity of candidate Salmonella GMMA vaccines in mice and 
serological analysis 
 
Five groups of eight 5-weeks old female CD1 mice were purchased from Charles 
River Laboratory and maintained at GSK Vaccines Animal Care Facility. Mice 
received two subcutaneous immunizations at 28 days interval with 200 µL/dose of 1 
µg of OAg formulated with Alhydrogel (final concentration 0.7 mg/mL Al3+). Mice 
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were bled before the first immunization (sera pooled for each group at day 0) and at 
days 14, 28 and 42 after the first immunization (collected as single sera). All animal 
protocols were approved by the local animal ethical committee (approval N. 
AEC201309) and by the Italian Minister of Health in accordance with Italian law and 
immunizations and bleeds were done by GSK Animal Care Facility. Individual mouse 
sera, collected at each time point, were tested for anti-OAg IgG antibody titers by 
ELISA by the GVGH Immunoassay Unit, as described by Lanzilao et al [119]. For 
each group, equal volumes of sera collected at day 42 from each mouse were pooled 
and tested for serum bactericidal activity (SBA) against S. Typhimurium D23580, an 
endemic clinical isolate from Malawi [67, 125], obtained from the Malawi-Liverpool-
Wellcome Trust Clinical Research Programme, Blantyre, Malawi, or against the 
laboratory strain S. Enteritidis CMCC4314, (corresponding to ATCC4931) obtained 
from the Novartis Master Culture Collection (NMCC), as previously described [119]. 
Bactericidal activity was determined by the GVGH Immunoassay Unit as serum 
dilutions necessary to obtain 50% colony forming units (CFU) reduction after 3 hours 
incubation at 37 °C, compared with CFU counted at time 0. To evaluate possible 
nonspecific inhibitory effects of baby rabbit complement (BRC) or mouse serum, 
bacteria were also incubated with SBA buffer and active BRC as negative control, 
and with pooled sera from a control placebo group diluted at the same dilutions of test 
sera (starting from 1:100) with active BRC. For all negative controls killing effect 
was not observed up to the highest serum concentration tested of 1:100 (assay’s 
baseline). 
Statistical and graphical analysis was performed using GraphPad Prism 6 software. 
The non-parametric Mann-Whitney test (two-tailed) and Kruskal-Wallis analysis with 
Dunn’s test for post hoc analysis were used to compare two or multiple groups, 
respectively. Response at day 14 and 42 for each group was compared by Wilcoxon 
matched-pairs signed rank test (two-tailed). 
 
2.3 Results 
 
As part of a previous work carried out at GVGH, several different S. Typhimurium 
and S. Enteritidis isolates were screened as sources of OAg for use in a bivalent 
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glycoconjugate vaccine against iNTS [119]. Based on the results obtained, SEn 618 
and STm 1418 strains were selected for use as GMMA-producing strains. They were 
genetically modified through deletion of tolR gene for GMMA overproduction and of 
further genes (ΔmsbB, ΔhtrB and ΔpagP) to reduce reactogenicity [124]. Some of the 
resulting GMMA (Scheme 1) were fully characterized and tested in mice. 
Interleukine-6 (IL-6) release was used as an indicator for proinfiammatory responses 
to Toll-like receptors (TLR) stimulation. The combination of ΔmsbB and ΔpagP 
mutations provoked the least stimulation of cytokine release from human PBMC 
compared to GMMA with wild type lipid A. The residual activity was largely due to 
TLR2 activation, although GMMA significantly signalled through TLR4 [124]. 
 
2.3.1 OAg characterization of SEn 618 wild type bacteria 
 
OAg from SEn 618 wild type bacteria was fully characterized and used as 
reference structure for comparison with OAg present on GMMA obtained from 
genetically modified GMMA-producing strains, in order to examine how mutations 
impacted on structural features. SEn 618 OAg exhibited high levels of purity, with 
protein and nucleic acid content <1% (w/w respect to sugar content) and endotoxin 
level <0.1 EU/µg of sugar, indicating complete removal of the lipid A. The OAg was 
characterized by one main population with average MW of 29.6 kDa. Based on the 
average number of repeating units (RU) and the mass contribution from O-
acetylation, the average MW was 18.9 kDa. The average number of RU was 
determined from the molar ratio of Rha (OAg chains sugar) and GlcNAc (core region 
sugar) from sugar composition analysis by HPAEC-PAD, the level of O-acetylation 
was determined by 1H NMR analysis.  
Composition analysis by HPAEC-PAD revealed the presence of Rha, Gal, and 
Man, the sugars constituting the backbone of the OAg chain, in a ratio 1:1:1, while a 
glucosylation level of 0.19 was found. This composition was confirmed by GLC 
analysis of the alditol acetates derivatives [149] (Table 1). In the absence of a 
monomer standard, Tyv was identified by GLC-MS and quantified by 1H NMR which 
yielded the expected molar ratio of 1:1 with respect to Rha. 
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Table 1. Sugar composition of SEn 618 wild type OAg by GLC and by 
HPAEC-PAD. 
Residues 
Molar ratios 
by GLC by HPAEC-PAD 
Rha 1.00 1.00 
Man 1.05 1.00 
Gal 1.04 1.08 
Glc 0.21 0.19 
 
The linkage positions for the constituent sugars of the OAg sample were 
determined by GLC and GLC-MS of the partially-methylated alditol acetate (PMAA) 
derivatives [150] (Table 2). As expected [129], the OAg chain contained terminal 
non-reducing 3,6-dideoxyhexose (t-Tyv), 4-linked Rha (4-Rha), 3-linked galactose (3-
Gal), 2,3-linked mannose (2,3-Man). As it was seen in other Salmonella strains 
analysed [130], the most intense signal of 4-Rha overlapped with the signal arising 
from terminal non-reducing glucose (t-Glc). The analysis of the PMAA derivatives on 
a non-polar column (HP-1, Agilent J&W, 30 m) allowed identification of a small 
amount of t-Glc. In addition, a similar small amount of 4-linked glucose (4-Glc) was 
found, indicating that short Glc chains can be linked to Gal, as reported for S. 
Enteritidis OAg [129]. 
 
Table 2. Glycosidic linkages in SEn 618 wild type OAg obtained by GLC-MS of PMAA derivatives 
on HP-1 column. 
OAg 
monosaccharides 
t-Tyv 4-Rha t-Glc 4-Glc 3-Gal 3,4-Gal* 2,3-Man 
Molar ratios 0.26 1.00 0.08 0.05 0.93 0.12 1.04 
*GLC on SP2330 column (Not integrable in HP-1 chromatogram). 
 
In order to determine the position of O-acetyl groups detected in the 1H NMR 
spectrum, the OAg was permethylated following the procedure reported by Prehm 
[153], which allows the retention of the O-acetyl groups in their native positions. 
Analysis of the corresponding PMAA derivatives was performed by GLC and GLC-
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MS. Comparing the chromatograms of the PMAA obtained with (Fig. 9-A) and 
without (Fig. 9-B) retention of the O-acetyl groups, a small amount of 2,4-Rha was 
present, in addition to the expected 4-Rha, indicating partial esterification with acetyl 
substituents of the 4-linked Rha on C-2 (data from GLC on SP2330 column, Supelco, 
30 m). 
 
 
 
Fig. 9. Comparison of GLC chromatograms of the PMAA derivatives obtained with (A) and without 
(B) retention of the native O-acetylation positions. The numbers indicate the position of glycosidic 
linkages. Major peak assignments are reported and the acetylated residue is reported in bold. 
 
Analysis of the OAg by 1H NMR (Fig. 10) showed two singulets at 2.16 and 2.20 
ppm designed as O-acetyl groups after treatment with NaOD 200 mM, with an O-
acetylation level close to 16%. By comparison with OAg from S. Typhimurium 
D23580 [130], it is possible to assign the two methyl signals of O-acetyl groups on C-
2 and C-3 of Rha. Anomeric protons were assigned after inspection of the COSY and 
TOCSY plots (data not shown). 
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Fig. 10. 1H NMR spectrum of the OAg purified from S. Enteritidis 618 wild type, with emphasis on the 
O-acetyl groups identified. 
 
GLC analysis of the chiral glycosides of the OAg sample showed that the hexoses 
were in the D absolute configuration and Rha in the L absolute configuration. This 
analysis could not be performed for Tyv due to the lack of a standard. 
All results obtained are consistent with the structure previously reported for S. 
Enteritidis OAg [129] (Fig. 1). 
 
2.3.2 OAg characterization of SEn 618 GMMA 
 
After the complete characterization of the OAg extracted from SEn 618 wild type, 
the structure of OAg chains present on the surface of GMMA produced by the 
mutated strains of SEn 618 were investigated. HPLC-SEC fluorescence emission 
profile of GMMA samples from all mutated strains revealed very low residual soluble 
proteins (< 5%), indicating good sample purity (Fig. 11). 
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Fig. 11. HPLC-SEC chromatogram of GMMA from SEn 618 ΔtolR strain (fluorescence emission 
profile; Sepax SRT-C 2000-1000 columns; PBS; 0.5 mL/min; 80 µL injected of GMMA 100 µg/mL 
protein content; V0 8.992 min; Vtot 17.033 min). 
 
The particle size of GMMA from SEn 618 mutated strains was similar, as 
estimated by HPLC-SEC analysis coupled with MALS detector (Table 3). The w/w 
ratio of OAg chains per mg of total protein was high for all SEn 618 GMMA. OAg 
chains constituted a low percentage of total LPS molecules containing core 
oligosaccharide, indicating that a large proportion of LPS molecules contain very few 
or no OAg repeating units (Table 3). 
 
Table 3. Characterization of GMMA from SEn 618 mutated strains. 
GMMA 
w/w 
OAg/GMMA 
protein ratio 
molar % 
OAg chains/total 
LPS 
nmol 
lipid A/mg 
GMMA protein 
nm radius 
(MALS) 
SEn 618 ΔtolR 0.6 14 156.6 22 
SEn 618 ΔtolR ΔmsbB 1.7 22 240.1 23 
SEn618 ΔtolR ΔmsbB 
ΔpagP 1.5 12 528.0 20 
 
Analysis by SDS-PAGE performed by on SEn 618 ΔtolR ΔmsbB ΔpagP GMMA 
(Fig. 12) showed no major changes in the protein pattern compared to GMMA with 
no lipid A modification (ΔtolR). 
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Fig. 12. SDS-PAGE protein profile of GMMA from SEn 618 ∆tolR (A), SEn 618 ∆tolR ∆msbB ∆pagP 
(B), 1418 ∆tolR (C), 1418 ∆tolR ∆htrB (D) and 1418 ∆tolR ∆msbB (E) strains. 10 µg (left side) and 5 
µg (right side) GMMA protein were loaded on a 10% SDS-PAGE gel. 
 
Following sugar extraction by acetic acid hydrolysis of GMMA suspensions, OAg 
populations were isolated by size exclusion chromatography and compared to the 
OAg populations purified from the wild type strain (Fig. 13). OAg populations from 
all GMMA and wild type strain showed a similar average number of repeating units 
close to 25. GMMA produced by ΔtolR single-mutant SEn 618 expressed a distinct 
additional OAg population of relatively higher molecular weight (MW), with an 
average of 70 repeating units. This population appeared to be present also as a 
shoulder in the HPLC-SEC profile of the OAg from the wild type strain (Fig. 13). The 
two OAg populations at different MW from ΔtolR GMMA were quantified by the 
phenol-sulphuric acid assay. The higher MW (HMW) and lower MW (LMW) 
fractions represented 22% and 44% respectively of the total amount of sugar 
extracted. For GMMA derived from the other two 618 mutant strains, OAg chains 
accounted for 75% (ΔtolR ΔmsbB) and 68% (ΔtolR ΔmsbB ΔpagP) of total sugar 
extracted. These percentages are in agreement with the molar ratios of OAg chains to 
total LPS molecules found (Table 3). 
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Fig. 13. HPLC-SEC chromatograms of OAg populations extracted from GMMA produced by mutated 
strains of SEn 618 and compared to OAg purified from the wild type SEn 618 isolate (dRI profiles; 
TSK gel 3000 PWXL column; NaPi 100 mM NaCl 100 mM 5% CH3CN pH 7.2; 0.5 mL/min; V0 11.20 
min; Vtot 23.29 min). 
 
All OAg populations derived from all mutated as well as wild type SEn 618 strains 
revealed similar sugar composition by HPAEC-PAD and NMR (Table 4), in 
agreement with that expected for S. Enteritidis OAg [129]. All samples were 
characterized by low glucosylation levels of 8-11%, compared to 19% for the wild 
type OAg (Table 4). 
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O-acetylation levels were low for all GMMA OAg samples and decreased with the 
addition of mutations into the GMMA-producing strain, from 16% found in the wild 
type (non-GMMA) OAg to 2% for the OAg purified from the ‘triple-mutant’ GMMA 
(Fig. 14). HMW OAg from SEn 618 ΔtolR GMMA had an O-acetylation level of 4% 
(Table 4). 
 
Table 4. Characterization of OAg populations extracted from GMMA produced by SEn 618 mutated 
strains and comparison with the OAg from the corresponding wild type strain. Sugar composition 
(molar ratio relative to Rha) and average number of repeating units (RU) were calculated by HPAEC-
PAD and HPLC-SEC/semicarbazide (assay for KDO quantification). O-acetylation (O-Ac) level was 
obtained from integration of the peak area of methyl signals of O-acetyl groups of 1H NMR spectra. 
OAg Tyv* Rha Man Gal Glc 
Number RU 
(peak MW**) 
O-Ac % 
SEn 618 wild type 1.00 1.00 1.00 1.08 0.19 
28 (HMW 88.3; 
LMW 27.3) 
16 
SEn 618 ΔtolR 
(HMW OAg) 
0.99 1.00 1.04 1.05 0.12 70 (90.3) 8 
SEn 618 ΔtolR 
(LMW OAg) 
0.93 1.00 0.99 1.07 0.11 23 (30.3) 4 
SEn 618 ΔtolR ΔmsbB 0.97 1.00 1.00 1.05 0.09 26 (30.4) 3 
SEn 618 ΔtolR ΔmsbB 
ΔpagP 
0.97 1.00 0.99 1.06 0.08 27 (29.5) 2 
*calculated by 1H NMR; **peak MW: molecular weight in kDa calculated by HPLC-SEC analysis 
by using dextrans as standards. 
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Fig. 14. 1H NMR spectra of the OAg populations from GMMA of the SEn 618 mutant strains (LMW 
OAg for SEn 618 ΔtolR mutant) and comparison with the mixed OAg purified from the corresponding 
wild type strain. 
 
2.3.3 OAg characterization of STm 1418 GMMA 
 
OAg from STm 1418 wild type strain has been fully characterized previously [128, 
130]. Table 5 details the main characteristics of GMMA from the corresponding 
mutant GMMA-producing strains. 
 
Table 5. Characterization of GMMA from STm 1418 mutated strains. 
GMMA 
w/w 
OAg/GMMA 
protein ratio 
molar % 
OAg chains/total 
LPS 
nmol 
lipid A/mg 
GMMA protein 
nm radius 
(MALS) 
STm 1418 ΔtolR 0.7 10 172.8 22 
STm 1418 ΔtolR ΔmsbB 0.03 <1 108.2 15 
STm 1418 ΔtolR ΔhtrB 0.02 0.45 154.8 11 
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As for SEn 618 GMMA, all preparations were free from soluble proteins, as 
indicated by HPLC-SEC analysis (data not shown). After the introduction of the 
ΔtolR mutation, the w/w ratio of OAg chains per total protein amount was high 
(0.66), indicating maintenance of good levels of OAg expression. However, after the 
introduction of ΔhtrB or ΔmsbB mutations in the ΔtolR strain, OAg to GMMA 
protein ratio was greatly reduced, consistent with inhibition of OAg production (Table 
5). At the same time, MALS analysis showed that GMMA-producing lower amount 
of OAg chains were characterized by reduced size with respect to tolR GMMA 
(Table 5). No major changes in the SDS-PAGE protein pattern after introduction of 
ΔhtrB and ΔmsbB mutations to reduce reactogenicity compared to GMMA with no 
lipid A modification (ΔtolR) were observed (Fig. 12). 
For ΔtolR ΔhtrB GMMA, the presence of an extra polysaccharide was revealed 
and identified as glycogen by 1H NMR [154] (Fig. 15-A). In ΔtolR ΔmsbB GMMA, 
very high levels of Glc were quantified by HPAEC-PAD analysis and HPLC-SEC 
(dRI) chromatography revealed the presence of an additional peak, thus strongly 
suggesting glycogen production by this mutant as well (Fig. 15-B). 
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Fig. 15. 1H NMR spectrum (A) and HPLC-SEC chromatogram (B) of the extra polysaccharide 
extracted from GMMA produced by STm 1418 ΔtolR ΔhtrB and ΔtolR ΔmsbB mutated strains. 
 
OAg from ΔtolR GMMA showed two main populations with different average 
MW, consisting of 75 and 25 repeating units respectively, similar to those OAg 
populations from the corresponding wild type strain, but with different relative 
proportions (Table 6, Fig. 16). 
 
 
Table 6. Characterization of OAg populations extracted from GMMA produced by STm 1418 
ΔtolR mutant and comparison with the OAg from the corresponding wild type strain. Sugar 
composition (molar ratio relative to Rha) and average number of repeating units (RU) were 
calculated by HPAEC-PAD and HPLC-SEC/semicarbazide (assay for KDO quantification). O-
acetylation (O-Ac) level was obtained from integration of the peak area of methyl signals of O-
acetyl groups of 1H NMR spectra. 
OAg Abe* Rha Man Gal Glc 
Number RU 
(peak MW**) 
O-Ac % 
STm 1418 wild type 1.00* 1.00 1.00 1.00 0.80 na 73 
STm 1418 ΔtolR 
(HMW OAg) 
0.91* 1.00 0.97 0.98 1.00 75 (104.7) 54 
STm 1418 ΔtolR 
(LMW OAg) 
0.93* 1.00 0.98 1.04 0.96 25 (32.9) 79 
*calculated by 1H NMR; na: not applicable. **peak MW: molecular weight in kDa calculated by 
HPLC-SEC analysis by using dextrans as standards. 
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Fig. 16. HPLC-SEC chromatograms of the OAg populations extracted from STm GMMA of the ΔtolR 
mutant and compared with the OAg purified from the wild type strain (TSK gel 3000 PWXL column; 
NaPi 100 mM NaCl 100 mM 5% CH3CN pH 7.2; 0.5 mL/min; V0 11.20 min; Vtot 23.29 min). The 
component eluting at 17.30 min in the ΔtolR OAg refers to the core oligosaccharide of the LPS. Core 
oligosaccharide fractions for wild type OAg were lost in the purification process. 
 
The two populations had the same sugar composition, in agreement with OAg 
from 1418 wild type strain, with glucosylation levels >80% (Table 6). Glycosidic 
linkages analysis confirmed that the main linkage for Glc was in position C-6 on the 
Gal residue (Table 7). 
 
Table 7. Glycosidic linkages analysis of STm 1418 wild type OAg and HMW, LMW OAg 
populations from ΔtolR GMMA (molar ratio relative to 2,3-Man). 
OAg from  
STm 1418 
t-Abe 4-Rha t-Glc 3-Gal 3,6-Gal 2,3-Man 
wild type* 0.16 0.87 0.63 0.26 0.59 1.00 
ΔtolR 
(HMW OAg)§ 
0.43 0.77 0.70 0.04 0.72 1.00 
ΔtolR 
(LMW OAg)§ 
0.64 0.77 0.67 0.14 0.64 1.00 
*GLC on SP2330 column; §GLC on HP1 column; t-Abe with low molar ratios due to its chemical 
lability in the analysis conditions. 
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O-acetyl groups quantification by Gas Liquid Chromatography (GLC) and Gas 
Liquid Chromatography Coupled to Mass Spectrometry (GLC-MS) [130] performed 
on these populations detected the presence of O-acetyl groups only on C-2 of Abe, 
with O-acetylation levels of 39% for the OAg population at HMW and 32% for that at 
LMW, compared to 52% for the wild type OAg (Table 8). 
 
Table 8. O-acetylation levels of STm 1418 wild type OAg and HMW, LMW OAg populations 
from ΔtolR GMMA calculated by GLC and 1H NMR. 
OAg from 
STm 1418 
% O-Ac on  
C-2 Abe  
by GLC 
% O-Ac on  
C-2 Rha  
by GLC 
% O-Ac on  
C-2 Abe  
by 1H NMR 
% O-Ac on  
C-2 Rha  
by 1H NMR 
wild type 52 nd 73 nd 
ΔtolR 
(HMW OAg) 
39 nd 42 12 
ΔtolR 
(LMW OAg) 
32 nd 69 10 
nd: not detected. 
 
1H NMR spectroscopy analysis confirmed the presence of O-acetyl groups on C-2 
of Abe (O-acetyl signal at 2.10 ppm, H-2 of Abe2OAc at 5.10 ppm) in both samples 
(43% for HMW, 69% for LMW OAg populations), as well as in the OAg produced by 
the wild type strain (73%) [130]. An additional peak at 2.17 ppm (12% for HMW, 
10% for LMW OAg populations) (Fig. 17) was tentatively attributed to the O-acetyl 
group on C-2 of Rha, by comparison with the O-acetylation pattern assigned to the 
OAg from S. Typhimurium D23580 strain [130]. 
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Fig. 17. 1H NMR spectra of the OAg populations from STm 1418 ΔtolR GMMA and comparison with 
the mixed OAg purified from the corresponding wild type strain. 
 
The low amount of OAg chains on the double mutant GMMA impeded their 
detailed structural characterization. 
 
2.3.4 Immunogenicity in mice 
 
Groups of mice were immunized with SEn 618 ΔtolR and ΔtolR ΔmsbB ΔpagP 
GMMA, and STm 1418 ΔtolR, ΔtolR ΔmsbB and ΔtolR ΔhtrB GMMA. All the 
GMMA candidate vaccines were compared at the same OAg dose of 1 µg. The main 
objective was to verify the ability of GMMA to induce an immune response and 
whether the observed OAg modifications, following the genetic manipulations 
required to generate GMMA-producing strains, affected immunogenicity in terms of 
anti-OAg responses. Fourteen days after the second injection, all GMMA were able to 
induce a serovar-specific anti-OAg IgG response, with no significant differences 
among GMMA of the same serovar (Mann-Whitney test for SEn 618 GMMA and 
Kruskal-Wallis for STm 1418 GMMA). However, more variability was observed in 
the anti-OAg IgG response induced in mice injected with SEn 618 ΔtolR ΔmsbB 
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ΔpagP GMMA (3 non-responders) compared to 618 ΔtolR GMMA, and with STm 
1418 ΔtolR ΔhtrB GMMA compared to 1418 ΔtolR GMMA. All GMMA were able to 
boost the anti-OAg IgG response (same p value of 0.0078 comparing day 14 and day 
42 response for each group) (Fig. 18). Immune sera were also bactericidal against S. 
Typhimurium D23580 or S. Enteritidis CMCC4314 (Fig. 18). 
 
 
 
Fig. 18. Summary graphs of anti-OAg IgG geometric means (bars) and individual antibody levels 
(dots) induced in CD1 mice by GMMA vaccines injected at days 0 and 28 at 1μg OAg dose. Mice were 
bled before the first immunization (pooled sera from each group at day 0) and at days 14, 28 and 42 
after the first immunization. ELISA limit of detection was calculated as 2.9 and as 2.2 ELISA units/mL 
for anti-O:9 and anti-O:4,5 IgG, respectively. Numbers above day 42 bars represent SBA results of 
pooled sera collected at day 42 from each group against S. Enteritidis CMCC4314 or S. Typhimurium 
D23580. SBA titers were calculated as the serum dilution necessary to obtain 50% bacterial killing 
after 3 hours incubation at 37 °C compared with bacteria counted at time 0. Each serum pool was tested 
in triplicate in three independent experiments, except for SEn 618 ΔtolR serum, which was tested in 
duplicate. Initial serum dilution was 1:100. 
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2.4 Discussion 
 
GMMA are nano-sized particles, displaying high-densities of repeated antigens 
and containing bacterial pathogen associated molecular patterns (PAMPs), with the 
potential to trigger strong immune responses [136, 137]. Furthermore, GMMA can be 
produced efficiently, economically and rapidly [114, 115, 122], making them an 
attractive vaccine candidate, particularly for low and middle income countries. 
A comprehensive panel of analytical methods has been assembled for GMMA 
characterization with particular attention to their surface OAg, which is a key target of 
protective antibody responses. Such methods allowed verification of whether 
mutations introduced into GMMA-producing strains impact on OAg expression and 
structure, enabling the identification of optimal potential GMMA candidate vaccines 
against iNTS. Furthermore, such methods are of fundamental importance in the 
process of vaccine development, to ensure consistency of production, vaccine efficacy 
and to monitor stability of GMMA vaccines. 
The ΔtolR mutation introduced to increase GMMA production (approximately 300 
mg GMMA OAg content obtained per liter of fermentation broth) was accompanied 
by changes in the OAg chain length distribution in both SEn 618 and STm 1418 
strains. In contrast to what was observed for SEn 618 ΔtolR GMMA, the ΔtolR 
mutation in the STm 1418 strain caused a reduction of the OAg population at HMW 
compared to the wild type strain. In addition, mutations to modify lipid A and reduce 
toxicity need to be carefully monitored as they may inhibit OAg production, as 
observed in this study with one of the STm 1418 clones. 
With STm 1418, a reduction in the amount of OAg was associated with the 
production of glycogen as additional polysaccharide on GMMA. Production of such 
polysaccharide was not observed in a panel of nontyphoidal Salmonella wild type 
strains previously characterized [119, 131]. This phenomenon has also been observed 
in other mutants, derived both from S. Enteritidis and S. Typhimurium GMMA-
producing strains, when genetic mutations have resulted in low OAg expression (data 
not shown). The reasons for this are not clear and it would be interesting to verify 
whether there is a correlation between lack of OAg production and glycogen 
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formation and what functional implications this may have. Glycogen has been 
described to be a major energy storage compound in many Enterobacteriaceae, 
including S. Typhimurium and S. Enteritidis and to accumulate in cytoplasmic 
granules [155]. It is a polysaccharide containing glucose units in a branched structure 
comprising predominantly α-1,4 linkages (90%) and a smaller number of α-1,6 
branching glucosyl linkages. It is usually produced in the presence of rich medium 
containing glucose, or when growth is limited by a lack of a required nutrient 
(ammonia, amino acids, sulphur or phosphate), or when the bacteria enter stationary 
phase of growth, or under stresses associated with infection and environmental 
survival [222]. Glycogen production in S. Enteritidis has previously been reported and 
shown to be related to virulence, colonization and resistance mechanisms, including 
the production of biofilm, obtained from glycogen cell stores [156]. The strongly 
decreased production of OAg chains and the associated overproduction of glycogen 
could be attributed to compensatory effects related to tolR and msbB/htrB gene 
deletions in the STm 1418 genotype. The introduction of mutations in the Tol 
pathway and the knock-out of msbB/htrB genes are reported to induce loss of 
regulation in genes encoding for the synthesis of the OAg repeating units, or for the 
synthesis and the accumulation of glycogen, in response to extra-cytoplasmic stress 
[223]. 
OAg chain length and O-acetylation level are parameters that are known to affect 
the immunogenicity of OAg-based vaccines [77, 80, 102, 119, 133]. Mutations 
introduced into the wild type strains affected also the OAg O-acetylation pattern. 
When tested in mice at the same OAg dose, all GMMA were able to induce anti-OAg 
IgG specific antibodies, with functional activity, independent of the OAg to total 
protein GMMA ratio and with no major impact of any OAg structural modification. 
The effective amount of OAg injected, rather than its density on GMMA, appears to 
determine the anti-OAg antibody response. In fact, when GMMA were injected at the 
same protein dose, anti-OAg IgG response induced by S. Typhimurium 1418 ∆tolR 
∆msbB/∆htrB GMMA was significantly lower than that induced by S. Typhimurium 
1418 ∆tolR (data not shown). The implication of this observation is that a higher OAg 
to GMMA ratio should permit the use of a lower amount of GMMA per vaccine dose 
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for the same anti-OAg antibody response. This will have potential benefits in relation 
to cost and safety of the vaccine. 
In a parallel work, same GMMA characterized here were also assessed for their 
reactogenicity. The combination of ΔmsbB and ΔpagP mutations resulted to be the 
optimal approach to minimize reactogenicity of S. Enteritidis and S. Typhimurium 
GMMA, resulting in uniformly penta-acylated lipid A [124]. GMMA from this triple 
mutant strain provoked the least stimulation of cytokine release from human PBMC, 
compared to GMMA with wild type lipid A, and stimulatory potential similar to that 
of a Shigella sonnei GMMA vaccine tested in Phase I clinical trials [115, 123]. S. 
Enteritidis and S. Typhimurium GMMA with reduced toxicity, without a major 
impact on OAg expression level, seem to be good components for a vaccine against 
iNTS. Mutations introduced to reduce GMMA reactogenicity have been verified not 
to have major impact on the protein pattern profile. A more accurate analysis will be 
done on the final selected strains in order to identify the nature and the amount of the 
most abundant proteins, considering that they may be additional key mediators of 
functional antibody. It will be important to verify batch to batch consistency, and to 
investigate the contribution that anti-protein antibodies can have on the overall 
immune response induced by GMMA vaccines. 
Simplicity of manufacturing process and low costs of production, coupled with 
encouraging immunogenicity data, make the GMMA vaccine approach particularly 
attractive. The comparison of OAg-GMMA with other candidate vaccines under 
development against iNTS, such as live attenuated and glycoconjugate vaccines, will 
be of great interest for the development of a successful and efficacious intervention 
against iNTS. 
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3. Determination of nontyphoidal Salmonella GMMA particle 
size distribution 
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3.1 Introduction 
 
Particle size and particle size distribution (PSD) are among the characteristics of 
GMMA to be investigated for their full characterization [157-159]. 
A number of techniques for particle size, shape and size distribution measurements 
are available and can be commonly employed in quality control as well as in research 
and development fields [160, 161]. However, as it will be described later, each 
methodology leads to different “observables” which have to be clearly defined. 
Depending on the nature of the product, the methodologies include Dynamic Light 
Scattering (DLS), Tunable Resistive Pulse Sensor (TRPS), Electron Microscopy 
(EM), Flow Cytometry (FC), Differential Centrifugation Sedimentation (DSC), and 
others. No gold standard exists for the detection of vesicles and each of these 
techniques has strengths and weaknesses. Some of them are labour intensive and time 
demanding, whereas others are cost effective and user friendly. For example, 
Transmission Electron Microscope (TEM) has well known drawbacks such as cost, 
lengthy sample preparation and analysis time and, above all, uncertainty on the real 
size of sample, with a multitude of possible measurement artifacts due to sample pre-
treatments. In the context of the characterization of NTS GMMA vaccines, TEM 
analysis has been previously employed to evaluate shape and size distribution of 
GMMA released by different STm and SEn mutants [124]. In that study, the results 
(size distribution and mean diameters), obtained after negative staining and manual 
measurements, were not different among all the samples analysed. Diameters ranged 
between 20 and 110 nm, with mean values between 40 and 50 nm (Fig. 19). 
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Fig. 19. TEM of GMMA purified from STm and SEn mutants (bar length = 100 nm) [124]. 
 
Here, PSD of GMMA produced by different S. Typhimurium and S. Enteritidis 
mutated strains have been investigated by means of three different size-analysing 
techniques: 
 
 Dynamic Light Scattering (DLS); 
 Multi-Angle Light Scattering (MALS); 
 Nanoparticle Tracking Analysis (NTA). 
 
Advantages, limitations and shortcomings of each type of instruments and methods 
are discussed, as well. 
A wide range of definitions for particle size exists [162]. Particles are three-
dimensional objects for which length, breadth and height should be considered in 
order to provide a complete description. All particle-sizing techniques have a unique 
target that is to provide a single figure indicative of the particle size. Most techniques 
used for size measurement assume that the particles being analysed are spherical and 
estimate the particle size as the diameter of the “equivalent sphere” that would give 
the value as the particle analysed. Unfortunately, nice spherical particles rarely exist, 
forming instead other shapes, with the complication that particles in a mixture could 
have different sizes. For irregular-shaped particles, the assigned equivalent sphere 
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approximation depends upon the method of measurement and the physical property 
underlying one specific technique. Description of particle size is not unique, but a 
combination of methods can provide a reliable description of the sample [162]. Of the 
many sphere-equivalent diameters that describe the size of a particle, the two most 
commonly used are hydrodynamic radius (Rh) and radius of gyration (Rg). 
Rh is defined as the radius of an equivalent hard sphere diffusing at the same rate 
as the particle under observation. Practically, the hydrodynamic size is indicative of 
the apparent size of the dynamic hydrated particle, considering the layer of solvent 
associated with the particle surface, taking into accounts its shape and behaviour in 
solution. In reality, the determined Rh closely reflects the apparent size adopted by the 
solvated particle. On the other hand, Rg is defined as the mass weighted average 
distance of each element of the particle from its center of mass. Both Rh and Rg can be 
used to gain a more complete description of particles and the ratio Rg/Rh (ρ) provides 
information about their structure and density [163]. The characteristic Rg/Rh value for 
a globular structure is ~0.775, which means that Rg is smaller than Rh. When particles 
deviate from globular to non-spherical or elongated structures, Rg/Rh ratio tends to 
values greater than 0.775. 
At last, measurement of particles concentration represents a ubiquitous 
requirement in the study of particulate samples. In many cases, the only knowledge of 
particle size and distribution is not enough, as particles concentration may also affect 
the pharmaceutical performance or the immune response of a particulate drug 
substance. There is a wide variety of applications in which the measurement of 
particle concentration is critically important, including biopharmaceutics 
development, protein aggregation studies, exosomes and microvesicles research [162-
165]. 
 
Dynamic Light Scattering (DLS) 
 
DLS, also known as photon correlation spectroscopy (PCS) or quasi elastic light 
scattering (QELS), is a popular and routinely technique for measurement of size and 
differential size distribution of small particles in suspension used since 1960s [161, 
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166, 167]. In general, the technique is best used for submicron particles and 
applications include the determination of the size distribution of nanogolds, proteins, 
latex and silica beads, colloids, emulsion systems, liposomes and extracellular 
vesicles. 
DLS is an ensemble measurement technique determining the average 
hydrodynamic diameter of particles dissolved or dispersed in a liquid by measuring 
the intensity fluctuations of scattered light produced by particles as they undergo 
Brownian motion [160, 168]. Analysis of these intensity fluctuations yields the rate of 
the random Brownian motion in liquid, modelled by the Stokes-Einstein equation 
reported below [166]. The Stokes-Einstein relation connects diffusion coefficient 
measured by dynamic light scattering to hydrodynamic diameter [169]. 
 
 
 
 Dh: hydrodynamic diameter; 
 Dt: translational diffusion coefficient; 
 kB: Boltzmann’s constant; 
 T: thermodynamic temperature; 
 η: dynamic viscosity. 
 
Sample temperature affects the particles rate and viscosity. The sample in a cell is 
illuminated with a laser beam: all particles crossing the beam will scatter light. The 
scattered light is collected with one of two detectors, either at a 90 degree (right 
angle) or 173 degree (back angle) scattering angle. The obtained optical signal shows 
random changes due to the randomly changing relative position of the particles in 
suspension under Brownian motion. The PSD is obtained by measuring these time-
dependent intensity fluctuations of the scattered light, followed by applying a 
mathematical model derived from Brownian motion and light scattering theory. 
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Using this technique, an intensity-weighted mean hydrodynamic diameter (Z-
average diameter) and a polydispersity index (PDI) are obtained. The term 
polydispersity is used to describe the amplitude of the distribution. PDI values smaller 
than 0.05 are rarely seen other than with highly monodisperse standards. Values 
greater than 0.7 indicate that the sample has a very broad size distribution and it is 
probably not suitable for the DLS technique. The values for different classes of 
dispersity are listed in Table 9. 
 
Table 9. Approximate values for polydispersity parameters. 
 Distribution type 
monodisperse polydisperse 
uniform narrow moderate broad 
PDI from DLS 0.0 0.0-0.1 0.1-0.4 >0.4 
 
A measurement is typical performed within 1 min and requires sample volumes as 
low as 20 µL. Sample concentration range is not a critical factor for DLS and particles 
can be dispersed in a variety of liquids, only whose refractive index and viscosity 
need to be known for interpreting data. 
The ease of use and the ability to analyse a large range of particulate sizes, 
materials and dispersion media has made DLS one of the most common and user-
friendly measurement techniques able to yield relatively precise and consistent results 
that can be obtained in a rather short period of time. 
 
Multi-Angle Light Scattering (MALS) 
 
MALS represents a static light scattering technique suitable for the measurement 
of the absolute molecular mass of polymers, as well as molecular size of particles 
expressed as the Rg value. Applications of MALS can be the determination of size of 
biopolymers such as polysaccharides, natural and synthetic polymers, large protein 
complexes such as virus-like particles, liposomes or exosomes, extracellular vesicles, 
and large protein aggregates [170]. 
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A laser source is most often used and the technique is also referred to as multi-
angle laser light scattering (MALLS) [171]. In the last few years, since all commercial 
light scattering instrumentations use laser sources instead of conventional light beams, 
mentioning the light source is not needed and the term MALS is more commonly 
used. MALS studies the angular dependence of the time-averaged scattering intensity 
to determine the mass-averaged root mean square radius (RMS), commonly known as 
radius of gyration Rg. 
In MALS analysis, a laser beam is passed through the sample chamber and the 
suspended particles crossing the path of the beam scatter light in all directions. Laser 
light can be scattered from different parts of the particle reaching the detectors with 
different phases (anisotropic scattering). MALS involves the measurement of 
scattered light intensity caught by multiple detectors placed at fixed angles around the 
particle. The number of angles varies between 2 and 20 angles, which are able to 
detect the re-radiated light simultaneously. The intensity of the light scattered is 
directly related to its molecular mass, as described by the Rayleigh equation reported 
below. 
 
 
 
 K: optical constant; 
 Rθ: Rayleigh ratio; 
 M: molecular mass; 
 A2: 2
nd virial coefficient; 
 C: sample concentration; 
 P(θ): shape (or form) factor. 
 
P(θ) takes into account the shape of the particle and allows obtaining size 
information from the angular dependence of the intensity of the scattered light. The 
total amount of light scattered at each angle is given by the contribution of each of the 
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scattering centers present in the volume of a large macromolecule, obtaining Rg value. 
MALS can examine sizes from 10 nm to several hundred nanometers, without 
calibration against standards or assumptions on shape. If the particle can be 
represented by a sphere, the Rg can be related to its geometrical dimensions 
(geometric radius, Rgeo) [172]. 
MALS detector can be coupled to a fractionation module such as size exclusion 
chromatography (SEC-MALS), representing the most common method for MALS 
characterization of size distribution of homogeneous or heterogeneous samples [173]. 
In this way, the sample is chromatographically separated by its hydrodynamic volume 
and molar mass (MM) and Rg can be assessed at each elution volume, achieving 
accurate size distributions limited in resolution only by the separation technique 
[163]. MALS coupled to a size exclusion chromatographic system provides accurate 
and reproducible gyrations size values, complemental to those obtained by other size-
analysing techniques. 
 
Nanoparticle tracking Analysis (NTA) 
 
NTA is an alternative light-scattering technique useful for the evaluation of size 
and enumeration of individual particles in liquids, ranging between 10 and 2000 nm 
in size [174, 175]. NTA allows the analysis of a wide range of different particles in a 
wide range of solvent types, with no need for multi-angle measurements. NTA can be 
employed for studying emulsion systems, virus-like particles, extracellular vesicles, 
evaluating also aggregation dynamics and drug delivery [157, 164]. The 
hydrodynamic radius Rh of particles is determined by NTA in a similar fashion as 
DLS [176]. Like DLS, the particle diameter is calculated via the Stokes-Einstein 
equation by direct measuring the diffusion coefficient of particles moving under 
Brownian motion, relating the rate of particle motion to particle size [177]. 
More practically, in a NTA experiment, a finely focused laser beam hits a dilute 
suspension of particles contained in the sample analysis module through a glass prism 
[175]. The low angle refracted laser beam illuminates the particles through the 
sample. Illuminated particles are visualized using a conventional optical microscope, 
  
SDBM - School of 
Molecular Biomedicine 
 
 
57 
 
fitted with a scientific digital camera which catches light scattered from the particles 
in the field of view. The particles are seen as small points of light moving rapidly 
under Brownian motion. NTA allows the direct, real-time visualization and analysis 
of particles in liquids, which provides a deeper understanding of the sample in 
analysis [176]. After the video collection, the NTA software tracks the center of each 
individual particle’s Brownian movement in two dimensions on a frame-by-frame 
basis and simultaneously calculates their size and total number [178]. By following 
each particle as centres of the spots of scattered light for a number of steps (video 
frames), the average distance moved between frames is then calculated and from this 
the diffusion coefficient for each particle is determined. The rate of individual particle 
movement is used to calculate the sphere equivalent hydrodynamic diameter by 
applying the two-dimensional Stokes-Einstein equation [164]: 
 
 
 
 <x,y>2: mean square displacement (MSD); 
 KB: Boltzmann’s constant; 
 Tts: thermodynamic temperature; 
 η: dynamic viscosity; 
 dh: hydrodynamic diameter. 
 
The additional ability of NTA to see particles directly and individually allows 
particle concentration to be estimated. Particle concentration can be estimated from 
extrapolating the number of particles detected at any given instant per volume unit 
through knowing the scattering volume. This goes well beyond the simple 
measurement of particle size. Analysis times can be as low as 10 seconds for optimum 
concentrations of particles between 2 x 108 and 2 x 109 particles/mL [175]. This range 
of concentration amounts to a range of 10-100 particles within the field of view, 
optimal to achieve precise estimates of particle concentration analysis. Too many 
  
SDBM - School of 
Molecular Biomedicine 
 
 
58 
 
particles can cause severe interference, while too few particles may not be 
representative of the sample, both of which can lead to misleading results. 
In addition, with fluorescent labelling, NTA can be used to determine the 
phenotype of a subgroup of vesicles [179]. 
NTA is expected to become an important tool in research fields, including 
bacteriology, vaccinology, immunology, biomedical diagnostics, material science, 
where the optical characterization of nanoparticles is of critical importance. 
 
3.2 Materials and methods 
 
3.2.1 NTS parent strains for GMMA production 
 
S. Typhimurium isolate SGSC1418 (LT-2 collection, University of Calgary), S. 
Typhimurium 2192 (SGSC2192, SARA collection), and S. Enteritidis SA618 
(CEESA EASSA II collection of Quotient Bioresearch Limited) were chosen as 
parent strains on the basis of a screen performed previously [119]. The Salmonella 
mutant strains used and their abbreviations are listed in Table 10. 
 
Table 10. Strains used in this study and their abbreviations. 
Strain abbreviation name Genotype 
STm 1418 ΔtolR S. Typhimurium 1418 ΔtolR::aph 
STm 1418 ΔtolR ΔwbaP S. Typhimurium 1418 ΔtolR::aph ΔwbaP::cat 
STm 2192 ΔtolR ΔpagP ΔmsbB S. Typhimurium 2192 ΔtolR::aph ΔpagP::cat ΔmsbB::tetRA  
SEn 618 ΔtolR ΔmsbB ΔpagP S. Enteritidis 618 ΔtolR::aph ΔmsbB::tetRA ΔpagP::cat 
 
Mutants were described in the previous chapter [124]. In the case of STm 1418 ΔtolR 
ΔwbaP, the chloramphenicol resistance gene cat was used to replace the wbaP gene. 
GMMA were produced and purified as described in the previous chapter [124]. After 
purification, all GMMA samples were suspended in PBS and then 0.22 µm filtered. 
 
3.2.2 GMMA protein quantification 
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GMMA quantities are expressed as total protein content estimated by micro BCA 
(Thermo Scientifics). A 2 mg/mL solution of serum bovine albumin (BSA) was used 
to create a calibration curve in the 5 to 20 µg/mL range. Samples were diluted with 
MilliQ water in order to obtain sample protein concentration in the range of the 
calibration curve. Samples and calibration curves were created in duplicates and to a 
final volume of 500 µL. The Micro BCA Reagent was prepared according to 
manufacturer’s instructions and 500 µL were added to each samples. Samples were 
incubated for 1 h at 60 °C in a pre-heated thermostatic bath. Cooled-down samples 
were analysed using a spectrophotometer and absorbance was measured at 562 nm. 
 
3.2.3 Dynamic Light Scattering (DLS) 
 
DLS measurements were performed with a Malvern Zetasizer Nano ZS (Malvern, 
Herremberg, Germany) equipped with a 633 nm He-Ne laser and operating at an 
angle of 173°. Scattering light detected at 173° was automatically adjusted by laser 
attenuation filters. For data analysis the viscosity and refractive index (RI) of PBS 
buffer solution (at 25 °C) were used. The software used to collect and analyse the data 
was the Zetasizer software version 7.11. Temperature was set at 25 °C. 80 µL of each 
sample at 50, 125, 200 µg/mL protein content were measured in duplicates in single-
use polystyrene micro cuvette (ZEN0040, Alfatest) with a path length of 10 mm. For 
GMMA STm 1418 ΔtolR ΔwbaP, 40 µL at 50 µg/mL protein content were measured 
once. The hydrodynamic diameter of GMMA was expressed by a Z-average value of 
three measurements for each replicate, providing also a PDI of the size values 
calculated. 
 
3.2.4 Size Exclusion Chromatography coupled to Multi-Angle Light Scattering 
(SEC-MALS) 
 
GMMA samples were analysed by HPLC-SEC with Tosoh TSKgel G6000PW (30 
cm x 7.5 mm) + G4000PW (30 cm x 7.5 mm) columns in series equilibrated in PBS 
(PBS tablets, Medicago) and with in-line UV, fluorescence emission, dRI (Refraction 
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index detector) and MALS detectors. A fused silica cell and a 660 nm laser source 
were used. A volume of 80 L of samples with concentrations of 150 and 100 g/mL 
protein content were injected and eluted with a flow rate of 0.5 mL/min (run time 70 
min). All dilutions were made in PBS (Dispersant RI 1.333). MALS data were 
collected and analysed using ASTRA 6 software (Wyatt Technology). The size of 
GMMA was expressed by the Rn, Rw and Rz values determined by Astra Particle 
template assuming spherical shape (Rgeo). Size values were obtained from the MALS 
detector without the need of the solute concentration and the sample RI increment. 
 
3.2.5 Nanoparticle Tracking Analysis (NTA) 
 
NS300 Nanosight instrument (Nanosight Ltd, Salisbury, UK) equipped with a 
CMOS camera and a 488 nm monochromatic laser beam was used. Data acquisition 
and processing were performed using NTA software 3.2 build 3.2.16. Automatic 
settings for the minimum track length, the minimal expected particle size and blur 
setting were applied. Viscosity settings for water were applied and automatically 
corrected for the temperature used. Measurements were performed at room 
temperature ranging from 22 to 25 °C. Particle movement was analysed by NTA 
software with camera level at 16, slider shutter at 1300 and slider gain at 512). 
Different detection threshold values were tested, adjusted for the sample appearance 
after dilution. Five movies of 30 s at 25 frames per second were recorded, generating 
five replicate histograms that were averaged. Several dilutions of the samples were 
analysed and duplicates were recorded for every diluted sample. GMMA samples 
were PBS diluted in low binding eppendorf tubes (Costar, Corning) and dilutions 
were prepared just before analysis. Samples were slowly injected in the sample 
chamber using a 1 mL syringe in 5 to 10 seconds, after gently mixing. Samples were 
recorded under controlled flow, using the NanoSight syringe pump (speed 20). Each 
video was then analysed to determine the respective mean and mode (particle size that 
appears most often within a given preparation) GMMA size. In addition to these 
values, standard deviation (SD) and percentile undersize values (D10, D50, D90) 
were collected. SD, D10, D50, D90 were a measure of the spread of PSD within the 
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samples. Concentrations of samples are reported either as particles per mL and 
particles per frame. 
 
3.2.6 HPLC-SEC 
 
In order to obtain more homogenous GMMA samples, a volume of 100 µL with a 
concentration of 1,000 µg/mL protein content was fractionated by HPLC-SEC. Tosoh 
TSKgel G6000PW (30 cm x 7.5 mm) + G4000PW (30 cm x 7.5 mm) columns in 
series equilibrated in PBS (PBS tablets, Medicago) were used with in-line UV 
detector. Samples were eluted with PBS at a flow rate of 0.5 mL/min (run time 70 
min). GMMA peaks were fractionated in 1.7 mL low binding eppendorf tubes 
monitoring the 280 nm elution profile and collecting fractions at the rate of one tube 
per minute. 
 
3.3 Results 
 
GMMA size distribution has been previously investigated by means of Atomic 
Force Microscope (AFM). AFM analysis was performed by Dr. Denis Scaini and Dr. 
Ilaria Rago at Elettra Sincrotrone Trieste (Area Science Park, Trieste, Italy). 
Unfortunately, no satisfactory results were achieved, proving the difficulty to yield 
positive results using this labour-intensive technique on GMMA samples. 
 
3.3.1 Size distribution analysis by DLS 
 
SEn 618 ΔtolR ΔmsbB ΔpagP, STm 2192 ΔtolR ΔpagP ΔmsbB, STm 1418 ΔtolR 
GMMA were analysed at 50, 125, 200 µg/mL protein concentrations. STm 1418 
ΔtolR ΔwbaP GMMA were analysed at 50 µg/mL protein content. Z-average 
diameter and PDI are summarized in Table 11. 
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Table 11. Z-average diameters and relative PDI values of SEn and STm GMMA analysed by 
DLS. 
GMMA 
Protein concentration 
µg/mL 
Z-average diameter 
nm 
PDI 
SEn 618 ΔtolR 
ΔmsbB ΔpagP 
50 111.07±0.93 0.15 
125 112.02±0.46 0.16 
200 112.32±0.89 0.15 
Mean value 111.80  
STm 2192 ΔtolR 
ΔpagP ΔmsbB  
50 103.47±0.69 0.19 
125 102.92±0.76 0.18 
200 102.48±0.67 0.19 
Mean value 102.96  
STm 1418 ΔtolR 
50 91.53±0.46 0.18 
125 91.45±0.88 0.17 
200 91.23±0.38 0.17 
Mean value 91.40  
STm 1418 ΔtolR 
ΔwbaP 
50 57.60 0.26 
 
No differences were found by analysing the samples at different protein 
concentrations. SEn 618 ΔtolR ΔmsbB ΔpagP GMMA exhibited a Z-average 
diameter of 111.80 nm. STm 2192 ΔtolR ΔpagP ΔmsbB and STm 1418 ΔtolR 
GMMA were characterized by a mean value of 102.96 and 91.40 nm, respectively. 
These GMMA showed a different average diameter with respect to SEn GMMA of 
~10 (7.9% less) and ~20 nm (18.2% less), respectively. STm 1418 ΔtolR ΔwbaP 
GMMA were characterized by a smaller size, 37.0 % less of the GMMA produced by 
the parent strain (STm 1418 ΔtolR) (Fig. 20). 
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Fig. 20. DLS size distribution of SEn 618 ΔtolR ΔmsbB ΔpagP, STm 2192 ΔtolR ΔpagP ΔmsbB, STm 
1418 ΔtolR and STm 1418 ΔtolR ΔwbaP GMMA. 
 
PDI values (Table 11) indicated a moderate polydispersity for all the GMMA samples 
analysed. 
SEn 618 ΔtolR ΔmsbB ΔpagP and STm 2192 ΔtolR ΔpagP ΔmsbB GMMA were 
fractionated by HPLC-SEC. Three adjacent fractions (Fig. 21) were collected and 
further analysed by DLS. 
 
 
 
Fig. 21. Size exclusion chromatography of SEn 618 ΔtolR ΔmsbB ΔpagP GMMA. UV detection at 280 
nm. Three different fractions were collected for further DLS analysis. 
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The average diameter and the PDI values of the collected fractions are summarized in 
Table 12. 
 
Table 12. Average diameters and relative PDI values of fractions of SEn 618 ΔtolR ΔmsbB 
ΔpagP and STm 2192 ΔtolR ΔpagP ΔmsbB GMMA analysed by DLS. 
GMMA 
Fraction 
 
Protein concentration 
µg/mL 
Z-average 
diameter 
nm 
PDI 
SEn 618 ΔtolR 
ΔmsbB ΔpagP 
1 40 116.30±0.89 0.14 
2 50 91.28±0.23 0.08 
3 40 84.10±0.62 0.16 
 Mean value 97.20  
STm 2192 ΔtolR 
ΔpagP ΔmsbB  
1 21 100.27±0.21 0.09 
2 50 81.69±0.25 0.06 
3 35 77.46±1.15 0.16 
 Mean value 86.47  
 
Fractions 2, corresponding to the central area of the GMMA samples, showed a lower 
PDI with respect to the corresponding PDI values of the unfractionated populations 
(Table 11). Fraction 1 of both SEn 618 and STm 2192 GMMA showed a particle size 
similar to that found for unfractionated GMMA, confirming that DLS over weights 
large particles. Fractions 2 and 3 for both GMMA samples showed mean 
hydrodynamic diameters strongly decreased respect to whole GMMA population 
(around 19% less for fractions 2 and 25% less for fractions 3). The mean size for the 
three fractions is smaller respect to the corresponding value of the unfractionated 
GMMA (13.1% less for SEn GMMA, 16.0% less for STm ones). 
 
3.3.2 Size distribution analysis by SEC-MALS 
 
HPLC-SEC fluorescence emission profile of GMMA samples from all the strains 
analysed revealed very low residual soluble protein contaminants (< 5%), indicating 
good purity of the samples. Considering this, almost all protein content resulted to be 
located in the GMMA thus providing an easy way to quantify GMMA content. 
GMMA preparations from SEn 618 ΔtolR ΔmsbB ΔpagP, STm 2192 ΔtolR ΔpagP 
ΔmsbB, STm 1418 ΔtolR GMMA were analysed at 100 and 150 µg/mL protein 
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content. STm 1418 ΔtolR ΔwbaP GMMA were analysed at 100 µg/mL protein 
content. 2 x Rn, 2 x Rw, and 2 x Rz, results obtained are reported in Table 13. 
 
Table 13. MALS diameter values and relative uncertainty values of SEn and STm GMMA 
analysed by SEC-MALS. 
GMMA 
Protein 
concentration 
µg/mL 
2 x Rn 
nm 
2 x Rw 
nm 
2 x Rz 
nm 
SEn 618 ΔtolR 
ΔmsbB ΔpagP 
100 73.20±0.88 74.60±0.90 76.20±0.91 
150 70.40±0.70 71.80±0.72 73.60±0.74 
Mean value 71.80 73.20 74.90 
STm 2192 ΔtolR 
ΔpagP ΔmsbB 
100 68.2±0.75 69.80±0.77 72.20±0.79 
150 67.40±0.67 69.00±0.69 71.40±0.71 
Mean value 67.80 69.40 71.80 
STm 1418 ΔtolR 
100 70.00±0.91 71.40±0.86 73.80±0.89 
150 70.00±0.91 71.60±0.86 73.80±0.89 
Mean value 70.00 71.50 73.80 
STm 1418 ΔtolR 
ΔwbaP 
100 (peak 1) 98.20 100.00 101.80 
100 (peak 2) 51.00 52.60 55.40 
 
Size distribution of GMMA samples was independent from the protein 
concentration at which samples were analysed. SEn 618 ΔtolR ΔmsbB ΔpagP (Fig. 
22), STm 2192 ΔtolR ΔpagP ΔmsbB and STm 1418 ΔtolR GMMA were 
characterized by a similar 2 x Rz value (~70 nm). 2 x Rz values obtained by SEC-
MALS were smaller than Z-average diameters obtained by DLS. Differences of ~40 
nm (33.0%) for SEn 618 ΔtolR ΔmsbB ΔpagP, ~30 nm (30.3%) for STm 2192 ΔtolR 
ΔpagP ΔmsbB and ~20 nm (19.1%) for STm 1418 ΔtolR GMMA were observed. 
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Fig. 22. SEC-MALS chromatogram of SEn 618 ΔtolR ΔmsbB ΔpagP GMMA, with indication of the 
Rw value corresponding to the apex of light scattering detection. 
 
Unlike DLS, showing one single population, SEC-MALS analysis of STm 1418 
ΔtolR ΔwbaP GMMA revealed two main peaks, with 2 x Rz of 101.80 and 55.40 nm, 
respectively (Fig. 23). In agreement with DLS analysis, size of STm 1418 ΔtolR 
ΔwbaP GMMA was confirmed to be smaller with respect to the other GMMA 
analysed (26.3%), but the gap between Z-average and 2 x Rz (3.8%), for the smaller 
population was not large, differently from what observed for the other GMMA 
analysed. 
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Fig. 23. SEC-MALS chromatogram of STm 1418 ΔtolR ΔwbaP GMMA, which were characterized by 
a double peak. 
 
Similarly to DLS analyses, samples deriving from HPLC-SEC fractionation (Fig. 
21) of SEn 618 ΔtolR ΔmsbB ΔpagP and STm 2192 ΔtolR ΔpagP ΔmsbB GMMA 
were analysed by SEC-MALS. Results relative to the collected fractions are 
summarized in Table 14 
 
Table 14. MALS diameter values and relative uncertainty values of fractions of SEn 618 ΔtolR 
ΔmsbB ΔpagP and STm 2192 ΔtolR ΔpagP ΔmsbB GMMA analysed by SEC-MALS. 
GMMA 
Fractions 
 
Protein 
concentration 
µg/mL 
2 x Rn 
nm 
2 x Rw 
nm 
2 x Rz 
nm 
SEn 618 
ΔtolR 
ΔmsbB 
ΔpagP 
1 40 78.60±4.09 79.40±4.05 80.20±4.01 
2 64 67.00±1.01 68.40±0.96 70.20±0.98 
3 41 58.00±1.51 59.20±1.48 61.2±1.53 
Mean value 67.87 69.00 70.53 
STm 2192 
ΔtolR 
ΔpagP 
ΔmsbB  
1 21 80.00±0.96 81.00±0.97 82.20±0.99 
2 50 67.60±0.81 68.20±0.82 70.00±0.84 
3 35 58.60±0.94 59.80±0.96 61.40±0.98 
Mean value 68.73 69.67 71.20 
 
Fractions 2 showed 2 x Rz values similar to the values found for SEC-MALS analysis 
of the whole GMMA population. Fractions 1 and 3, instead were characterized by 
higher (~10 nm) and lower (~10 nm) size values, respectively. 
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3.3.3 Size distribution analysis by NTA 
 
GMMA from SEn 618 ΔtolR ΔmsbB ΔpagP (Fig. 24), STm 2192 ΔtolR ΔpagP 
ΔmsbB, STm 1418 ΔtolR and STm 1418 ΔtolR ΔwbaP GMMA were analysed by 
NTA. Screen gain and camera level (shutter speed and camera gain) were set at values 
2 and 16, respectively, and they were selected based on the visually brightest 
detection of particles without the occurrence of abundant over-scattering events. 
Detection threshold (the scattering intensity threshold above which particles are 
tracked) was initially set at the value of 3. 
 
 
 
Fig 24. NTA graph of SEn 618 ΔtolR ΔmsbB ΔpagP GMMA, in which particle size, particle 
concentration and relative intensity are plotted together. 
 
Mean and mode hydrodynamic diameters for SEn 618 ΔtolR ΔmsbB ΔpagP 
GMMA analysed at different dilutions are reported in Table 15. 
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Table 15. Mean and mode hydrodynamic diameter of SEn 618 ΔtolR ΔmsbB ΔpagP GMMA analysed by NTA. 
Sample 
dilution 
Protein 
concentration 
µg/mL 
Mean 
nm 
Mode 
nm 
SD 
nm 
D10 
nm 
D50 
nm 
D90 
nm 
10000x 
(1) 1.39 x 10
-1
 106.2±1.3 88.6±2.9 37.4±1.0 54.5±2.1 88.8±1.7 152.0±2.5 
10000x 
(2) 1.39 x 10
-1
 106.5±0.8 90.2±3.7 38.4±1.2 56.6±2.0 88.2±1.7 148.5±2.0 
25000x 
(1) 5.82 x 10
-2
 99.3±1.3 80.5±2.2 35.7±1.1 51.3±2.3 81.7±1.8 134.4±2.7 
25000x 
(2) 5.82 x 10
-2
 105.3±2.1 84.0±2.9 35.6±0.6 59.0±1.9 87.2±1.9 143.9±4.2 
50000x 
(1) 2.90 x 10
-2
 90.3±1.8 70.3±6.1 36.2±1.4 44.4±1.8 73.2±2.0 128.9±4.1 
50000x 
(2) 2.90 x 10
-2
 97.4±2.7 87.8±6.1 35.6±1.1 51.1±2.1 81.4±2.7 131.5±4.5 
75000x 
(1) 1.93 x 10
-2
 92.0±1.4 76.1±4.2 39.1±3.2 45.3±1.9 72.7±1.6 128.9±4.3 
75000x 
(2) 1.93 x 10
-2
 94.5±3.2 82.5±3.8 32.6±1.5 52.2±4.9 77.2±2.7 131.3±5.6 
100000x 
(1) 1.45 x 10
-2
 83.9±2.2 61.6±7.3 33.6±1.4 37.6±1.8 69.5±3.7 124.1±7.7 
100000x 
(2) 1.45 x 10
-2
 92.0±2.4 74.3±8.9 35.0±0.9 42.8±1.3 76.2±3.1 136.5±3.1 
125000x 
(1) 1.16 x 10
-2
 78.7±1.9 59.8±1.7 36.7±2.5 36.3±1.5 57.5±2.4 109.3±1.6 
125000x 
(2) 1.16 x 10
-2
 83.5±1.7 71.1±4.2 35.0±1.3 36.4±3.1 66.5±1.1 119.2±2.6 
Average  93.4 77.1 36.1 46.1 76.0 131.8 
 
SEn 618 ΔtolR ΔmsbB ΔpagP GMMA were characterized by averaged mean and 
mode values of 93.4 nm and 77.1 nm, respectively. NTA analyses did not show an 
acceptable reproducibility among experiments. Standard deviation SD, D10, D50 and 
D90 percentile values showed that GMMA sample was quite polydisperse. 
NTA technique was also investigated to calculate particles concentration. Effective 
protein concentrations (µg/mL) relative to each diluted sample were related to the 
measured concentrations provided by NTA (particles/mL) by calculation of 
particles/µg ratios. Linearity in the ratio among dilutions was expected. Results are 
summarized in Table 16. 
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Table 16. Particles concentration values of SEn 618 ΔtolR ΔmsbB ΔpagP GMMA analysed by NTA. 
Sample 
dilution  
Protein 
concentration 
µg/mL 
Particles/mL Particles/frame Particles/ µg 
10000x (1) 1.39 x 10
-1
 2.59 x 10
9
 131.2 1.86 x 10
10
 
10000x (2) 1.39 x 10
-1
 2.50 x 10
9
 127.0 1.80 x 10
10
 
25000x (1) 5.82 x 10
-2
 1.57 x 10
9
 79.8 2.70 x 10
10
 
25000x (2) 5.82 x 10
-2
 1.34 x 10
9
 68.2 2.30 x10
10
 
50000x (1) 2.90 x 10
-2
 1.10 x 10
9
 55.7 3.79 x10
10
 
50000x (2) 2.90 x 10
-2
 9.49 x 10
8
 48.2 3.27 x 10
10
 
75000x (1) 1.93 x 10
-2
 7.24 x 10
8
 36.7 3.75 x 10
10
 
75000x (2) 1.93 x 10
-2
 6.40 x 10
8
 32.5 3.32 x 10
10
 
100000x (1) 1.45 x 10
-2
 7.39 x 10
8
 37.5 5.11 x 10
10
 
100000x (2) 1.45 x 10
-2
 5.76 x 10
8
 29.2 3.99 x 10
10
 
125000x (1) 1.16 x 10
-2
 8.29 x 10
8
 42.1 7.12 x 10
10
 
125000x (2) 1.16 x 10
-2
 7.74 x 10
8
 39.3 6.65 x 10
10
 
 
At the different dilutions, there was no clear correlation between protein content and 
particles concentration. Linearity in particles/µg ratios was obtained only for three 
dilution factors (50000x, 75000x and 100000x). 
Different detection threshold values were applied in order to investigate the effect 
of this variable on the analysis (Table 17). 
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Table 17. Influence of detection threshold on NTA size and concentration estimations of SEn 618 ΔtolR 
ΔmsbB ΔpagP GMMA. 
Sample 
dilutions 
Detection 
threshold 
Protein 
concentration 
µg/mL 
Mean 
nm 
Mode 
nm 
Particles/
mL 
Particles/
frame 
Particles/ 
µg 
50000x 3 2.90 x 10
-2
 92.90 81.70 1.02 x 10
9
 51.95 3.53 x 10
10
 
 5 2.90 x 10
-2
 98.45 90.40 8.06 x 10
8
 40.90 2.78 x 10
10
 
 7 2.90 x 10
-2
 100.80 94.55 7.10 x 10
8
 36.05 2.45 x 10
10
 
 9 2.90 x 10
-2
 102.70 91.00 6.26 x 10
8
 31.80 2.16 x 10
10
 
 11 2.90 x 10
-2
 105.15 97.65 5.54 x 10
8
 28.10 1.91 x 10
10
 
 14 2.90 x 10
-2
 107.50 102.35 4.75 x 10
8
 24.10 1.64 x 10
10
 
 17 2.90 x 10
-2
 109.80 101.80 4.22 x 10
8
 23.9 1.45 x 10
10
 
Average   102.38 94.21    
75000x 3 1.93 x 10
-2
 92.20 77.25 6.82 x 10
8
 34.6 3.25 x 10
10
 
 5 1.93 x 10
-2
 99.15 89.00 5.20 x 10
8
 26.40 2.69 x 10
10
 
 7 1.93 x 10
-2
 101.50 87.75 4.57 x 10
8
 23.15 2.37 x 10
10
 
 9 1.93 x 10
-2
 104.45 93.40 4.02 x 10
8
 20.35 2.08 x 10
10
 
 11 1.93 x 10
-2
 106.65 85.90 3.57 x 10
8
 18.15 1.85 x 10
10
 
 14 1.93 x 10
-2
 110.00 90.45 3.06 x 10
8
 15.50 1.58 x 10
10
 
 17 1.93 x 10
-2
 112.65 101.95 2.72 x 10
8
 13.80 1.41 x 10
10
 
Average   103.80 89.24    
 
Increasing the detection threshold, large GMMA particles were detected and tracked, 
resulting in increased size values (both mean and mode), whereas the GMMA 
concentration decreased, due to the reduction of the number of detectable GMMA. 
Small or low scattering particles were not considered by NTA software in the 
calculation of the resulting size and concentration. Detection threshold needs to be 
selected by the operator according to the sample and to its dilution to have consistent 
results. Table 18 summarizes analysis performed on different diluted samples, by 
adjusting the detection threshold and obtaining consistent results both in terms of size 
and concentration (Fig. 25). 
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Table 18. Detection threshold values adjusted for scalar dilutions of SEn ΔtolR ΔmsbB ΔpagP GMMA. 
Sample 
dilution 
Detection 
threshold 
Protein 
concentration 
µg/mL 
Mean 
nm 
Mode 
nm 
Particles/
mL 
Particles/
frame 
Particles/ 
µg 
10000x 3 1.39 x 10
-1
 106.05 86.65 2.55 x 10
9
 129.1 1.83 x 10
10
 
25000x 7 5.82 x 10
-2
 108.40 90.85 1.10 x 10
9
 6ì58.35 1.90 x 10
10
 
50000x 11 2.90 x 10
-2
 105.15 97.65 5.54 x 10
8
 28.10 1.91 x 10
10
 
75000x 11 1.93 x 10
-2
 106.65 85.90 3.57 x 10
8
 18.15 1.85 x 10
10
 
100000x 14 1.45 x 10
-2
 103.90 98.40 2.82 x 10
8
 14.30 1.95 x 10
10
 
Average   106.03 91.89   1.89 x 10
10
 
 
 
 
Fig. 25. Linear correlation between particles/mL concentration measured by NTA at specific detection 
threshold values and effective protein concentration (µg/mL) of SEn 618 ΔtolR ΔmsbB ΔpagP 
GMMA. 
 
Mean value found by this way was in agreement with Z-average by DLS (106.03 vs 
111.80 nm). To be noted that mode values similar to the DLS hydrodynamic diameter 
of fraction 2 obtained after fractionation of the GMMA sample (91.89 vs 91.28 nm) 
were achieved. 
The analysis of a more homogenous sample was performed by analysing fraction 2 
from SEC fractionation of SEn 618 ΔtolR ΔmsbB ΔpagP (Fig. 21). The fraction was 
analysed at two different dilutions (1000x and 2000x) (Table 19). Video and analysis 
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settings were selected before analysis in accordance to sample visualization (screen 
gain 2, camera level 16, and detection threshold 7). 
 
Table 19. Size and concentration estimations of fraction 2 analysed by NTA after HPLC-SEC fractionation of SEn 
618 ΔtolR ΔmsbB ΔpagP GMMA. 
Sample 
dilution 
µg/ 
mL 
Mean 
nm 
Mode 
nm 
SD 
nm 
D10 
nm 
D50 
nm 
D90 
nm 
Particles/
mL 
Particles/ 
frame 
Particles/ 
µg 
1000x  
6.39 x 
10
-2
 
92.6 79.2 21.6 60.8 77.7 112.9 1.53 x 10
9
 77.6 
2.39 x 
10
10
 
2000x  
3.20 x 
10
-2
 
93.2 83.6 24.8 60.5 78.4 110.8 6.69 x 10
8
 33.95 
2.09 x 
10
10
 
Average  92.9 81.4 23.2 60.6 78.1 111.8 
  2.24 x 
1010 
 
More similarity between mean and mode hydrodynamic diameter was observed, 
differently from what found for the unfractionated GMMA. Lower SD and D90 and 
higher D10 values clearly showed that a more homogenous sample was obtained. The 
average value of the mean diameters for the two dilutions calculated at the same 
detection threshold is very similar to the DLS hydrodynamic diameter measured for 
the same fraction (92.9 vs 91.3 nm). Linearity of concentration at the two dilutions 
tested was observed. 
STm 2192 ΔtolR ΔpagP ΔmsbB, STm 1418 ΔtolR and STm 1418 ΔtolR ΔwbaP 
GMMA were also analysed by NTA. Several analysis were done per each sample at 
different dilutions, by selecting the more appropriate video and analysis values, being 
sure to obtain consistent results both in terms of size and concentration. Table 20 
summarizes results obtained. 
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Table 20. NTA results of SEn 618 ΔtolR ΔmsbB ΔpagP, STm 2192 ΔtolR ΔpagP ΔmsbB, STm 
1418 ΔtolR and STm 1418 ΔtolR ΔwbaP GMMA. 
GMMA sample Mean nm Mode nm Particles/µg 
SEn 618 ΔtolR 
ΔmsbB ΔpagP 
Whole 
population 
106.0 91.9 1.89 x 10
10
 
Central 
fraction (2) 
92.9 81.4 / 
STm 2192 ΔtolR 
ΔmsbB ΔpagP 
Whole 
population 
102.5 78.6 1.09 x 10
10
 
Central 
fraction (2) 
83.6 77.4 / 
STm 1418 ΔtolR 
Whole 
population 
95.8 85.6 1.47 x 10
10
 
Central 
fraction (2) 
84.9 74.5 / 
STm 1418 ΔtolR 
ΔwbaP 
Whole 
population 
77.0 52.30 3.32 x 10
9
 
 
Unfractionated and SEC central fraction of STm 2192 ΔtolR ΔmsbB ΔpagP and STm 
1418 ΔtolR GMMA showed a similar behaviour as seen for SEn GMMA. The mode 
diameters of the unfractionated samples were similar to the mean values of the 
fraction corresponding to the central area of the GMMA samples. NTA analysis of 
STm ΔtolR ΔwbaP GMMA revealed a high difficulty in proper tracking and 
enumerating particles, probably due to their smaller dimensions and to their higher 
polydispersity (Fig. 23, 26). 
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Fig. 26. NTA graphs of STm 1418 ΔtolR ΔwbaP GMMA. 
 
3.3.4 Comparison of DLS, MALS and NTA results 
 
Dimensional analyses performed on SEn 618 ΔtolR ΔmsbB ΔpagP, STm 2192 
ΔtolR ΔpagP ΔmsbB, STm 1418 ΔtolR and STm 1418 ΔtolR ΔwbaP GMMA are 
summarized in Table 21. 
 
Table 21. Summary of the analyses performed by DLS, SEC-MALS and NTA on SEn 618 ΔtolR ΔmsbB 
ΔpagP, STm 2192 ΔtolR ΔpagP ΔmsbB, STm 1418 ΔtolR and STm 1418 ΔtolR ΔwbaP GMMA. 
GMMA sample 
DLS SEC-MALS NTA 
Z-average 
diameter  
nm 
2 x Rn 
nm 
2 x Rw 
nm 
2 x Rz 
nm 
Mean 
diameter  
nm 
Mode 
diameter  
nm 
SEn 618 
ΔtolR 
ΔmsbB 
ΔpagP 
Whole 
population 
111.8 71.8 73.2 74.9 106.0 91.9 
Central 
fraction (2) 
91.3 67.9 69.0 70.5 92.9 81.4 
STm 2192 
ΔtolR 
ΔmsbB 
ΔpagP 
Whole 
population 
103.0 67.8 69.4 71.8 102.8 78.6 
Central 
fraction (2) 
81.7 68.7 69. 7 71.2 83.6 77.4 
STm 1418 
ΔtolR 
Whole 
population 
91.4 70.0 71.5 73.8 95.8 85.6 
Central 
fraction (2) 
na na na na 84.9 74.5 
STm 1418 
ΔtolR 
ΔwbaP 
Whole 
population 
57.6 51.0 52.6 55.4 77.0 52.3 
na: not analysed. 
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Unfractionated GMMA shed by SEn 618 ΔtolR ΔmsbB ΔpagP, STm 2192 ΔtolR 
ΔpagP ΔmsbB, STm 1418 ΔtolR were characterized by different DLS hydrodynamic 
diameters, ranging from 111.8 to 91.4 nm. STm 1418 ΔtolR ΔwbaP, instead, showed 
an average hydrodynamic size of 57.6 nm. For all OAg-positive (OAg+) GMMA, Z-
average size by DLS was higher compared to the 2 x Rz values obtained by SEC-
MALS. Not the same was found for OAg-negative (OAg-) GMMA, suggesting that 
the values by DLS were not only related to the overestimation of large particles by 
this method. The difference observed could be related to the presence of the OAg 
chains displayed on GMMA surface, which play an important role in determining the 
behaviour of GMMA in solution. OAg+ GMMA were in fact characterized by a 
similar SEC-MALS diameter value of around 70 nm. 
OAg chains specificities, including tridimensional conformation, number of 
repeating units, O-acetylation and glucosylation level, as well as the amount of lipid 
A, its structure and the percentage of OAg chains respect to total LPS molecules can 
determine the overall size of GMMA (Table 22). By looking at these characteristics, it 
was found a correlation between DLS diameters and number of OAg chains per 
GMMA particle (Fig. 27). 
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Table 22. Characterization of SEn 618 ΔtolR ΔmsbB ΔpagP, STm 2192 ΔtolR ΔpagP ΔmsbB, STm 1418 ΔtolR 
and STm 1418 ΔtolR ΔwbaP GMMA trying to correlate GMMA size with their main features. 
GMMA 
sample 
OAg 
Lipid 
A 
type 
Z-
average 
nm 
2 x Rz 
nm 
µg 
protein/
GMMA 
OAg 
MM 
kDa 
molar 
% OAg/ 
Lipid A  
OAg 
molecules/ 
GMMA 
Lipid A 
molecules/ 
GMMA 
SEn 618 
ΔtolR 
ΔmsbB 
ΔpagP 
OAg+ penta 111.8 74.9 
5.30 x 
1011 
30.0 16.6 2812 16960 
STm 
2192 
ΔtolR 
ΔmsbB 
ΔpagP 
OAg+ penta 103.0 71.8 
9.19 x 
1011 
34.6 10.2 2204 21527 
STm 
1418 
ΔtolR 
OAg+ 
hepta/ 
hexa 
91.4 73.8 
6.78 x 
1011 
32.9 7.0 768 11035 
STm 
1418 
ΔtolR 
ΔwbaP 
OAg- 
hepta/ 
hexa 
57.6 55.4 
3.01 x 
1010 
/ / / 49248 
 
 
 
Fig. 27. Correlation between DLS Z-average diameter and MALS 2 x Rz values and number of OAg 
chains per GMMA particle. 
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Average size of OAg chains was similar for all OAg+ GMMA tested and no 
correlation was found between GMMA size and protein or lipid A content (Fig 28, 
29). 
 
 
 
Fig. 28. Lack of correlation between DLS Z-average diameter and MALS 2 x Rz values and number of 
lipid A molecules per GMMA particle. 
 
 
 
Fig. 29. Lack of correlation between DLS Z-average diameter and MALS 2 x Rz values and µg protein 
per GMMA particle. 
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As expected, NTA hydrodynamic mean diameters of unfractionated OAg+ GMMA 
were found to be similar to the Z-average values determined by DLS (Table 21). NTA 
presented the advantage to provide not only an average size value like DLS, but also a 
mode value, overcoming the problem of the DLS analysis. Analysing both 
unfractionated OAg+ GMMA samples and the SEC fractions corresponding to the 
central area of the GMMA population allowed better understanding of this. In fact, 
the NTA mode values of the unfractionated samples were in agreement with the DLS 
Z-average diameters of the central fraction of the OAg+ GMMA samples. Moreover, 
as expected, the mode values of the unfractionated and mean diameters of the central 
fractions both obtained by NTA were in good accordance. An appreciable aspect 
provided by NTA is represented by a deeper evaluation of GMMA samples. In 
particular, SD, D10, D50 and D90 percentile values add more information on particle 
sample characterization. For unfractionated GMMA, the difference between mean and 
mode values, as well as SD, D10, D50 and D90 values, clearly showed that GMMA 
samples were quite polydisperse. This moderate polydispersity made the analysis 
more difficult and the need to adjust the video and analysis settings during NTA 
sample visualization was indispensable. Fractionation of GMMA represented the way 
to achieve more homogeneity in size and scattering intensity shown by each particle 
visualized. Analysis of more homogeneous samples made manageable to obtain more 
consistent and reproducible results, requiring also a quite slight or no adjustment of 
NTA software settings. More homogeneity was also observed by the smaller gap 
between mean and mode sizes, as well as the low SD value and the small gap between 
D10 and D90 percentile values. In the case of the STm 1418 ΔtolR ΔwbaP OAg- 
GMMA, NTA was able to confirm a smaller size respect to the other GMMA and 
similarity was observed with DLS and MALS size values (~50 nm), confirming that 
OAg- ΔwbaP GMMA are much smaller respect to OAg+ ones. Z average and 2 x Rz 
values resulted more in agreement, suggesting that the OAg shell around GMMA 
plays a role in determining the behaviour of GMMA in solution. 
It was above reported that NTA data interpretation was quite complex, both in size 
and concentration determination. 
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3.5 Discussion 
 
Particle size distribution is an important parameter to check quality, consistency of 
production and stability of GMMA samples. Here, DLS, MALS and NTA were 
compared for the analysis of GMMA from different strains. 
DLS allowed precise and reliable GMMA particle size analysis in few minutes, 
with rapid and simple sample preparation and instrument set up. A major drawback of 
DLS is that it is inherently sensitive to the presence of large particles in the sample in 
analysis [176] as verified by analysing unfractionated and fractionated GMMA 
samples. It is expected that the DSL Z-average size distribution of polydisperse 
samples is biased by even a small number of large particles, because such particles 
scatter light more efficiently than small ones [180, 181]. DLS measurements require 
careful data interpretation, especially when polydisperse or multimodal particle 
samples are investigated, including comparison with other size-analysing techniques, 
also based on different physical properties. 
SEC-MALS is a rapid and robust method for GMMA size characterization, able to 
separate, characterize and quantify generally occurring contaminants, such as free 
soluble protein and DNA. Both DLS and MALS provide size measurements based on 
absolute analyses of samples in solution, independently of calibration standards. DLS 
and MALS technologies are complementary and independent, analysing different 
properties of the scattered light. 
NTA is an alternative light scattering technology that simultaneously but 
individually tracks and analyses the trajectories of GMMA in suspension. Many of the 
problems associated with ensemble techniques as DLS are overcome. NTA can detect 
small, weakly-scattering particles among large, strong-scattering ones that would 
dominate the size distribution of a particle sample analysed by DLS. NTA is also able 
to resolve bimodal particle populations at resolutions that are significantly better than 
those achieved by DLS [176]. NTA not only allows size determination, but also 
counting particles number. However, for NTA analysis, a range of parameters need to 
be adjusted both for video capture (camera gain and shutter speed) and data 
elaborations (filter settings, background subtraction, removal of blurring, minimum 
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track length, minimum expected particle size and detection threshold). 
Standardization of the NTA techniques is difficult to be achieved due to the high 
number of options that the user can select before a NTA experiment [164], which is 
highly operator dependent [157, 162, 176, 178, 182]. Our study confirmed that 
detection threshold is one of the parameters that can strongly affect both size and 
concentration NTA estimations [162]. In particular, NTA analyses did not show an 
acceptable reproducibility among experiments performed using scalar-diluted samples 
at a fixed detection threshold value, both in GMMA size and concentration. Fixed 
video capture and video analysis parameters should not be used and a skilled operator 
is required in order to achieve reproducible size and concentration values. 
In conclusion, all the three techniques provided complementary information 
allowing a more complete evaluation of GMMA size. 
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4. KDO reactivity and selectivity in the synthesis of OAg-
CRM197 glycoconjugate vaccines 
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4.1 Introduction 
 
Covalent conjugation of the OAg component of LPS to an appropriate carrier 
protein represents one of the main strategies for the development of a bivalent vaccine 
against iNTS [72, 79, 80, 108]. In the strategy adopted by GVGH, S. Typhimurium 
and S. Enteritidis OAg chains are independently linked to CRM197, a non-toxic variant 
of diphtheria toxin [105] as carrier protein [77, 107]. The terminal unit of the LPS 
core oligosaccharide (OS), the 3-Deoxy-D-manno-oct-2-ulosonic acid (KDO) sugar, 
is expected to be involved in the selective linkage of OAg to the protein through the 
introduction of linker molecules, without impact on epitopes of OAg chain, which is 
the key target antigen for immunogenicity [106]. Reductive amination of KDO with 
adipic acid dihydrazide (ADH) and activation of free ADH hydrazide group with 
adipic acid bis-(N-hydroxysuccinimide) ester (SIDEA) are then followed by 
conjugation to the lysine residues of CRM197 [106, 107] (Scheme 2). 
 
 
 
Scheme 2. OAg conjugation steps for the synthesis of OAg-CRM197 glycoconjugates [106]. 
 
OAg chains are extracted from bacteria, by performing direct acetic acid 
hydrolysis in the fermentation broth [118]. Hydrolysis cleaves the labile linkage 
between the core OS and the lipid A of LPS, releasing the OAg chains in the 
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supernatant and leaving the lipid A within the bacterial pellet (Fig. 30). The resulting 
OAg chains have KDO as the reducing terminus, available for conjugation [73, 183, 
184]. 
 
 
 
Fig. 30. Salmonella OAg chains extraction by acetic acid hydrolysis performed directly on bacteria. 
OAg chains are released in the fermentation broth removed of the toxic lipid A [118]. 
 
This process was successfully applied to various Salmonella enterica serovars, 
obtaining good yields of high-quality material. However, there is no evidence that, 
after this acid treatment on bacteria, the KDO is left at the reducing end with its native 
structure [185-187]. 
Previous attempts of identification of the terminal KDO were complicated by the 
presence of many OAg repeating units with respect to only one KDO sugar per chain. 
Furthermore structural rearrangements of KDO in unreactive forms to classical 
methods for KDO quantification can happen [187-193]. After mild acid hydrolysis of 
the LPS for lipid A removal, the terminal KDO may undergo lactonization, formation 
of anhydro derivatives, and other not well characterized artifacts which make 
identification and quantification of KDO much complex [194, 195] (Fig. 31). 
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Fig. 31. 4-linked phosphate-KDO structural rearrangements observed during mild acid hydrolysis for 
lipid A removal (adapted from Sioud et al) [196]. 
 
The high reactivity of KDO in reductive amination reactions has been imputed to the 
formation of anhydro derivatives (Fig. 31), which have the ketone group not involved 
in an hemiketal linkage [194, 197]. 
In order to facilitate the investigation on KDO structure and reactivity, core OS 
from OAg- GMMA and oligosaccharides deriving from the exopolysaccharide 
produced by B. cepacia strain BTS13 containing KDO [198] were used as model 
molecules. Core OS was also used as model for the synthesis and the characterization 
of CRM197 conjugates. 
These studies have contributed to better characterize the Salmonella antigens and 
help to improve manufacturing processes for OAg-based glycoconjugate vaccines 
synthesis and characterization. 
 
  
SDBM - School of 
Molecular Biomedicine 
 
 
86 
 
4.2 Materials and Methods 
 
4.2.1 B. cepacia strain BTS13 for exopolysaccharide (EPS) production 
 
B. cepacia strain BTS13 [199] was isolated from a cystic fibrosis patient attending 
the Cystic Fibrosis Regional Centre of Friuli-Venezia Giulia (Trieste, Italy). The EPS 
was obtained as already described [198]. 
 
4.2.2 B. cepacia BTS13 EPS hydrolysis and oligosaccharides purification 
 
Mild acid hydrolysis (v/v 1% acetic acid at 100 °C for 3 h) was performed on a 2 
mg/mL EPS solution. After evaporation of the acid under reduced pressure, the 
oligosaccharides were recovered by freeze-drying. Gel filtration chromatography on a 
Bio-Gel P-10 column (90 cm x 1.6 cm i.d., Bio-rad) with differential refractive index 
detection (dRI, WGE Dr. Bures Δn-1000, Labservice Analytica) was used to 
fractionate the oligosaccharides of different size. The mobile phase was NaNO3 0.05 
M at the flow rate of 8 mL/h. Fractions were collected at 15 min intervals and were 
desalted by gel filtration chromatography on a Bio-Gel P-2 column (90 cm x 1.6 cm 
i.d., flow rate 8 mL/h, Bio-Rad). 
 
4.2.3 STm 1418 ∆tolR ∆wbaP GMMA production and characterization 
 
GMMA were produced and purified as described in the Chapter 3. 
 
4.2.4 LPS core OS purification 
 
For extraction of the LPS core OS from GMMA, a mild acid hydrolysis (v/v 2% 
acetic acid at 100 °C for 1 h) was performed directly on the GMMA suspension 
(protein concentration of 1 mg/mL). The core OS released into the supernatant was 
recovered following centrifugation (14000 rpm, 1 h, 4 °C). The acidic supernatant 
was evaporated under reduced pressure and washed 3 times with water, in order to 
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remove the residual acetic acid, and then freeze-dried. Gel filtration chromatography 
was performed as described above on the same Bio-Gel P-10 column. Fractions were 
desalted by gel filtration chromatography on a Bio-Gel P-2 column (90 cm x 1.6 cm 
i.d., flow rate 8 mL/h, Bio-Rad) or on a Sephadex G-10 column (14 cm x 1.6 cm i.d., 
flow rate 1.6 ml/min, GE Healthcare Life Sciences). 
 
4.2.5 De-phosphorylation of core OS 
 
LPS core OS was solubilized in 48% HF at a concentration of 40 mg/mL, and 
mixed at 4 °C for 48 h. Residual HF was neutralized by adding CaCO3 powder. De-
phosphorylated core OS was purified on PD-10 desalting column packed with 
Sephadex G-25 resin (GE Healthcare Life Sciences) and freeze-dried. 
 
4.2.6 Reduction of native and de-phosphorylated core OS 
 
Native and de-phosphorylated core OS were solubilized in water at a concentration 
of 8 mg/mL and NaBH4 was added. The solutions were mixed at RT for 16 h. At the 
end, residual NaBH4 was neutralized by adding 50% AcOH. Products were 
evaporated under reduced pressure three times with 10% AcOH in MeOH and three 
times with MeOH. Reduced oligosaccharides were purified on PD-10 desalting 
column packed with Sephadex G-25 resin (GE Healthcare Life Sciences) and freeze-
dried. 
 
4.2.7 LPS core OS characterization 
 
Structural analysis of purified core OS and/or its derivatives was performed by 
HPAEC-PAD, HPLC-SEC after derivatization with semicarbazide, and 1H NMR, as 
reported in Chapter 2. Heptose (Hep) was estimated by HPAEC-PAD after de-
phosphorylation with HF and acid hydrolysis of the core OS to release the 
monosaccharides. Commercial monosaccharide was used for building the calibration 
curves in the range 0.5-10 µg/mL. Core OS samples, diluted to have Hep content in 
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the range 0.5-10 µg/mL, were hydrolysed at 100 °C for 4 h in 1 M trifluoroacetic acid 
(TFA). After the hydrolysis, samples were chilled at 2-8 °C for about 30 min, dried by 
SpeedVac overnight, dissolved in water, and filtered using 0.45-µm Acrodisc (PALL) 
filters before chromatographic analysis. HPAEC-PAD was performed with a Dionex 
ICS3000 equipped with a CarboPac PA10 column (4 x 250 mm) coupled with a PA10 
guard column (4 x 50 mm). A flow rate of 1 mL/min was used, eluting with 18 mM 
NaOH for 20 min and then with 100 mM AcONa in 28 mM NaOH for 10 min. The 
effluent was monitored using an electrochemical detector in the pulse amperometric 
mode with a gold working electrode and an Ag/AgCl reference electrode. The Dionex 
standard quadruple-potential waveform for carbohydrates was used. The resulting 
chromatographic data were processed using Chromeleon software 6.8. The standards 
were hydrolysed and analysed in the same way as samples. 2,4,6-trinitrobenzene 
sulfonic acid (TNBS) colorimetric method was performed for amino groups 
quantification [200, 201]. 
 
4.2.8 ESI-MS analysis 
 
Electrospray Ionization mass spectra were recorded on a Bruker Esquire 4000 ion 
trap mass spectrometer connected to a syringe pump for the injection of the samples. 
The instrument was calibrated using a tune mixture provided by Bruker. 
Oligosaccharides were dissolved in 50% aqueous methanol-11 mM NH4OAc. 
Samples were injected at 180 μL/h. Detection was performed both in the positive and 
negative ion modes. 
 
4.2.9 MALDI-TOF-MS analysis 
 
Matrix-Assisted Laser Desorption Ionization - Time of Flight mass spectra were 
recorded by UltraFlex III MALDI-TOF/TOF instrument (Bruker GmBH) in linear 
mode and with negative ion detection or by a Perceptive (Framingham, MA, USA) 
Voyager STR equipped with delayed extraction technology. Ions formed by a pulsed 
UV laser beam (nitrogen laser, k = 337 nm) were accelerated by 24 kV. The mass 
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spectra were the result of 256 laser shots. The samples for analysis were prepared by 
mixing 2 μL of product and 2 μL of 2,5-dihydroxybenzoic acid (DHB) 50 mg/mL in 
50% acetonitrile (ACN) v/v as matrix solution. 2 μL of each mixture were deposited 
on samples plate, dried at room temperature for 10 min and subjected to the 
spectrometer analysis. 
 
4.2.10 Reaction of core OS with adipic acid dihydrazide (ADH) 
 
Core OS were solubilized in 100 mM AcONa pH 4.5 at a concentration of 40 
mg/mL. ADH and NaBH3CN were added as solids, both with a ratio 2.4:1 by weight 
with respect to the oligosaccharide (quantified based on Gal quantification by 
HPAEC-PAD). The solution was mixed at 30 °C for 2 h. The reaction mixture was 
diluted in 6 M NaCl and purified on a Biogel P-10 column (90 cm x 1.6 cm i.d., Bio-
Rad). The mobile phase was NaNO3 0.05 M at the flow rate of 0.15 mL/min. Biogel 
P-10 fractions corresponding to the reaction product were desalted by gel filtration 
chromatography on a Sephadex G-10 column 28 mL (14 cm x 1.6 cm i.d., flow rate 
1.6 ml/min, GE Healthcare Life Sciences). 
 
4.2.11 Characterization of core OS-ADH intermediate 
 
Derivatized core OS were characterized by HPAEC-PAD for neutral sugars 
quantification and by HPLC-SEC for verifying aggregation or degradation after 
modification. TNBS colorimetric method was used for total NH2 group quantification 
after introduction of ADH using ADH as standard and subtracting the number of NH2 
groups already present on the un-derivatized oligosaccharide. Free ADH was detected 
by Reversed Phase - High Performance Liquid Chromatography (RP-HPLC) after 
derivatization with TNBS. A 600 nmol/mL solution of ADH was used to create a 
calibration curve in the 0.8 to 20 nmol/mL of amino groups range. Samples were 
diluted with MilliQ water in order to obtain sample amino groups concentration in the 
range of the calibration curve. Samples and calibration curves were created in 
duplicates and to a final volume of 250 µL. A volume of 250 μL of 70 mM Sodium 
  
SDBM - School of 
Molecular Biomedicine 
 
 
90 
 
Phosphate pH 7.5 solution and a volume of 250 μL of 0.1% solution of TNBS were 
added to standards and samples. Samples were incubated for 2 h at 40 °C in a pre-
heated thermostatic bath. Cooled-down samples (10 µL injected) were eluted on a 
Kinetex reversed-phase column (2.6 µm, 50x4.6 mm, Phenomenex) on a Waters 
Acquity H Class UPLC system with in-line UV, fluorescence emission, dRI detectors. 
Samples were eluted with a flow rate of 1.0 mL/min and eluent mixture was generated 
by pump system. The eluent program (total run time 50 minutes) was: 90% water, 
10% ACN in isocratic condition for 10 min; linear gradient to 10% water, 90% ACN 
in 10 minutes; 10% water, 90% ACN in isocratic condition for 10 minutes; 90% 
water, 10% ACN in isocratic condition for 20 minutes (column re-equilibration). 
Detection was done at 425 nm. The amount of free ADH was calculated using the 
calibration curve built with the peak areas of derivatized ADH standards at 425 nm. 
Activation on the terminus KDO with ADH was calculated as moles of linked 
ADH/moles of core OS % (taking into account Gal amount derived by HPAEC-PAD 
analysis). 
 
4.2.12 Reaction of core OS-ADH and core OS with adipic acid bis-(N-
hydroxysuccinimide) ester (SIDEA) 
 
For verifying reactivity of PPEtN NH2 groups at two different pH, 
oligosaccharides were dissolved at 10 mg/mL in DMSO/H20 9:1 with addition of 
triethanolamine (TEA) (molar ratio TEA/total NH2 groups = 5) or in DMSO/HCl 82.5 
ppm 9:1 (v/v). When the oligosaccharides were completely solubilized, SIDEA was 
added as solid (molar ratio SIDEA/total NH2 groups = 3). The solution was mixed at 
RT for 3 h. In the case of core OS derivatization, unreacted free SIDEA was then 
precipitated by addition of water (90% volume in the resulting solution) and then 
washing the pellet with water (3 times with 1/2 of the volume added for the 
precipitation) and the supernatant lyophilized. For core OS-ADH, reaction product 
was precipitated by addition of 1,4-dioxane (90% volume in the resulting solution) 
and then the pellet was washed with the same organic solvent (3 times with 1/2 of the 
volume added for the precipitation) to remove residual free SIDEA and lyophilised. 
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Reaction conditions were adjusted for the synthesis of the intermediates to be 
conjugated to CRM197. Core OS and core OS-ADH were dissolved in DMSO/HCl 
82.5 ppm 9:1 (v/v) at a concentration of 5 mg/mL (core OS-ADH) or 10 mg/mL (core 
OS). After their complete solubilisation, SIDEA was added as solid (molar ratio 
SIDEA/total NH2 groups = 12). The solution was mixed at RT for 1 h. Purification 
was performed by precipitation of unreacted SIDEA by addition of HCl 82.5 ppm 
(1:1 v/v respect to reaction mixture) and precipitation of oligosaccharides by addition 
of ethanol (90% volume in the resulting solution). The pellet was then washed with 
the same organic solvent (twice with 1.5 times of the reaction volume), to remove 
residual free SIDEA, and lyophilised. 
 
4.2.13 Characterization of SIDEA-derivatized core OS intermediates 
 
SIDEA-derivatized intermediates were characterized by HPAEC-PAD for neutral 
sugars quantification and by HPLC-SEC for verifying aggregation or degradation 
after modification on TSK gel G3000 PWXL column (30 cm x 7.8 mm; particle size 7 
µm, Tosoh Bioscience) and with UV, fluorescence emission, dRI detectors. TNBS 
colorimetric method was used for the residual NH2 groups quantification after 
introduction of SIDEA using 6-aminohexanoic acid (core OS) or ADH (core OS-
ADH) as standard. Total active ester groups introduced with SIDEA were quantified 
by RP-HPLC as N-hydroxysuccinimide (NHS) groups. A 100 nmol/mL solution of 
NHS was used to create a calibration curve of NHS in the 3 to 50 nmol/mL range. 
Samples were diluted with MilliQ water in order to obtain samples NHS 
concentration in the range of the calibration curve Samples and calibration curves 
were created in duplicates. A volume of 50 µL was injected and analysed on a 
Gemini-NX C18 reversed-phase column (5.0 µm, 110A, 250x4.6 mm, Phenomenex) 
on a Waters Acquity H Class UPLC system with in-line UV, fluorescence emission, 
dRI detectors. Samples were eluted with a flow rate of 1.0 mL/min and eluent mixture 
was generated by pump system. The eluent program (total run time 8 minutes) was: 
80% 10 mM tert-butyl ammonium bromide (TBABr) in 0.17% ammonium hydroxide, 
20% ACN in isocratic condition for 8 min. Detection was done at 260 nm. Percentage 
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of derivatization with SIDEA was calculated as molar ratio % of derivatized NH2 
groups/total NH2 groups present prior the reaction by TNBS colorimetric assays. 
Percentage of active ester groups was calculated as molar % of total active NHS 
groups introduced/derivatized NH2 groups. 
 
4.2.14 Synthesis of core OS-CRM197 conjugates 
 
SIDEA-derivatized core OS intermediates were solubilized in 100 mM NaH2PO4 
buffer pH 7.2 and CRM197 was added to give a protein concentration of 5 mg/mL and 
a molar ratio of active ester groups to CRM197 of 30 to 1. The reactions were mixed at 
RT for 3 h. Conjugates were purified by 2 mL Vivaspin (cut off 30 kDa, Sartorius 
AG) against 5 mM NaH2PO4 pH 7.2. 
 
4.2.15 Characterization of purified OS-CRM197 conjugates 
 
Neutral sugars content was quantified by HPAEC-PAD, protein content by micro 
BCA protein assay and the molar ratio of oligosaccharide content (relative to Gal 
amount by HPAEC-PAD) with respect to protein amount was calculated. HPLC-SEC 
analysis was used to characterize conjugates, in comparison with unconjugated 
oligosaccharide and free CRM197. Conjugates were eluted on a TSK gel 3000PW-XL 
with guard column in 0.1 M NaCl, 0.1 M NaH2PO4, 5% CH3CN, pH 7.2, mobile 
phase at the flow rate of 0.5 mL/min. Core OS average loading on CRM197 was 
determined by MALDI-TOF analysis. A volume of 2 µL of conjugates was mixed 
with 2 µL of a saturated solution of Super DHB in 50% acetonitrile solution 
containing 0.1% TFA. A volume of 2 µL of the mix was spotted on a MTP 384 
stainless steel target (Bruker Daltonics GmbH, Bremen, Germany) and allowed to air-
dry. Measurements were recorded on an UltraFlex III (Bruker GmBH) MALDI-
TOF/TOF MS in linear mode. External calibration was performed by spotting a 
volume of 2 µL of protein calibration standard II (Bruker Daltonics) containing the 
following proteins: trypsinogen (23,982 Da), protein A (44,613 Da) and bovine serum 
albumin (66,431 Da). All mass spectra were recorded by summing up to 400 laser 
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shots. The Flex Analysis software packages provided by the manufacturer were used 
for data processing. Glycoconjugates were analysed by SDS-PAGE for verifying 
conjugate formation. 7% Tris-acetate gels (NuPAGE, Invitrogen) were used. The 
samples (5-20 µL with a protein content of 5-10 µg) were mixed with NuPAGE LDS 
sample buffer (1/5 v/v). The gel, containing loaded samples, was electrophoresed at 
45 mA in NuPAGE Tris-Acetate SDS running buffer (20x, Invitrogen) and stained 
with Simply Blue Safe Stain (Invitrogen). 
 
4.2.16 Synthesis and characterization of OAg-ADH-SIDEA-CRM197 conjugate 
 
The conjugate was produced by Renzo Alfini and characterized as described by 
Stefanetti et al [107]. OAg purified from 2192 S. Typhimurium strain was used for 
conjugation. OAg-CRM197 conjugate with an OAg/protein ratio of 2.29 and an 
average number of 5 sugar chains linked to CRM197 was subjected to chemical de-
glycosylation and trypsin digestion as the core OS-CRM197 conjugates. 
 
4.2.17 Glycoconjugates de-glycosylation by trifluoromethanesulphonic acid 
(TFMS) [202]. 
 
Such procedure was applied to core OS-CRM197 and OAg-ADH-SIDEA-CRM197 
conjugates. An amount of 200 µg of protein was diafiltered using 30 kDa Vivaspin 2 
(Sartorius AG) against water for a complete removal of salt and lyophilized. The 
reactive mixture was prepared under N2, mixing TFMS and anisole in a ratio 10:1 v/v. 
A volume of 50 µL was added under N2 to the lyophilized samples and gently mixed. 
After a complete dissolution, the solution was mixed at 4 °C for 2 h. The reaction was 
stopped by adding 60% pyridine at -20 °C. The solution was dialysed at 4 °C against 
50 mM NH4HCO3 pH 8 in Slide-a-Lyzer membrane (cut off 10 kDa, Thermofisher) 
for pyridine and monosaccharides removal. 
 
4.2.18 Trypsin digestion of de-glycosylated conjugates 
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An amount of 100 µg of TFMS-de-glycosylated conjugates in 50 mM NH4HCO3 
pH 8 was subjected to trypsin enzymatic digestion. A 200 µg/mL trypsin solution was 
added to give a w/w ratio of CRM197 to trypsin of 20 to 1. The solution was mixed at 
37 °C for 16 h and stored at -80° C. 
 
4.2.19 MALDI-MS analysis for peptide mapping 
 
Spectra were recorded by UltraFlex III MALDI-TOF/TOF instrument (Bruker 
GmBH) both in reflection and linear mode and with positive ion detection (m/z range 
between 500 and 5800) by Dr. Laura Salvini (Toscana Life Sciences, Siena, Italy). A 
volume of 2 µL of de-glycosylated/digested conjugates was mixed with 2 µL of a 
saturated solution of α-cyano-4-hydroxycinnamic (HCAA) in 50% ACN solution 
containing 0.1% TFA. A volume of 2 µL of the mix was spotted on a MTP 384 
stainless steel target (Bruker Daltonics GmbH, Bremen, Germany) and allowed to air-
dry. MS analysis data were elaborated using Biotools and Sequence editor softwares 
(Bruker, GmBH). 
 
4.2.20 LC-ESI-MS analysis for peptide mapping 
 
Conjugates peptide mapping analysis was performed by Dr. Stefano Gotta (GSK 
Analytical R&D Mass Spectrometry, Siena, Italy). De-glycosylated/digested 
conjugates were separated by liquid chromatography (LC) on an ACQUITY UPLC I-
Class system (Waters) coupled to a Q Exactive Plus HRMS (Thermo Scientific). 
Peptides were loaded and separated on an Acquity UPLC CSH C18 130Å column (1 
mm X 150 mm, 1.7 µm, Waters) set at 50 °C using a flow rate of 0.05 mL/min in 
gradient mode. Mobile phase A consisted of 3% ACN 0.1% formic acid in water and 
mobile phase B of 0.1% formic acid in ACN. The following gradient was used: 0-
28% B in 40 min, 28-85% B in 5 min, holding at 85% B for 5 min and re-
equilibration at 0% B for 10 min. The injection volume was 10 μL. For each sample 
the LC-MS/MS runs were performed in triplicate. The mass spectrometric method 
used was an automated Data-Dependent Acquisition (DDA) based on the top 5 
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precursors. The acquisition software was XCalibur, version 3.0.63 (Thermo 
Scientific) and the mass spectrometer was a Q Exactive Plus from Thermo Scientific. 
The ESI source was operated in positive mode with the following parameters: 
capillary temperature, 320 °C; spray voltage, 3.5 kV; sheath gas (nitrogen) flow rate, 
35; and aux gas flow, 15. Data was acquired using full MS scan (resolution: 70.000; 
AGC target: 3e6; Maximum IT: 200 ms; scan range: m/z 300-1600) and collision 
induced dissociation (CID) based data dependent MS/MS (DDMS2) (Resolution: 
17.500; AGC target: 1e5; Maximum IT: 150 ms; Loop count: 5; TopN = 5; Isolation 
window: m/z 3.0; Scan range: m/z 200-2000; NCE: 26; Underfill ratio: 3.8%; 
intensity threshold: 2.5e4; Apex trigger: 6-12 s; Dynamic exclusion: 12 s). 
Peptide identifications, ion map alignment, and area quantification were carried out 
using the software Peak Studio 8.0 (BSI, Waterloo, ON) with the following 
parameters: 15 ppm parent mass error tolerance and 0.05 Da fragment mass tolerance, 
a maximum of 4 allowed missed cleavages, semi-tryptic specificity. Oxidation (M), 
de-amidation (NQ), pyro-Gln (Q), and the specific linker-carbohydrate adducts on 
lysine (K), were set as variable modifications. Database search was performed using a 
custom database made of the CRM197 sequence and a consistent list of classical 
contaminants. False discovery rate (FDR) estimation was enabled by the use of a 
corresponding decoy database. A FDR <0.1% was applied as a confidence filter of 
peptide identifications. 
 
4.3 Results 
 
4.3.1 Characterization of core OS from STm 1418 ΔtolR ΔwbaP GMMA 
 
With the aim of facilitating the investigation on KDO structure and reactivity, 
GMMA shed by a mutant of S. Typhimurium 1418 strain with tolR and wbaP gene 
deletions (STm 1418 ΔtolR ΔwbaP) were produced. The deletion wbaP led to the 
synthesis of LPS lacking the OAg repeats [203]. Their absence with the achievement 
of a lipo-oligosaccharide (LOS) on GMMA surface, made easier to verify the KDO 
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presence, to evaluate its structure after mild acid hydrolysis and to study its reactivity 
in the conjugation process to CRM197. 
Sugar composition of purified core OS (Table 23) is in agreement with Salmonella 
LPS structure reported in the literature [204] (Fig.32). 
 
Table 23. Characterization of core OS extracted from STm 1418 ∆tolR ∆wbaP GMMA. Neutral 
sugars were determined by HPAEC-PAD, HPLC-SEC/semicarbazide was used for KDO 
quantification, and TNBS colorimetric assay for pyrophosphorylethanolamine (PPEtN) 
quantification. 
Core OS Gal Glc GlcNAc Hep* KDO PPEtN 
Molar ratios 1.00 0.95 0.43 1.54 0.52 0.49 
*Hep quantification after core OS de-phosphorylation. 
 
 
 
Fig. 32. Salmonella LPS core OS structure, as reported in literature for Salmonella strains [204]. 
 
Core OS resulted 100% substituted with PPEtN (as verified by TNBS), indicating 
also PPEtN stability in the extraction conditions. 
The extracted oligosaccharide was analysed by ESI-MS (both positive and 
negative ion polarity (Fig. 33). 
 
  
SDBM - School of 
Molecular Biomedicine 
 
 
97 
 
 
 
Fig. 33. ESI-MS spectrum of core OS (positive ion polarity). Ion having 1972.4 u corresponds to the 
sodium adduct of the core OS. Ion having 1892.5 u was attributed to core OS lacking a phosphate 
group (P), ion at 1848.5 u corresponds to the core OS lacking PEtN group. Ion having 1769.5 u was 
attributed to the core OS lacking P and PEtN (or PPEtN). 
 
The presence of only one KDO unit per core OS chain after mild acid hydrolysis was 
confirmed. In the positive ion polarity mass spectrum, the ion having 1972.4 u 
corresponds to the sodium adduct of core OS reported in Fig. 32 [204], and ions 
lacking pyrophosphorylethanolamine (PPEtN), phosphorylethanolamine (PEtN) and 
phosphate (P) groups were detected. The ion at 1870.5 u was selected for performing 
tandem mass spectra (MS2), that resulted in the molecular fragmentations consistent 
with the Salmonella LPS core OS structure (data not shown). Differently from data 
reported in literature, the presence of terminal KDO in its native form was verified. 
The ions shifted of 18 u (elimination of a water molecule) from the pseudomolecular 
ions were also detected but these dehydrated forms are commonly observed in 
positive and negative ion polarity mass spectra of carbohydrates. Data were 
confirmed by MALDI-MS analysis. 
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1H NMR spectrum of core OS (Fig. 34) showed the typical signals of the terminal 
non-reducing KDO in its native form, in equilibrium between the α and β forms.  
 
 
 
Fig. 34. 1H NMR spectrum of Salmonella LPS core OS. Three small signals between 2.4 and 1.8 ppm 
were attributed to the two H-3 of non-reducing KDO, involved in the equilibrium between the α and β 
forms. The resonance at 2.1 ppm was attributed to the methyl group of the N-acetyl substituent of 
GlcNAc. Resonances at 3.1 and 4.2 ppm were attributed to the protons of PPEtN. 
 
Assignments of the major peaks were done according to the literature [205, 206]. Bi-
dimensional NMR spectra of the native core OS were rather complex due to the non-
stoichiometric presence of phosphate groups and to the α and β equilibrium of KDO. 
In order to simplify the NMR spectra, the core OS A was subjected to reduction and 
to de-phosphorylation, performed independently and sequentially (Scheme 3). 
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Scheme 3. Structural modifications performed on native core OS and indication of the analytical 
methods performed on each oligosaccharide sample. 
 
The three different samples were compared with the native unmodified core OS by 1H 
NMR, which confirmed the success of the reactions showing modifications of 
resonances of the anomeric protons the core OS sugars and KDO H-3 signals (Fig. 
35). 
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Fig. 35. 1H NMR spectrum of modified core OS. Complete removal of phosphate substituents was 
obtained. Simplification of oligosaccharide anomeric protons resonances after de-phosphorylation and 
variation of the KDO H-3 signals after reduction were observed. 
 
MALDI-MS analysis (both in positive and negative ion polarity) of the reduced/de-
phosphorylated core OS gave the expected ions (Fig. 36) and again confirmed the 
presence of no anhydro KDO. 
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Fig. 36. MALDI-MS spectrum of reduced/de-phosphorylated core OS recorded in positive (b) and 
negative (c) ion polarity. In panel b, ion having 1690.3 u was attributed to the sodium adduct of the 
reduced/de-phosphorylated core OS structure (a). In panel c, ion having 1666.8 u was attributed to the 
reduced/de-phosphorylated core OS structure (a). 
 
4.3.2 Characterization of the oligosaccharides from B. cepacia BTS 13 EPS 
 
The EPS produced by BTS13 strain of B. cepacia was also used for KDO structure 
evaluation, since the repeating unit of the BTS13 EPS contains one KDO residue, 
linked as the KDO in Salmonella LPS molecules [198] (Fig. 37). 
 
 
 
Fig. 37. Repeating unit of the EPS produced by B. cepacia BTS13 [198]. 
 
The EPS was subjected to mild acid hydrolysis to cleave the acid-labile ketosidic 
linkage between the position 2 of KDO and the position 3 of Gal. Oligosaccharides of 
1, 2 and 3 repeating units having the KDO at the reducing end were obtained. The 
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tetrasaccharide (BTS13 tetra) was used for KDO structure investigation. ESI-MS 
analysis confirmed the presence of the terminal KDO unit in its native form, as 
already assessed by the analysis performed on the Salmonella LPS core OS (data not 
shown). 
 
4.3.3 Investigation on KDO reactivity 
 
The reaction of imine formation with semicarbazide [148] was used for evaluating 
KDO reactivity, comparing different terminal KDO-containing and KDO-related 
molecules. OAg from STm 2192 wild type strain and BTS13 tetra were compared 
with KDO ammonium salt and sodium pyruvate, an α-keto acid structurally correlated 
to the KDO anhydro compounds [191, 193, 194] (Fig. 31), at the same KDO molar 
concentration, in the reaction with semicarbazide (Fig. 38). 
 
 
 
Fig. 38. Scheme of the reaction of derivatization of the C=O group of KDO with semicarbazide. 
 
The kinetic of reaction performed at 30 °C was monitored by HPLC-SEC, analysing 
the absorbance (Abs) of the reaction products at 252 nm (Fig. 39). It has been 
previously verified in GVGH that the reaction with semicarbazide gave high 
absorbance values with α-ketoacid compounds (like KDO and pyruvic acid), while 
absorptions 100 folds lower were obtained for sugars like Rha, Glc and fructose. 
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Fig. 39. Kinetic of reaction of KDO monosaccharide (ammonium salt), sodium pyruvate, STm 2192 
OAg and BTS13 tetra with semicarbazide (Abs area of the reaction products peak detected at 252 nm 
over time). All samples were analysed at the same KDO molar concentration. 
 
The reaction rate of the KDO monosaccharide was slower than the reaction of the 
KDO at the reducing end of OAg and BTS13 tetra samples, which was interestingly 
similar to that of pyruvate. Having established that KDO is in its native form at the 
end of OAg chains, its high reactivity in the imine formation might be due to its C-5 
linkage to the sugar chain. 
 
4.3.4 Core OS conjugation to CRM197 
 
ADH and SIDEA were introduced on core OS molecules according to Scheme 2. 
ADH was expected to react with the terminal KDO units, whereas the reaction step 
with SIDEA could involve amino groups of both ADH and PPEtN, for which a 100% 
substitution was found. SIDEA reaction was investigated with and without 
derivatization of KDO with ADH (Scheme 4). 
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Scheme 4. Reactions performed on core OS chains for the conjugation with CRM197. 
 
Core OS reductive amination with ADH 
 
Reaction of core OS with ADH was performed in order to investigate on the first 
step of conjugation (Scheme 2 and 4) and verify the effective involvement of KDO in 
the reaction. Synthesis and purification processes were optimized for reaction of short 
oligosaccharide chains and showed high yield of activation (100%) and recovery after 
purification (72%). A very low amount of free ADH (0.8% respect to total ADH) was 
also detected. MALDI-MS (negative ion polarity) of core-OS-ADH confirmed the 
expected product formation (ion at 2106.6 u). Sodium counterions, due to the 
presence of carboxyl and phosphate groups, as well core OS lacking 
phosphorylethanolamine (PEtN) were detected (Fig. 40). Presence of dimers (core 
OS-ADH-core OS) or unreacted core OS (or with reduced KDO) were not detected. 
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Fig. 40. MALDI-MS spectrum of core OS-ADH (negative ion polarity). The ion at 2106.6 u was 
attributed to the formation of the reaction product, whereas the ion at 1983.4 was attributed to the 
reaction product lacking phosphorylethanolamine PEtN. 
 
HPLC-SEC analysis showed a single peak confirming no dimers formation. Analysis 
of core-ADH by semicarbazide showed no further KDO reactivity, suggesting that 
C=O group of the KDO was effectively the sugar involved in this reaction. 
 
Synthesis of core OS-SIDEA intermediate 
 
Core OS-SIDEA intermediate was synthetized without introduction of ADH on the 
terminal KDO to verify PPEtN reactivity. Reaction was performed in basic and acidic 
conditions (Table 24). Introduction of SIDEA on core OS chain was confirmed at 
both pH values by MALDI-MS analysis (Fig. 41), with 90% PPEtN groups 
derivatized in both cases, as estimated by TNBS assay. Moreover, stability of the 
products after 8 days at 37 °C was verified. 
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Fig. 41. MALDI-MS spectra of the core OS-SIDEA compounds synthetized at high and low pH. The 
ion at 2075.4 u was attributed to the formation of the reaction product, with activation of PPEtN amino 
groups with SIDEA. 
 
Analysis of core OS-SIDEA compound by HPLC-SEC showed a peak (20% dRI area 
respect to the main peak) that could be attributed to dimers formation. 
The reaction conditions for the synthesis of the core OS-SIDEA intermediate were 
adjusted in order to minimize the formation of dimers and SIDEA hemiester reactive 
group hydrolysis (Table 24). 
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Table 24. Characterization of core OS-SIDEA intermediates obtained by working in different 
conditions. 
Reaction conditions 
% NH2 derivatization 
(by TNBS) 
% active ester groups 
(by RP-HPLC)* 
Core OS concentration 10 
mg/mL, Core OS 
concentration 10 mg/mL, 
DMSO/H2O 9:1 + TEA 
(molar ratio TEA/total NH2 
groups = 5), SIDEA/total NH2 
groups molar ratio 3, RT, 3h 
90.2 nd 
Core OS concentration 10 
mg/mL, DMSO/HCl 82.5 ppm 
9:1, SIDEA/total NH2 groups 
molar ratio 3, RT, 3h 
91.2 nd 
Core OS concentration 10 
mg/mL, DMSO/HCl 82.5 ppm 
9:1, SIDEA/total NH2 groups 
molar ratio 12, RT, 1h 
64.4 75.6 
*with respect to PPEtN NH2 group reacted; nd = not determined. 
 
An acceptable PPEtN amino group derivatization was obtained, together with a good 
retention of reactive SIDEA hemiester groups, available for conjugation. 
Analysis by MALDI-MS confirmed the synthesis of the active intermediate (Fig. 42). 
 
  
SDBM - School of 
Molecular Biomedicine 
 
 
108 
 
 
 
Fig. 42. MALDI-MS spectra of the core OS-SIDEA intermediate synthetized at low pH. The ion at 
2173.6 u was attributed to the core OS derivatized with SIDEA on PPEtN amino group (a), the ion at 
2076.4 u was attributed to the same product after hydrolysis of the NHS ester (b). 
 
Core OS-SIDEA product was analysed by HPLC-SEC which showed the absence of 
dimers (data not shown). The core OS-SIDEA intermediate was used for conjugation 
to CRM197. 
 
Synthesis of core OS-ADH-SIDEA intermediate 
 
After introduction of ADH, SIDEA could react both with ADH hydrazide amino 
group and PPEtN amino group (Scheme 4, Table 25). 
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Table 25. Characterization of core OS-ADH-SIDEA intermediates obtained by working in 
different conditions. 
Reaction conditions 
% NH2 derivatization 
(by TNBS) 
% active ester groups 
(by RP-HPLC)* 
% 
dimerization 
Core OS concentration 10 
mg/mL, Core OS 
concentration 10 mg/mL, 
DMSO/H2O 9:1 + TEA 
(molar ratio TEA/total NH2 
groups = 5), SIDEA/total NH2 
groups molar ratio 3, RT, 3h 
91.6 20.8 50.0 
Core OS concentration 10 
mg/mL, DMSO/HCl 82.5 ppm 
9:1, SIDEA/total NH2 groups 
molar ratio 3, RT, 3h 
93.8 32.1 29.0 
Core OS concentration 5 
mg/mL, DMSO/HCl 82.5 ppm 
9:1, SIDEA/total NH2 groups 
molar ratio 12, RT, 1h 
93.4 47.2 22.0 
*with respect to reacted NH2 groups. 
 
Reaction of PPEtN NH2 with SIDEA was confirmed also in the presence of ADH 
linker, both at high and low pH. Derivatization occurred on ADH and PPEtN of the 
same molecule. The percentage of derivatized amino groups (including both ADH 
and PPEtN) was in fact of 92% at high pH and of 94% at low pH, respectively. Major 
part of the active groups resulted hydrolysed, especially at high pH. 
MALDI-MS analysis of the products confirmed the simultaneous reaction of the two 
amino groups present on the oligosaccharide chains (Fig. 43) and the reaction product 
of core OS-ADH with SIDEA was designed as core OS-ADH-(SIDEA)2. 
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Fig. 43. MALDI-MS (negative ion polarity) spectra of core OS-ADH derivatized with ADH at high 
and low pH. The ion at 2343.5 u was attributed to the formation of the reaction product, with activation 
of both ADH and PPEtN amino groups with SIDEA. 
 
HPLC-SEC analysis revealed that core OS-ADH-(SIDEA)2 products were 
characterized by a double peak, due to possible dimerization of the product during the 
reaction, with dimer species constituting 50% and 29% of the total area for the 
product obtained at high and low pH, respectively. 
The reaction with SIDEA was then performed at low pH, with a shorter reaction time 
and with a high excess of SIDEA with respect to amino groups content, in order to 
minimize hemiester groups hydrolysis and dimerization side products (Table 25). 
93% NH2 groups resulted derivatized with 47% active ester groups. MALDI-MS 
analysis of the product again confirmed the simultaneous reaction of the two amino 
groups present on the oligosaccharide chains with SIDEA. In this case dimers 
formation was not completed abolished as revealed by HPLC-SEC analysis (dimer 
was 22% of the total area by dRI). The intermediate obtained was conjugated to 
CRM197. 
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Conjugation with CRM197 
 
Core OS-ADH-(SIDEA)2 and core OS-SIDEA intermediates were conjugated to 
the lysine (Lys) residues of CRM197. Analysis by HPLC-SEC (fluorescence 
detection), SDS-PAGE and MALDI-MS confirmed conjugate formation [207] (Fig. 
44). 
 
 
 
Fig. 44. HPLC-SEC (a), SDS-PAGE (b) and MALDI-MS (c) analysis of conjugates. 
 
In the case of the core OS-ADH-(SIDEA)2 conjugate a smear at molecular weight of 
around 100 kDa, in addition to that between 55 and 66 kDa, was detected in the gel, 
suggesting the formation of protein dimers (Fig. 44-b). For both conjugates, MALDI-
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MS spectra showed an average number of 5 oligosaccharide chains linked per 
CRM197 (Fig. 44-c). 
 
4.3.5 Glycosylation sites of core OS- and OAg-CRM197 conjugates 
 
OS-CRM197 conjugates were subjected to de-glycosylation procedure with TFMS. 
SDS-PAGE of the resulting products showed that the reaction was successful without 
impact on CRM197 integrity (Fig. 45). Same procedure was then applied to a S. 
Typhimurium 2192 OAg-ADH-SIDEA-CRM197 conjugate, characterized by having 
an average number of 5 sugar chains conjugated to CRM197. 
 
 
 
Fig. 45. SDS-PAGE analysis of TFMS-mediated de-glycosylated conjugates compared to CRM197. 
 
After de-glycosylation, the products were subjected to trypsin digestion and 
analysed by MALDI-MS [208]. In the case of the core OS-SIDEA-CRM197 conjugate, 
the linkage between the oligosaccharide chain and CRM197 can be formed only 
through the active ester group of SIDEA linked to PPEtN (Scheme 4). In the case of 
core OS-ADH-(SIDEA)2-CRM197, as for OAg-ADH-SIDEA-CRM197, the linkage to 
CRM197 can be formed through both the SIDEA linked to PPEtN and the SIDEA 
linked to ADH, introduced through reductive amination of terminal KDO (Scheme 4). 
The sugar chain could be attached through one point to CRM197, or form a bridge on 
the protein. Also two molecules of CRM197 can be linked to the same sugar chain. 
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TFMS has been reported to mediate the cleavage of the glycan bonds, leaving 
intact the innermost monosaccharide bound to the Lys residue [202, 209], but 
chemical structures due to solvolysis side reactions or to the lability of the 
phosphodiester linkage of PPEtN or of KDO-ADH-SIDEA linkages were also taken 
into account [210-212] (Table 26). Some of such chemical structures can clearly be 
specifically associated to the linkage of the sugar chain through the SIDEA linker on 
PPEtN or on ADH. 
 
Table 26. Structural modifications of Lys residues searched after chemical de-glycosylation and 
enzymatic digestion of CRM197 conjugates. 
Name Structure and chemical formula 
Conjugation 
site on the sugar 
chain 
Core OS-SIDEA 
C15H28NO15P2 
PPEtN 
Core OS-SIDEA-deHep 
 
C8H16NO9P2 
PPEtN 
Core OS-SIDEA-deP 
 
C8H15NO6P 
PPEtN 
Core OS-SIDEA-dePP 
 
C8H14NO3 
PPEtN 
Core OS-Adipoyl 
 
C6H9O3 
PPEtN/KDO 
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Core OS-ADH2-KDO 
 
C20H35N4O11 
KDO 
Core OS-ADH2 
 
C12H19N2O5 
KDO 
Core OS-ADH 
 
C6H11N2O2 
KDO 
 
The modification called “core OS-Adipoyl” (Table 26) does not allow discriminating 
between the two conjugation sites on the sugar chain (referred as “Undetermined” in 
MS analysis). 
MALDI-MS analysis (Fig. 46) allowed identifying CRM197 peptides having Lys 
residues with these modifications, without further information on the specific amino 
acids actually involved in the conjugation (Fig. 47). For unmodified CRM197, average 
sequence coverage of 55.3% was found. In the case of the conjugates, CRM197 
average coverage was of 64.7, 59.0 and 21.0% for core OS-SIDEA-CRM197, core OS-
ADH-(SIDEA)2-CRM197 and OAg-ADH-SIDEA-CRM197, respectively. 
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Fig. 46. MALDI-MS spectra of de-glycosylated and digested core-SIDEA-CRM197 conjugate. 
 
 
 
Fig. 47. Summary of the MALDI-MS analysis performed on core OS and OAg conjugates. CRM197 
peptides having Lys residues modified by the custom structural modifications due to glycoconjugation 
were grouped depending on occurrence of modifications in tryptic peptides. 
 
A central area of CRM197 (peptides 194-274) was found to be the most efficiently 
conjugated in all the conjugates. Different structural modifications on Lys residues 
(Table 26) were found, obtaining information on the regioselectivity of the 
conjugation process (Fig. 48). 
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Fig. 48. Summary of the MALDI-MS analysis performed on core OS and OAg conjugates. CRM197 
peptides having Lys residues modified by the custom structural modifications due to conjugation were 
grouped depending on occurrence of modifications in tryptic peptides. Specific structural modifications 
were grouped depending on the regiochemistry of conjugation occurred. 
 
For both core OS-ADH-(SIDEA)2-CRM197 and OAg-ADH-SIDEA-CRM197, 
conjugation resulted involving both SIDEA linked to PPEtN and SIDEA linked to 
ADH. 
Semiquantitive LC-ESI-MS analysis represented an improvement with respect to 
MALDI-MS and allowed to identify the specific Lys residues involved in 
conjugation. The three TFMS-de-glycosylated and trypsin digested conjugates were 
analysed and peptides with the expected mass value increment relative to the custom 
structural modifications were identified. Their corresponding fragmentation spectra 
were manually inspected for confirmation of the effective modification on Lys 
residues. List of Lys residues modified by conjugation for each conjugate is reported 
in Table 27. 
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Table 27. Summary of the LC-ESI-MS analysis performed on core OS and OAg conjugates. Lys 
residues modified by the custom structural modifications due to conjugation were grouped depending 
on the clustered area of tryptic peptides having the expected mass value increments. Lys residues were 
ranked according to a colour scale: the widest clustered areas were represented in red, the smallest in 
green. 
 
Peptide mapping by LC-ESI-MS confirmed that this conjugation chemistry is a highly 
random process involving a high number of Lys residues. In fact over thirty-nine 
CRM197 Lys residues available for conjugation, twenty-four sites common to core OS 
conjugates were found modified. Some Lys residues were found unmodified in the 
case of the OAg conjugate. In particular, no conjugation was found for K24, K385, 
K447, K474 and K522. 
In the case of core OS-ADH-(SIDEA)2-CRM197 conjugate, the majority of 
conjugation involved the SIDEA linker present on the PPEtN group of the core OS 
(Fig. 49). 
 
Conjugation
Core OS-
SIDEA-
CRM197
Core OS-
ADH(SIDEA)2-
CRM197
OAg-ADH-
SIDEA-CRM197
Site Clustered Area Clustered Area2 Clustered Area3
24 2,E+07 8,E+06 0,E+00
33 8,E+06 3,E+06 3,E+05
37 1,E+07 6,E+06 2,E+05
76 0,E+00 3,E+05 2,E+05
82 2,E+06 1,E+06 2,E+05
90 3,E+06 2,E+06 1,E+05
95 4,E+06 3,E+06 3,E+05
103 4,E+04 2,E+06 6,E+05
104 9,E+04 6,E+05 5,E+04
125 2,E+05 2,E+06 1,E+06
214 6,E+06 4,E+06 7,E+05
221 9,E+06 7,E+06 3,E+06
227 2,E+06 1,E+06 1,E+06
236 1,E+06 9,E+06 4,E+06
242 1,E+07 8,E+06 8,E+05
244 8,E+05 6,E+05 4,E+04
385 1,E+06 5,E+05 0,E+00
445 4,E+06 2,E+06 3,E+05
447 6,E+05 3,E+05 0,E+00
474 6,E+06 3,E+06 0,E+00
498 2,E+07 2,E+07 1,E+06
516 1,E+07 4,E+06 9,E+05
522 2,E+06 5,E+05 0,E+00
526 3,E+06 2,E+06 6,E+04
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Fig. 49. Regioselectivity of core-ADH-(SIDEA)2-CRM197 conjugate. Conjugation “via PPEtN” was 
preferred with respect to conjugation “via KDO”. 
 
The same data were plotted to display the regioselectivity of conjugation of each 
identified site of linkage (Fig. 50). 
 
 
 
Fig. 50. Regioselectivity of conjugation of each identified site of linkage, relative to core OS-ADH-
(SIDEA)2-CRM197 conjugate. 
 
Quite all the Lys residues were linked “via PPEtN”, except for K125 and K445 which 
preferred conjugation “via KDO”, although the effective contribute of the 
“undetermined” chemistry should be considered. In the case of OAg-ADH-SIDEA-
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CRM197 conjugate, the majority of the Lys residues structural modifications found 
was referred to the “undetermined” chemistry, with no major information about the 
effective conjugation chemistry involved. 
In Fig. 51, the 3D structure of CRM197 was displayed showing the exposition of the 
modified residues for the three conjugates tested. Colour coding had the following 
meaning: 
 surface colour from red to blue, passing through white, represented the b-
factor of residues, going from the more flexible areas in red to the more rigid 
areas in blue; 
 all lysines in the CRM197 sequence were highlighted in magenta. The ones 
which were found conjugated are highlighted in green, and the most 
conjugated ones (Table 27) are highlighted in yellow. 
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Fig. 51. 3D structure of CRM197 with conjugated residues highlighted, relative to core-SIDEA-CRM197 
(a), core OS-ADH-(SIDEA)2-CRM197 (b) and OAg-ADH-SIDEA-CRM197 (c) conjugates. 
 
Lys surface exposed were preferably conjugated. In particular, glycosylation sites 
were found to be in those regions of CRM197 characterized by more flexibility [213]. 
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4.4 Discussion 
 
GVGH conjugation approach for the synthesis of a vaccine against iNTS was 
based on the linkage of OAg chains to the carrier protein CRM197, after the 
introduction of ADH and SIDEA as linker molecules on the terminal KDO [106] 
(Scheme 2). However, presence and effective structure of KDO at the terminus of the 
OAg chains was never verified.  
Here, for the first time, it was shown that the process of acid hydrolysis for OAg 
extraction directly from bacteria results in the presence of KDO at the reducing end of 
the sugar chains in its native structure, without formation of anhydro compounds or 
other artifacts, in contrast with scientific literature which has often reported about 
KDO structural alterations consequent to acid treatment. McNicholas et al reported 
that un-substituted KDO monosaccharide is rapidly converted in compounds 
following structural rearrangements, unreactive to the analytical methods for KDO 
quantification (periodic acid-thiobarbituric acid and semicarbazide assays) [191]. In 
my study, 1H-NMR spectrum showed the characteristic signals for KDO at 2.4 and 
1.8 ppm (equatorial H-3 and axial H-3 of KDO, respectively) and the absence of 
resonances due to olefinic or furoic KDO derivatives. At the same time, MS data 
clearly confirmed the presence of native KDO sugar after mild acid hydrolysis since 
the exact molecular mass of the native KDO-containing oligosaccharide were 
detected in ESI-MS and MALDI-MS spectra. Moreover, the absence of other KDO 
structural artifacts in MS spectra and the molecular fragmentation obtained by MS2, 
further confirmed this finding. Also McNicholas et al reported that no structure 
modifications occur in the case of 5-O-glycosyl-KDO [191]. The characterization of 
the oligosaccharides obtained after same mild acid hydrolysis applied to the EPS 
produced by B. cepacia strain BTS13 confirmed presence of KDO in its native form. 
The repeating unit of this PS contains the KDO sugar linked to the Gal unit in 
position 5 and results obtained are further confirmation that when the KDO is linked 
in 5, mild hydrolysis does not cause rearrangements. On the other hand, these 
structural rearrangements of KDO after acid hydrolysis have been reported when 
phosphate groups were linked to KDO at position 4 (Fig. 31) such as in Bordetella 
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[214], Vibrio [196] and Aeromonas [215] LPS. After mild acid hydrolysis, the 
phosphate group was easily released and eliminated (β-elimination mechanism), with 
following formation of a mixture of 4,7-anhydro- and 4,8-anhydro-3-Deoxy-oct-2-
ulosonic acid units. 
The KDO high reactivity in reaction of reductive amination was imputed to the 
formation of more reactive forms, characterized by having the ketone group not 
implicated in the sugar ring formation and more available for the reaction [194, 214]. 
Here, high reactivity of KDO in the reductive amination reaction was confirmed but 
could not be attributed to the formation of more reactive compounds [196]. The OAg 
and the BTS13 tetrasaccharide, at the same molar concentration of KDO, showed 
very similar kinetic of reaction with semicarbazide, corroborating the high reactivity 
of the KDO in its native structure and linked in position 5 to the sugar chain. In our 
case, KDO fast kinetic of reaction, comparable to sodium pyruvate and higher than 
KDO monosaccharide, could be attributed to its linkage to the sugar chain. 
The step of reaction with SIDEA was deeply evaluated. OAg chains extracted from 
Salmonella bacteria were characterized by having a non-stoichiometric substitution 
with pyrophosphorylethanolamine (PPEtN) groups [106] and the use of ADH was 
preferred to the use of only SIDEA to guarantee a higher OAg chains conjugation 
efficiency [106]. In addition, lack of stability of the pyrophosphorylethanolamine 
linkage was also hypothesized. Here, it was verified that, even by performing the 
reaction with SIDEA at low pH and in the presence of ADH, conditions that could 
favour selectivity of ADH toward SIDEA, simultaneous reaction of PPEtN NH2 
group and ADH occur with formation of an intermediate having two SIDEA linkers 
per sugar chain. This of course can have an impact on the formation of the following 
conjugate, opening possibility to protein dimers formation, as verified in the case of 
core OS-ADH-(SIDEA)2-CRM197. Preliminary data we obtained indicate stability of 
PPEtN groups. More work can be done in this context to verify the possibility to 
prefer direct conjugation on PPEtN NH2 group for OAg chains having a 
stoichiometric substitution so to allow formation of more defined conjugates. 
Peptide mapping analysis of the conjugates confirmed that the conjugation 
chemistry used was highly random, involving a large number of Lys residues, with 
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preference for those surface exposed [216, 217]. K24, K37, K221, K242, K498, and 
K516 for core OS-SIDEA-CRM197, K24, K236, K242 and K498, for core OS-ADH-
(SIDEA)2-CRM197, K125, K221 and K236 for OAg-ADH-SIDEA-CRM197 were 
found more involved in glycosylation (Fig. 51, in yellow). There were some 
differences in conjugation site selectivity among the conjugates tested and respect to 
what reported by Moginger et al and Crotti et al in their studies of conjugation of just 
linker molecules or short oligosaccharides to CRM197 [216, 218]. In comparison with 
OAg-CRM197 conjugate, 5 additional Lys residues, K24, K385, K447, K474 and 
K522, were linked to core OS, suggesting that saccharide chain length can impact on 
conjugation site selectivity. Less accessible Lys can become available to shorter OS 
chains. Furthermore, the incorporation of one sugar chain could challenge the 
insertion of a second glycan moiety by steric hindrance or by causing conformational 
changes in the protein structure, masking some Lys in origin available, especially in 
the more flexible CRM197 regions (Fig. 51, in red). 
Peptide mapping analysis has not only allowed identification of the glycosylation 
sites on the protein, but also to understand the regioselectivity of the conjugation 
process. For both OS-ADH-(SIDEA)2-CRM197 and OAg-ADH-SIDEA-CRM197, the 
linkage of sugar chains to CRM197 seems to highly involve the SIDEA linker on 
PPEtN. This makes still more important to verify the stability of such linkage. 
This work contributed to better understand the conjugation process used for the 
synthesis of Salmonella OAg-CRM197 conjugates. The analytical methods developed 
can be applied to the characterization of other OAg-based glycoconjugate vaccines. 
The protocol developed for peptide mapping of the conjugates allows in depth 
characterization of the conjugates, and can be used to verify consistency of batch to 
batch production [219, 220]. It can also support investigation on the relationship 
between conjugate structure and immunogenicity [121, 221], improving rational 
vaccine design in the future. 
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Development of analytical methods is of fundamental importance for vaccines 
release, to verify consistency of production, to assess their stability over time and 
assure a consistent immune response. Characterization of glycoconjugate vaccines is a 
complex procedure that involves tests on starting materials such as purified 
polysaccharides and carrier proteins, the derivatized intermediates prior to 
conjugation and the final purified glycoconjugate. Here a panel of analytical methods 
has been developed and used for full characterization of OAg-CRM197 conjugate and 
its intermediates. In the case of GMMA only characterization of the final product is 
needed. However, GMMA are quite complex structures and careful characterization 
of key target antigens for immune response and of GMMA as particles is needed. 
We have verified that mutations introduced in S. Typhimurium and S. Enteritidis 
wild type strains to increase GMMA release and reduce LPS toxicity can have an 
impact on OAg expression. The effective amount of OAg injected, rather than its 
density on GMMA, seems to determine the anti-OAg antibody response, a higher 
OAg to GMMA protein ratio should allow the use of a lower amount of GMMA per 
vaccine dose with potential benefits in relation to cost and safety of the vaccine. NTS 
GMMA having a penta-acylated lipid A, provoking the least stimulation of cytokine 
release from human PBMC compared to GMMA with wild type lipid A, and 
maintaining a good expression of OAg chains appear to be optimal components for a 
vaccine against iNTS. 
S. Typhimurium and S. Enteritidis GMMA particle size distributions have been 
evaluated by means of different size-analysing techniques. All are fast methods that 
provide complementary information allowing a more complete evaluation of GMMA 
size. Number of OAg chains on the GMMA surface determines the behaviour of 
GMMA in solution, affecting hydrodynamic radius by DLS and NTA, but not 
gyration radius by MALS. MALS, coupled to a size exclusion chromatography 
module, allows checking of the purity of GMMA preparations. Like other 
methodologies based on scattered light, DLS batch measurements are inherently 
sensitive to the presence of large particles in polydisperse samples and is not able to 
distinguish subpopulations in multimodal samples. NTA allows single particles 
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visualization and their counting. This also allows determination of antigens density on 
GMMA surface.  
Here for the first time, we have been able to identify KDO presence and structure 
at the terminus of OAg chains after their extraction by acetic acid hydrolysis of 
bacteria. Differently from what reported in literature, KDO maintained its native 
form, with no rearrangements in anhydro compounds. Anyway high reactivity of 
KDO in reaction of reductive amination was confirmed and related to its linkage to 
the OAg chain. All the steps for OAg conjugation to CRM197 were in depth 
investigated, confirming that the conjugation chemistry used is highly random on the 
protein, but also not selective on the OAg chain. The linkage to the protein not only 
involves the terminal KDO sugar, but also the PPEtN group of the core region. This 
can result in protein dimers formation. Stability studies should be performed to verify 
that these two kinds of linkage involved in the process are equally stable. Alternative 
chemistries could be used to assure selective conjugation of the OAg chains, resulting 
in better defined and more consistent final products. 
The methods developed and used here can be extended to the characterization of 
other OAg-based vaccines. In particular the method to study the glycosylation sites on 
the protein can support the investigation of the relation between conjugate structure 
and immune response, driving the rational design of improved conjugate vaccines. 
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Invasive nontyphoidal Salmonella disease (iNTS) is a leading cause of death and morbidity in Africa. The
most common pathogens are Salmonella enterica serovars Typhimurium and Enteritidis. The O-antigen
portion of their lipopolysaccharide is a target of protective immunity and vaccines targeting O-antigen
are currently in development. Here we investigate the use of Generalized Modules for Membrane
Antigens (GMMA) as delivery system for S. Typhimurium and S. Enteritidis O-antigen. Gram-negative
bacteria naturally shed outer membrane in a blebbing process. By deletion of the tolR gene, the level
of shedding was greatly enhanced. Further genetic modifications were introduced into the GMMA-
producing strains in order to reduce reactogenicity, by detoxifying the lipid A moiety of lipopolysaccha-
ride. We found that genetic mutations can impact on expression of O-antigen chains. All S. Enteritidis
GMMA characterized had an O-antigen to protein w/w ratio higher than 0.6, while the ratio was 0.7
for S. TyphimuriumDtolR GMMA, but decreased to less than 0.1 when further mutations for lipid A detox-
ification were introduced. Changes were also observed in O-antigen chain length and level and/or posi-
tion of O-acetylation. When tested in mice, the GMMA induced high levels of anti-O-antigen-specific IgG
functional antibodies, despite variation in density and O-antigen structural modifications.
In conclusion, simplicity of manufacturing process and low costs of production, coupled with encour-
aging immunogenicity data, make GMMA an attractive strategy to further investigate for the develop-
ment of a vaccine against iNTS.
 2016 Published by Elsevier Ltd.1. Introduction
Salmonella enterica Typhimurium and Enteritidis are the most
common serovars responsible for invasive nontyphoidal Salmonella
disease (iNTS) in Africa [1–4], resulting in case-fatality rates of
around 20% [5]. iNTS is closely associated with malaria and malnu-
trition among African infants and children, and with HIV infection
in all age groups [6]. Antibiotics are not always available in rural
African settings, and increasing levels of multidrug-resistance are
limiting their effectiveness [7–9], making this disease a high prior-
ity for vaccine development. Currently, there are no licensed vacci-nes against iNTS and efforts are ongoing to identify protective
antigens and best strategies for vaccine development [10,11].
Antibodies directed against the O-antigen (OAg) portion of
Salmonella lipopolysaccharide (LPS) have been shown to be able
to mediate killing [12–16] and protect against infection in animal
models [14,15,17]. S. Typhimurium and S. Enteritidis OAg share a
common backbone consisting of galactose (Gal), rhamnose (Rha),
and mannose (Man), which serologically constitutes epitope O:12
[18]. A different 3,6-dideoxy-hexose residue is linked to Man in
these two serovars: abequose (Abe), conferring O:4 specificity to
S. Typhimurium, or tyvelose (Tyv), conferring O:9 specificity to S.
Enteritidis (Fig. 1) [19,20]. Salmonella OAg can demonstrate high
levels of heterogeneity in terms of chain length and variation
in O-acetylation and glucosylation of the repeating units
[14,21–24]. For S. Typhimurium, Abe may be O-acetylated at
Fig. 1. OAg repeating unit structure of (a) S. Typhimurium (O:4,5) and (b) S. Enteritidis (O:9).
420 G. De Benedetto et al. / Vaccine 35 (2016) 419–426position C-2, which adds the O:5 specificity [25]. The additional
presence of O-acetyl groups at C-2 and C-3 of Rha has also been
reported [22,26]. OAg chains can also be variably glucosylated,
with glucose (Glc) linked at C-4 (O:122 specificity) or C-6 (O:1
specificity) to Gal [21,27]. Studies in mice indicated that all these
structural modifications can impact the immunogenicity of the
corresponding glycoconjugate vaccines [14,23].
We are investigating a Generalized Modules for Membrane
Antigens (GMMA) [28] approach to the development of a bivalent
vaccine against S. Typhimurium and S. Enteritidis [29]. Gram-
negative bacteria naturally shed outer membrane as blebs
[30,31]. The release of blebs can be greatly increased by genetic
manipulation of the bacteria resulting in GMMA. In Salmonella,
deletion of the tolR gene affects the stability of the linkage between
the inner and the outer membrane, and results in an enhanced
shedding process [28,29,32,33]. GMMA derived from the surface
of Gram-negative bacteria contain potent immunostimulatory
components, such as lipoproteins and LPS, which can contribute
to their immunogenicity, but also to reactogenicity [30,31]. In
GMMA vaccine development, removal or modification of such
components may alter the balance between reactogenicity and
immunogenicity. One way to reduce the reactogenicity of LPS is
to modify its acylation pathway, for example by deletion of msbB,
pagP and htrB genes [29].
In this study, we report that mutations introduced to increase
GMMA release and decrease reactogenicity are associated with
changes in the structure of surface OAg. We investigate the impact
of these changes on the antibody response to GMMA in mice and
serum bactericidal activity of these antibodies in vitro.2. Materials and methods
2.1. Strains
Salmonella enterica serovar Typhimurium isolate SGSC1418
(STm 1418) (LT-2 collection [34], University of Calgary) and Enter-
itidis SA618 (SEn 618) (CEESA EASSA II collection [35] of Quotient
Bioresearch Limited), both isolated from animals, were chosen asScheme 1. GMMA of S. Enteritidis and S. Typhimurium mutated strains chosen for
characterization [29].parent strains [23]. Mutants were generated as previously
described [29] (Scheme 1).2.2. GMMA production and characterization
GMMAwere produced and purified as described [29]. Total pro-
tein content was estimated by Lowry assay [36,37]. OAg sugar con-
tent was quantified by High-Performance Anion-Exchange
Chromatography coupled to Pulsed Amperometric Detector
(HPAEC-PAD) as previously described [21], after performing acid
hydrolysis directly on GMMA. GMMA components did not interfere
in the quantification of the OAg sugar monomers. The amount of
core reducing end KDO (2-keto-3-deoxy-octonate) was assumed
equal to the amount of lipid A and quantified by semicarbazide/
High Performance Liquid Chromatography - Size Exclusion Chro-
matography (HPLC-SEC) method after sugar extraction [21]. The
percentage of OAg chains was calculated as the molar ratio of their
KDO divided by total KDO, including LPS molecules with just core.
Lipid A structures were investigated by Matrix-Assisted Laser
Desorption/Ionization-Mass Spectrometry (MALDI-MS) [29]. Pro-
tein pattern profile was analyzed by SDS-PAGE analysis (SI).2.3. OAg purification and characterization
OAg extraction and purification from wild type bacteria was
performed as previously described [38]. For extraction of the OAg
from GMMA, a similar procedure was used as detailed in SI. Gel fil-
tration chromatography with differential refractive index (dRI)
detection was used to fractionate the OAg chains obtained after
extraction from GMMA. Samples were run on Sephacryl S300 col-
umn (90 cm  1.6 cm i.d.). The mobile phase was NaNO3 0.05 M at
the flow rate of 8 mL/h. Fractions from Sephacryl S300 were
desalted by gel filtration chromatography on Biogel P2 column
(90 cm  1.6 cm i.d., flow rate 8 mL/h) or on a Bioline preparative
chromatographic system equipped with Superdex G30 column
(90 cm  1.0 cm i.d., flow rate 1.5 mL/min). OAg structural analysis
was performed as previously reported [21]. OAg peak molecular
weight (MP) was calculated by HPLC-SEC analysis by using dex-
trans as standards on TSK gel G3000 PWXL column
(30 cm  7.8 mm; particle size 7 lm; Cat. N. 808021) with TSK
gel PWXL guard column (4.0 cm  6.0 mm, particle size 12 lm;
Cat. N. 808033) (Tosoh Bioscience) and with in-line dRI detector.
80 lL of samples 100 lg/mL polysaccharide content were injected
and eluted at the flow rate of 0.5 mL/min with 0.1 NaCl, 0.1
NaH2PO4, 5% CH3CN, pH 7.2 as mobile phase.2.4. High-Performance Liquid Chromatography - Size Exclusion
Chromatography/Multi-Angle Light Scattering (HPLC-SEC/MALS)
GMMA samples were analyzed by HPLC-SEC with Sepax SRT-C
2000-1000 columns in series (Cat. N. 235980-7830; 235950-
7830) equilibrated in PBS and with in-line UV, fluorescence emis-
sion, dRI and MALS detectors. 80 lL of samples 100 lg/mL protein
content were injected and eluted with a flow rate of 0.5 mL/min.
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(Wyatt Technology).2.5. Immunogenicity of candidate Salmonella GMMA vaccines in mice
and serological analysis
Five groups of eight 5-weeks old female CD1 mice were pur-
chased from Charles River Laboratory and maintained at Novartis
Vaccines Animal Care. Mice received two subcutaneous immuniza-
tions at 28 days interval with 200 lL/dose of 1 lg of OAg formu-
lated with Alhydrogel (final concentration 0.7 mg/mL Al3+). Mice
were bled before the first immunization (sera pooled for each
group at day 0) and at days 14, 28 and 42 after the first immuniza-
tion (collected as single sera). All animal protocols were approved
by the local animal ethical committee (approval N. AEC201309)
and by the Italian Minister of Health in accordance with Italian
law. Individual mouse sera, collected at each time point, were
tested for anti-OAg IgG antibody titers by ELISA, as previously
described [23]. For each group, equal volumes of sera collected at
day 42 from each mouse were pooled, and tested for serum bacte-
ricidal activity (SBA) against S. Typhimurium D23580, an endemic
clinical isolate from Malawi [8,39], obtained from the Malawi-
Liverpool-Wellcome Trust Clinical Research Programme, Blantyre,
Malawi, or against the laboratory strain S. Enteritidis CMCC4314,
(corresponding to ATCC4931) obtained from the Novartis Master
Culture Collection (NMCC), as previously described [23]. Bacterici-
dal activity was determined as serum dilutions necessary to obtain
50% colony forming units (CFU) reduction after 3 h incubation at
37 C compared with CFU counted at time 0. To evaluate possible
nonspecific inhibitory effects of baby rabbit complement (BRC) or
mouse serum, bacteria were also incubated with SBA buffer and
active BRC as negative control, and with pooled sera from a control
placebo group diluted at the same dilutions of test sera (starting
from 1:100) with active BRC. For all negative controls we did not
observe any killing effect up to the highest serum concentration
tested of 1:100 (assay’s baseline).
Statistical and graphical analysis was performed using Graph-
Pad Prism 6 software. The non-parametric Mann-Whitney test
(two-tailed) and Kruskal-Wallis analysis with Dunn’s test for post
hoc analysis were used, respectively, to compare two or multiple
groups. Response at day 14 and 42 for each group was compared
by Wilcoxon matched-pairs signed rank test (two-tailed).3. Results
As part of our previous work, several different S. Typhimurium
and S. Enteritidis isolates were screened as sources of OAg for use
in a bivalent glycoconjugate vaccine against iNTS [23]. Based on
the results obtained, SEn 618 and STm 1418 strains were also
selected for use as GMMA-producing strains. They were genetically
modified through deletion of tolR gene for GMMA overproduction
and of further genes (DmsbB, DhtrB and DpagP) to reduce reacto-
genicity [29]. IL-6 release was used as an indicator for proinflam-Table 1
Characterization of GMMA from SEn 618 and STm 1418 mutated strains.
GMMA w/w
OAg/GMMA protein ratio
m
OAg cha
SEn 618 DtolR 0.6
SEn 618 DtolR DmsbB 1.7
SEn618 DtolR DmsbB DpagP 1.5
STm 1418 DtolR 0.66
STm 1418 DtolR DmsbB 0.03
STm 1418 DtolR DhtrB 0.02matory responses to toll like receptors (TLR) stimulation. The
combination of DmsbB and DpagP mutations provoked the least
stimulation of cytokine release from human PBMC compared to
GMMA with wild type lipid A. We also found that the residual
activity was largely due to TLR2 activation, although GMMA signif-
icantly signaled through TLR4 [29]. Some of the resulting GMMA
(Scheme 1) were here fully characterized and tested in mice.
3.1. OAg characterization of SEn 618 GMMA
OAg from SEn 618 wild type bacteria was fully characterized, as
detailed in SI (Tables S1, S2; Fig. S1), and used as a comparison
with OAg present on GMMA obtained from genetically modified
GMMA-producing strains, in order to examine how mutations
impacted on structural features.
HPLC-SEC fluorescence emission profile of GMMA samples from
all mutated strains revealed very low residual soluble proteins
(<5%), indicating good sample purity (Fig. S2). The particle size of
GMMA from all mutated strains was similar, as estimated by
HPLC-SEC analysis coupled with MALS detector (Table 1). The
w/w ratio of OAg chains per mg of total protein was high for all
SEn 618 GMMA. OAg chains constituted a low percentage of total
LPS molecules containing core oligosaccharide, indicating that,
for all mutants, a large proportion of LPS molecules contain very
few or no OAg repeating units (Table 1). Analysis by SDS-PAGE per-
formed on SEn 618 DtolR DmsbB DpagP GMMA (Fig. S3) showed no
major changes in the protein pattern compared to GMMA with no
lipid A modification (DtolR).
Following sugar extraction by acetic acid hydrolysis of GMMA
suspensions, OAg populations were isolated by size exclusion chro-
matography and compared to the OAg population purified from the
wild type strain (Fig. 2). OAg populations from all GMMA and wild
type strain showed a similar average number of repeating units
close to 25. GMMA produced from DtolR single-mutant SEn 618
expressed an additional OAg population of relatively higher molec-
ular weight (MW), with an average of 70 repeating units. This pop-
ulation also appeared to be present as a shoulder in the HPLC-SEC
profile of the OAg from the wild type strain. The two OAg popula-
tions at different MW from DtolR GMMA were quantified by the
phenol-sulfuric acid assay. The higher MW (HMW) and lower
MW (LMW) fractions represented 22% and 44% respectively of
the total amount of sugar extracted. For GMMA derived from the
other two 618 mutant strains, OAg chains accounted for 75% (DtolR
DmsbB) and 68% (DtolR DmsbB DpagP) of total sugar extracted.
These percentages are in agreement with the molar ratios of OAg
chains to total LPS molecules found (Table 1).
All OAg populations derived from all mutated as well as wild
type SEn 618 strains revealed similar sugar composition by
HPAEC-PAD and NMR (Table 2), in agreement with that expected
for S. Enteritidis OAg [19]. All samples were characterized by low
glucosylation levels of 8–11%, compared to 19% for the wild type
OAg (Table 2).
O-acetylation levels were low for all S. Enteritidis OAg samples
and decreased with the addition of mutations into theolar %
ins/total LPS
nmol
lipid A/mg GMMA protein
nm radius (MALS)
14 156.6 22
22 240.1 23
12 528.0 20
10 172.8 22
<1 108.2 15
0.45 154.8 11
Table 2
Characterization of OAg populations extracted from GMMA produced by SEn 618 and STm 1418 mutated strains and comparison to the OAg from corresponding wild type strains.
Sugar composition (molar ratio to Rha) and average number of repeating units (RU) calculated by HPAEC-PAD and HPLC-SEC/semicarbazide (assay for KDO quantification). O-
acetylation (O-Ac) level calculated by 1H NMR.
OAg Tyv/Abea Rha Man Gal Glc Number RU (MPb) O-Ac %
SEn 618 wild type 1.00 1.00 1.00 1.08 0.19 28 (27.3) 16
SEn 618 DtolR (HMW OAg) 0.99 1.00 1.04 1.05 0.12 70 (90.3) 8
SEn 618 DtolR (LMW OAg) 0.93 1.00 0.99 1.07 0.11 23 (30.3) 4
SEn 618 DtolR DmbB 0.97 1.00 1.00 1.05 0.09 26 (30.4) 3
SEn 618 DtolR DmsbB DpagP 0.97 1.00 0.99 1.06 0.08 27 (29.5) 2
STm 1418 wild type 1.00a 1.00 1.00 1.00 0.80 na 73
STm 1418 DtolR (HMW OAg) 0.91a 1.00 0.97 0.98 1.00 75 (104.7) 54
STm 1418 DtolR (LMW OAg) 0.93a 1.00 0.98 1.04 0.96 25 (32.9) 79
a Calculated by 1H NMR; na: not applicable.
b MP: peak molecular weight in kDa calculated by HPLC-SEC analysis by using dextrans as standards.
Fig. 2. HPLC-SEC chromatograms of OAg populations extracted from GMMA produced by mutated strains of SEn 618 and compared to OAg purified from the wild type SEn
618 isolate (dRI profiles; TSK gel 3000 PWXL column; NaPi 100 mM NaCl 100 mM 5% CH3CN pH 7.2; 0.5 mL/min; V0 11.20 min; Vtot 23.29 min).
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GMMA) OAg to 2% for the OAg purified from the ‘triple-mutant’
GMMA (Table 2 and Fig. S4).
3.2. OAg characterization of STm 1418 GMMA
OAg from STm 1418 wild type strain has been fully character-
ized previously [21] (Table 2, Figs. 3 and S5–S6). Table 1 details
the main characteristics of S. Typhimurium GMMA from corre-
sponding mutant GMMA-producing strains. As for SEn 618 GMMA,
all preparations had low residual soluble proteins, as indicated by
HPLC-SEC analysis (data not shown). After the introduction of the
DtolR mutation, the w/w ratio of OAg chains per total protein
amount was high (0.66), indicating maintenance of good levels of
OAg expression. However, after the introduction ofDhtrB orDmsbB
mutations in the DtolR strain, OAg to GMMA protein ratio was
greatly reduced, consistent with inhibition of OAg production
(Table 1). At the same time, MALS analysis showed that GMMA
producing lower amounts of OAg chains were characterized by
reduced size with respect to DtolR GMMA (Table 1). As for SEn
618 GMMA, analysis of GMMA by SDS-PAGE analysis (Fig. S3)showed similar proteins profile after introduction of mutations to
reduce reactogenicity compared to GMMA with no lipid A modifi-
cation (DtolR).
For DtolR DhtrB GMMA, the presence of an extra polysaccharide
was revealed, identified as glycogen by 1H NMR [40] (Fig. S5A). In
DtolR DmsbB GMMA, very high levels of Glc were quantified by
HPAEC-PAD analysis and HPLC-SEC (dRI) chromatography revealed
the presence of an additional peak, thus strongly suggesting glyco-
gen production by this mutant as well (Fig. S5B).
OAg from DtolR GMMA showed two main populations with dif-
ferent average MW, consisting of 75 and 25 repeating units respec-
tively, similar to those OAg populations from the corresponding
wild type strain, but with different relative proportions (Table 2,
Fig. 3). The two populations had the same sugar composition, in
agreement with OAg from 1418 wild type strain, with glucosyla-
tion levels >80% (Table 2). Glycosidic linkage analysis confirmed
that the main linkage for Glc was in position C-6 on the Gal residue
(Table S4).
O-acetyl groups quantification by Gas Liquid Chromatography
(GLC) and Gas Liquid Chromatography Coupled to Mass Spectrom-
etry (GLC-MS) [21] performed on these populations detected the
Fig. 3. HPLC-SEC chromatograms of the OAg populations extracted from STm GMMA of the DtolRmutant and compared to the OAg purified from the wild type strain (TSK gel
3000 PWXL column; NaPi 100 mM NaCl 100 mM 5% CH3CN pH 7.2; 0.5 mL/min; V0 11.20 min; Vtot 23.29 min). The component eluting at 17.30 min in the DtolR OAg refers
to the core of the LPS. Core fractions for wild type OAg were lost in the purification process.
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levels of 39% for the OAg population at HMW and 32% for that at
LMW, compared to 52% for the wild type OAg (Table S5). 1H
NMR spectroscopy analysis [21] confirmed the presence of
O-acetyl groups on C-2 of Abe (O-acetyl signal at 2.10 ppm, H-2
of Abe2OAc at 5.10 ppm) in both samples (43% for HMW, 69% for
LMW OAg populations), as well as in the OAg produced by the wild
type strain (73%). An additional peak at 2.17 ppm (12% for HMW,
10% for LMW OAg populations) (Fig. S6) was tentatively attributed
to the O-acetyl group on C-2 of Rha, by comparison with the
O-acetylation pattern assigned to the OAg from S. Typhimurium
D23580 strain [21].
The low amount of OAg chains on the double mutant GMMA
impeded their detailed structural characterization.
3.3. Immunogenicity in mice
Groups of mice were immunized with SEn 618 DtolR and DtolR
DmsbBDpagP GMMA, and STm 1418DtolR,DtolRDmsbB andDtolR
DhtrB GMMA. All the GMMA candidate vaccines were compared at
the same OAg dose of 1 lg. The main objective was to verify the
ability of GMMA to induce an immune response and whether the
observed OAg modifications, following the genetic manipulations
required to generate GMMA-producing strains, affected immuno-
genicity in terms of anti-OAg responses. Fourteen days after the
second injection, all GMMA were able to induce a serovar-
specific anti-OAg IgG response, with no significant differences
among GMMA of the same serovar (Mann-Whitney test for SEn
618 GMMA and Kruskal-Wallis for STm 1418 GMMA) (Fig. 4).
However, more variability was observed in the anti-OAg IgG
response induced in mice injected with SEn 618 DtolR DmsbB
DpagP GMMA (3 non-responders) compared to 618 DtolR GMMA,
and with STm 1418 DtolR DhtrB GMMA compared to 1418 DtolR
GMMA. All GMMA were able to boost the anti-OAg IgG response
(same p value of 0.0078 comparing day 14 and day 42 response
for each group). Immune sera were also bactericidal in vitro against
S. Typhimurium D23580 or S. Enteritidis CMCC4314 (Fig. 4).4. Discussion
GMMA are nano-sized particles, displaying high-densities of
antigens and containing bacterial pathogen associated molecular
patterns (PAMPs), with the potential to trigger strong immune
responses [30,31]. Furthermore, GMMA can be produced effi-
ciently, economically and rapidly [28,32,33], making them an
attractive vaccine candidate, particularly for low and middle
income countries.
A comprehensive panel of analytical methods has been assem-
bled for GMMA characterization with particular attention to their
surface OAg, which is a key target of protective antibody responses.
Such methods allowed verification of whether mutations intro-
duced into GMMA-producing strains impact on OAg expression
and structure, enabling the identification of optimal potential
GMMA candidate for inclusion in a vaccine against iNTS. Further-
more, such methods are of fundamental importance in the process
of vaccine development, to ensure consistency of production, vac-
cine efficacy and to monitor stability of GMMA vaccines.
The DtolR mutation introduced to increase GMMA production
(approximately 300 mg OAg, obtained per liter of fermentation
broth of SEn 618 DtolR and STm 1418 DtolR GMMA) was accompa-
nied by changes in the OAg chain length distribution in both SEn
618 and STm 1418 strains. In contrast to what was observed for
SEn 618 DtolR GMMA, the DtolR mutation in the STm 1418 strain
selected caused a reduction of the OAg population at HMW com-
pared to the wild type strain. In addition, mutations to modify lipid
A and reduce toxicity need to be carefully monitored as they may
inhibit OAg production, as observed in this study with STm 1418
clones.
With STm 1418, a reduction in the amount of OAg was associ-
ated with the production of glycogen as additional polysaccharide
on GMMA. Production of such polysaccharide was not observed in
the panel of nontyphoidal Salmonella wild type strains we previ-
ously characterized [22,23]. We have also observed this phe-
nomenon in other mutants, derived both from S. Enteritidis and
S. Typhimurium GMMA-producing strains, when genetic
Fig. 4. Summary graphs of anti-OAg IgG geometric means (bars) and individual antibody levels (dots) induced in CD1 mice by GMMA vaccines injected at days 0 and 28 at
1 lg OAg dose. Mice were bled before the first immunization (pooled sera from each group at day 0) and at days 14, 28 and 42 after the first immunization. ELISA limit of
detection was calculated as 2.9 and as 2.2 ELISA units/mL for anti-O:9 and anti-O:4,5 IgG, respectively. Numbers above day 42 bars represent SBA results of pooled sera
collected at day 42 from each group against S. Enteritidis CMCC4314 or S. Typhimurium D23580. SBA titers were calculated as the serum dilution necessary to obtain 50%
bacterial killing after 3 h incubation at 37 C compared with bacteria counted at time 0. Each serum pool was tested in triplicate in three independent experiments, except for
SEn 618 DtolR serum, which was tested in duplicate. Initial serum dilution was 1:100.
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The reasons for this are not clear and it would be interesting to ver-
ify whether there is a correlation between lack of OAg production
and glycogen formation and what functional implications this may
have. Glycogen has been described to be produced in enteric bac-
teria for energy storage and to accumulate in cytoplasmic granules
[41]. Most specifically, glycogen production in S. Enteritidis has
previously been shown to be related to virulence, colonization
and resistance mechanisms; it is usually produced under limiting
growth conditions or environmental stresses [42].
OAg chain length and O-acetylation level are parameters that
are known to affect the immunogenicity of OAg-based vaccines
[14,17,23,25]. Mutations introduced into the wild type strains also
affected the OAg O-acetylation pattern. When tested in mice at the
same OAg dose, all GMMA were able to induce anti-OAg IgG speci-
fic antibodies, with functional activity, independent of the OAg
density on GMMA and with no major impact of any OAg structural
modification. The effective amount of OAg injected, rather than its
density on GMMA, may determine the anti-OAg antibody response.
The implication of this observation is that a higher OAg to GMMA
ratio should permit the use of a lower amount of GMMA per vac-
cine dose for the same anti-OAg antibody response. This will have
potential benefits in relation to cost and safety of the vaccine.In parallel work, same GMMA characterized here were assessed
for their reactogenicity. We showed that the combination of
DmsbB and DpagP mutations is the optimal approach to minimize
reactogenicity of S. Enteritidis and S. Typhimurium GMMA, result-
ing in uniformly penta-acylated lipid A [29]. GMMA from this triple
mutant strain provoked the least stimulation of cytokine release
from human PBMC, compared to GMMA with wild type lipid A,
and stimulatory potential similar to that of a Shigella sonnei GMMA
vaccine tested in Phase I clinical trials [29,32]. S. Enteritidis and S.
Typhimurium GMMA with reduced toxicity, without a major
impact on OAg expression level, seem to be good components for
a vaccine against iNTS. We have verified that mutations introduced
to reduce GMMA reactogenicity do not have a major impact on the
protein pattern profile. A more accurate analysis will be done on
final selected strains in order to identify nature and amount of
the most abundant proteins, considering that they may be addi-
tional key mediators of functional antibody. It will be important
to verify batch to batch consistency, and to investigate the contri-
bution that anti-protein antibodies can have on the overall
immune response induced by GMMA vaccines.
Simplicity of manufacturing process and low costs of produc-
tion, coupled with encouraging immunogenicity data, make the
GMMA vaccine approach particularly attractive. The comparison
G. De Benedetto et al. / Vaccine 35 (2016) 419–426 425of OAg-GMMA with other candidate vaccines under development
against iNTS, such as live-attenuated and glycoconjugate vaccines,
will be of great interest for the development of a successful and
efficacious intervention against iNTS.
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